Les troubles respiratoires du sommeil dans les maladies génétiques chez l’enfant : diagnostic et prise en charge by Amaddeo, Alessandro
HAL Id: tel-02272360
https://tel.archives-ouvertes.fr/tel-02272360
Submitted on 27 Aug 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Les troubles respiratoires du sommeil dans les maladies
génétiques chez l’enfant : diagnostic et prise en charge
Alessandro Amaddeo
To cite this version:
Alessandro Amaddeo. Les troubles respiratoires du sommeil dans les maladies génétiques chez l’enfant :
diagnostic et prise en charge. Médecine humaine et pathologie. Université Paris-Est, 2018. Français.
￿NNT : 2018PESC0066￿. ￿tel-02272360￿
! "!
!"#$%&'#(%)*+&#',%'()
%-./0)1.-2.34/0)'-506-07)10)/4)850)02)10)/4)74629!
)
:;<(;&+(!
*42=./.>50)02)30-=03-=0)-/565?@0))
#$%&'(%!)'!"*!+,-.!*/"0!1,-!
+/0774613.)+A+::%;)
!
:54>6.725-)02)B3570)06)-=43>0)107)23.@C/07)
307B5342.5307)1@)7.DD05/)1467)/07)D4/41507)
>96925?@07)10)/E06F462)
!
"#$%&!'()(*+&!,-)!.!
*3)G35>5220)H+!&;!I)) ) !658037529)10)*4357,:07-43207) ) :530-20@3)
G3@6.)J;!#') ) ) !658037529)*4357)%72) ) ) <.,:530-20@3)
!
/&01)&%!'2!32)4!.!
*3):4D506)J%K%&) ) ) !658037529)10)*4357):07-43207) ) &4BB.320@3)
*3)H301035-)J;H+';) ) !658037529)10)$03745//07) ) ) &4BB.320@3)
*3)L046,J.@57)*%*#") ) !658037529)10)K306.C/0,+/B07) )
*3)'25M6)$%&N!J'()) ) !658037529)1E+62O03B) ) )
!
!
! *!
'@DD43P)
)
+CC3085425.6)/572)
)
QR! :0F56525.6)461)B3084/06-0).F)':G)56)-=5/1306)
4R! ;C723@-2580)7/00B)157.310301)C3042=56>)
CR! <06234/)4B6.047))
SR! :5FF03062)-/565-4/)06252507)56)':G)
)
TR! *=P75.B42=./.>P)461)357U)F4-2.37)F.3);'+')56)-=5/1306)
)
VR! </565-4/)D465F072425.67).F)':G)
)
WR! <.670?@06-07).F)':G)56)-=5/1306)
!
XR! :54>6.757).F)':G)56)-=5/1306)
)
YR! (3042D062).F);'+')56)-=5/1306)
)
ZR! <.6256@.@7)B.752580)453O4P)B3077@30)461)6.656847580)80625/425.6)
)
[R! *307062425.6).F)2=0)307043-=)B3.M0-2)
)
Q\R!)#DB3.80D062)461)1080/.BD062).F)60O)154>6.725-)2../7)F.3)':G)56)-=5/1306)
4R! $4/51425.6).F)4)7@B34720364/)B3077@30)7067.3)F.3)7/00B)4B604)-/4775F5-425.6)
56)-=5/1306R)
CR! *@/70)O480)4DB/52@10)301@-25.6)47)4)7@33.>420)F.3)-.325-4/)43.@74/)1@356>)
7/00B)=PB.B604)56)-=5/1306R)
-R! *@/70)2346752)25D0)47)4)2../)2.)-=434-2035]0).C723@-2580)461)-06234/)4B6047)
56)-=5/1306R)
)
QQR!)".656847580)80625/425.6)F.3)2=0)23042D062).F)':G)56)-=5/1306)
4R! <.6256@.@7) B.752580) 453O4P) B3077@30) F.3) @BB03) 453O4P) .C723@-25.6) 56)
56F4627)O52=)*50330)&.C56)'0?@06-0R)
! 2!
CR! J.6>) 203D) -.6256@.@7) B.752580) 453O4P) B3077@30) 461) 6.656847580)
80625/425.6)56)-=5/1306^)#6525425.6)-3520354)56)304/)/5F0R)
-R! ;@2B425062)56525425.6).F)/.6>,203D)-.6256@.@7)B.752580)453O4P)B3077@30)56)
-=5/1306)
)
QSR!)<.6-/@75.6)461)B037B0-25807)
)
QTR!)+660_07!
4R! 3'(&-,)!.)''1!,1(',!4(!564)7-'(8!'91'-4'(5'!,&!,!.4(:)'!5'(&'-;!
CR! #)''1<74.$-7'-'7! =-',&64(:! ,(7! 4&.! +,(,:'+'(&! 4(! 564)7-'(! >4&6!
,56$(7-$1),.4,;!
-R! ?=.&-%5&4@'! .)''1! ,1(',! 4(! A$>(! .B(7-$+'8! C'('D4&.! $D! .%-:'-B! ,(7!
($(4(@,.4@'!-'.14-,&$-B!.%11$-&;!
1R! #)''1!4(!4(D,(&.!>4&6!5$(:'(4&,)!+B,.&6'(45!.B(7-$+'.;!
0R! E',(4(:! D-$+! )$(:! &'-+! 5$(&4(%$%.! 1$.4&4@'! ,4->,B! 1-'..%-'! $-! ($(4(@,.4@'!
@'(&4),&4$(!4(!564)7-'(;!
FR! #)''1! .&%7B! ,.! ,! 74,:($.&45! &$$)! D$-! %('91),4('7! -'.14-,&$-B! D,4)%-'! 4(! 4(D,(&.!
6$.14&,)4F'7!4(!&6'!GH3I;!
>R! J$(:<&'-+!($(<4(@,.4@'!@'(&4),&4$(!4(!564)7-'(;!
=R! 3,(! &6'! ,(,)B.4.! $D! =%4)&<4(! .$D&>,-'! $D! 3GKG! 7'@45'.! -'1),5'! 1$)B:-,16B! 4(!
564)7-'(L!
!
QVR!G5C/5.>34B=P)
)
! M!
&97@D9)
J'.! &-$%=)'.! 7%! .$++'4)! 56'F! )'.! '(D,(&.! ,@'5! %('!+,),74'! :N(N&4O%'! .$(&! D-NO%'(&.!+,4.!
.$%@'(&!.$%.!74,:($.&4O%N.!'&!.$%.!&-,4&N.;!J,!1)%1,-&!7'.!'(D,(&.!.%4@4.!7,(.!)'.!M/!5'(&-'!7'!
-NDN-'(5'!7'!+,),74'.!-,-'.!7'!)PQR14&,)!S'5T'-!1'%@'(&!1-N.'(&'-!7'.!&-$%=)'.!-'.14-,&$4-'.!
'&!(N5'..4&'-!7$(5!7P%('!N&%7'!7%!.$++'4);!3'.!,($+,)4'.!$(&!='.$4(!7PU&-'!&-,4&N'.!,@'5!%('!
1-4.'! '(! 56,-:'! +%)&474.541)4(,4-'! '&V$%! W! &-,@'-.! %('! @'(&4),&4$(! ($(4(@,.4@';! ! X(! 1)%.! ),!
1$..4=4)4&N!7'!7N@')$11'-!7'.!&'56(4O%'.!7'.!+'.%-'.!16B.4$)$:4O%'!1'%&!,47'-!W!,+N)4$-'-!'&!
.4+1)4D4'-!)'!1,-5$%-.!74,:($.&4O%'!56'F!5'.!'(D,(&.;!
A'1%4.!)'!7N=%&!7'!&6Y.'!ZP,4!.%4@4!)'.!7'%9!,9'.!1-4(541,%9!7'!+,!-'56'-56'!8!)P'91)$-,&4$(!'&!
)'! 74,:($.&45! 7'.! &-$%=)'.! -'.14-,&$4-'.! 7%! .$++'4)! 56'F! )'.! '(D,(&.! ,B,(&! %('! +,),74'!
:N(N&4O%'! '&! )'%-! 1-4.'! '(! 56,-:';! J,! 1-'+4Y-'! N&%7'! ,! 5$(5'-(N! ),! @,)47,&4$(! 56'F! )P'(D,(&!
7P%(! 5,1&'%-! .%.<.&'-(,)[! 5,1,=)'! 7'! 7$(('-! 7'.! 4(D$-+,&4$(.! 5$(5'-(,(&! )'.! 'DD$-&.!
-'.14-,&$4-'.! 1'(7,(&! )'.! N&%7'.! 7%! .$++'4);! J,! 7'%94Y+'! N&%7'! ,! ,(,)B.N! )P%&4)4&N! 7'!
-N7%5&4$(.!7'!)P,+1)4&%7'!7'!)P$(7'!7'!1$%).!1'(7,(&!%('!1$)B.$+($:-,164'[!5$++'!+'.%-'!
7'.! -N@'4).! 5$-&45,%9! )4N.! ,%9! N@Y('+'(&.! -'.14-,&$4-'.;! \P,4! ,%..4! 1,-&4541N! W! %('! &-$4.4Y+'!
N&%7'! 5$(5'-(,(&! ),! @,)47,&4$(! 7%! &'+1.! 7'! &-,(.4&! 7'! )P$(7'! 7'! 1$%).! ]^^G_[! 1$%-! ),!
5,-,5&N-4.,&4$(!7'.!,1(N'.!56'F!)P'(D,(&!
X(! 5'! O%4! 5$(5'-('! )'! 7'%94Y+'! 1,-&4! Z'! +'! .%4.! 5$(5'(&-N! .%-! )'! &-,4&'+'(&! 7'.! &-$%=)'.!
-'.14-,&$4-'.! 7%! .$++'4);! J,! 1-'+4Y-'! N&%7'! ,! 5$(5'-(N! )P'DD45,54&N! 7%! &-,4&'+'(&! 1,-! GG3!
7,(.!%('!5$6$-&'!7P'(D,(&.!,B,(&!%('!.NO%'(5'!7'!G4'--'!`$=4(;!J,!7'%94Y+'!N&%7'!,!1'-+4.!
7P,(,)B.'-!)'.!5-4&Y-'.!7'!7N=%&!7'!@'(&4),&4$(!($(4(@,.4@'!]aSH_!$%!GG3!7,(.!%('!1$1%),&4$(!
7P'(D,(&!,B,(&!7'.!+,),74'.!:N(N&4O%'.!6N&N-$:Y('.;!\P,4!'(.%4&'!5$(5)%!%('!N&%7'!.%-!)'!7N=%&!
7P%(!&-,4&'+'(&!1,-!GG3!'(!,+=%),&$4-';!JPN&%7'!'.&!,5&%'))'+'(&!'(!-N@4.4$(!7,(.!%('!-'@%'!
4(&'-(,&4$(,)';! \P,4! ,%..4! 5$)),=$-N! 7,(.! )P,(,)B.'! 7'.! 7$((N'.! '&! 7,(.! ),! -N7,5&4$(! 7'.!
1)%.4'%-.!N&%7'.!5$(5'-(,(&!)'.!5,-,5&N-4.&4O%'.!7'.!&-$%=)'.!-'.14-,&$4-'.!7%!.$++'4)!'&!7'!
)'%-!1-4.'!'(!56,-:'!56'F!7'.!'(D,(&.!1$-&'%-.!7'!&-4.$+4'!*"[!7'!+B,.&6N(4'!5$(:N(4&,)'!'&!
7P,56$(7-$1),.4';!!
!
!
!
!
!
!
!
! b!
'@DD43P)
#)''1! 74.$-7'-'7! =-',&64(:! ]#AC_! 4(! 564)7-'(!>4&6! :'('&45! 74.',.'.! ,-'! D-'O%'(&! =%&! $D&'(!
%(7'-74,:($.'7!,(7!($&! &-',&'7;!c$.&!$D! &6'!1,&4'(&.! D$))$>'7! 4(! &6'!,)+$.&!M/!5'(&'-.! D$-!
-,-'! 74.',.'.! ,&! S'5T'-P.! 364)7-'(! 6$.14&,)! 5$%)7! 1-'.'(&! .$+'! T4(7! $D! #AC! ,(7! &6%.!
('5'..4&,&'! ,! .)''1! '9,+;! d$-! &6'.'! 564)7-'(! #AC! .6$%)7! ='! &-',&'7! =B! ,!+%)&4<74.541)4(,-B!
&',+!>4&6!'91'-&4.'! 4(!($(4(@,.4@'!@'(&4),&4$(;!c$-'$@'-[! &6'!1$..4=4)4&B! &$!7'@')$1!.4+1)'-!
,(7!'DD454'(&!&$$)!&$!4+1-$@'!&6'!74,:($.4.!$D!#AC!>$%)7!)',7!&$!,(!4+1-$@'+'(&!D$-!&6'!5,-'!
$D!&6'.'!564)7-'(;!d$-!&64.!-',.$([!7%-4(:!+,!G6A!1-$:-,+!H!1,-&4541,&'7!4(!&6'!7'@')$1+'(&!
,(7! @,)47,&4$(! $D! &6-''! &$$).! &6,&! 5$%)7! .4+1)4DB! .)''1! '9,+.! 4(! &6'.'! 564)7-'(;! ^6'! D4-.&!
1-$Z'5&!H!7'@')$1'7!5$(5'-('7!&6'!@,)47,&4$(!$D!,!.%1-,.&'-(,)!1-'..%-'!.'(.$-!&$!56,-,5&'-4F'!
.)''1! ,1(',! 7%-4(:! .)''1! '9,+;! ^6'! .'5$(7! 1-$Z'5&! H! 5,--4'7! $%&! -':,-7.! &6'! %.'! $D! &6'!
@,-4,&4$(.! $D! 1%).'! >,@'! ,+1)4&%7'! ]GEK_[! ,! .4+1)'! &$$)! ,)-',7B! 4(&':-,&'7! 4(! .&,(7,-7!
-'.14-,&$-B! .)''1! '9,+! ,.! ,! .%--$:,&'! $D! 5$-&45,)! +45-$,-$%.,).;! ^64.! .&%7B! ,4+'7! ,&! &6'!
@,)47,&4$(!$D!,!.%--$:,&'!$D!5$-&45,)!+45-$,-$%.,).!4(!$-7'-!&$!-'1),5'!&6'!.&,(7,-7!XXe!.4:(,)!
D$-!&6'4-!7'&'5&4$(!,(7!&$!.4+1)4DB!&6'!74,:($.&45!>$-T!%1!$D!#AC!4(!564)7-'(;!A%-4(:!+B!G6A!
1-$:-,+[!H!,).$!5$)),=$-,&'!&$!,($&6'-!.&%7B!5$(5'-(4(:!&6'!%.'!$D!1%).'!&-,(.4&!&4+'!]G^^_!D$-!
&6'!56,-,5&'-4F,&4$(!$D!-'.14-,&$-B!'@'(&.!7%-4(:!1$)B:-,16B;!^64.!.&%7B!,4+'7!,&!7'@')$14(:!
,!.4+1)4D4'7!&$$)!4(!$-7'-!&$!4(5-',.'!&6'!,55%-,5B!$D!.&,(7,-7!.)''1!'9,+.;!^6'!.'5$(7!,9'!$D!
+B! -'.',-56! 5$(5'-('7! &6'! &-',&+'(&! $D! #AC! 4(! 564)7-'(! >4&6! :'('&45! ,(7! 5$(:'(4&,)!
74.$-7'-.;!^6'!D4-.&!.&%7B!5$(5'-('7!&6'!%.'!$D!3GKG!4(!&6'!&-',&+'(&!,):$-4&6+!$D!,!.'-4'.!$D!
4(D,(&.!>4&6!G4'--'!`$=4(!.'O%'(5';!^64.!.&%7B!64:6)4:6&'7!&6'!%.'D%)('..!$D!3GKG!4(!,@$474(:!
&-,56'$.&$+B!4(!&64.!1,-&45%),-!:-$%1!$D!1,&4'(&.!>4&6!.'@'-'!?#K#;!^6'!.'5$(7!.&%7B!,4+'7!
,&!&6'!47'(&4D45,&4$(!$D!$=Z'5&4@'!5-4&'-4,!&6,&!)',7!&$!&6'!4(4&4,&4$(!$D!3GKG!$-!SHa!4(!564)7-'(!
,(7!4(D,(&.;!H!,).$!5$)),=$-,&'7!&$!&6'!5$(5'1&4$([!7,&,!,(,)B.4.!,(7!7-,D&!-'7,5&4$(!$D!,!.'5$(7!
+,(%.5-41&!-':,-74(:!&6'!5-4&'-4,!,%&6$-4F4(:!&6'!>',(4(:!D-$+!3GKG!,(7!SHa!4(!564)7-'(;!K!
&64-7! ,-&45)'! 5$(5'-(4(:! ,! 1-$:-,+!$D! $%&1,&4'(&! 4(4&4,&4$(! $D! 3GKG! 4(! 564)7-'(! 4.! 5%--'(&)B!
%(7'-! -'@4.4$(! 4(! &6'! \$%-(,)! $D! 3)4(45,)! ,(7! #)''1! c'7454(';! H! ,).$! 5$)),=$-,&'7! 4(! &6'!
5$(5'1&4$([!7,&,!,(,)B.4.!,(7!+,(%.5-41&!-'@4.4$(!$D!$&6'-!1,1'-.!-':,-74(:!&6'!7'.5-41&4$(!
,(7! +,(,:'+'(&! $D! #AC! 4(! 564)7-'(! >4&6! A$>(! .B(7-$+'[! 5$(:'(4&,)! +B,.&6'(4,! ,(7!
,56$(7-$1),.4,;!!
! f!
+CC3085425.6)/572)
KK#c!!!! K+'-45,(!K5,7'+B!$D!#)''1!c'7454('!
KQH!!! ! K1(',!6B1$1(',.!4(7'9)
K^Q!!! ! K7'($&$(.4)),-!6B1'-&-$16B!
CcH!!! ! C$7B!+,..!4(7'9!
CG! ! C)$$7!1-'..%-'!
33Q#!!!! 3$(:'(4&,)!5'(&-,)!6B1$@'(&4),&4$(!.B(7-$+'!
3QK^! ! 364)76$$7!K7'($&$(.4))'5&$+B!^-4,)!
3GKG! ! 3$(&4(%$%.!1$.4&4@'!,4->,B!1-'..%-'!
3#K!!! ! 3'(&-,)!.)''1!,1(',.!
3#C!!! ! 36'B('<#&$T'.!=-',&64(:!!
3^!!! ! 3$+1%&'7!&$+$:-,16B!!
AH#X!!! ! A-%:<4(7%5'7!.)''1!'(7$.5$1B!
X3e!!! ! X)'5&-$5,-74$:-,+!
XXe!! ! X)'5&-$'(5'16,)$:-,+!
XS^!! ! X,-!($.'!,(7!&6-$,&!!
H3#K!! ! H74$1,&645!3#K!
cKG!! ! c',(!,-&'-4,)!1-'..%-'!
cA?! ! c,(74=%),-!74.&-,5&4$(!$.&'$:'('.4.!
c`H!! ! c,:('&45!-'.$(,(5'!
SHa! ! S$(4(@,.4@'!@'(&4),&4$(!
S`Xc!! S$(<-,147!'B'!+$@'+'(&!
?AH!! ! ?9B:'(!7'.,&%-,&4$(!4(7'9!
?Q!! ! ?=.&-%5&4@'!6B1$@'(&4),&4$(!
?Q#!! ! ?='.4&B!6B1$@'(&4),&4$(!.B(7-$+'!
?cK! ! ?-&6$1'745!+,(74=%),-!,7@,(5'+'(&!
?#K#!! ! ?=.&-%5&4@'!.)''1!,1($',!.B(7-$+'!
G'&3?*! ! X(7<'914-,&$-B!5,-=$(!74$947'!
G#!! ! G-4+,-B!.($-4(:!!
G#e!! ! G$)B.$+($:-,16B!
G#g!! ! G'74,&-45!#)''1!g%'.&4$((,4-'!!
G&53?*! ^-,(.5%&,('$%.!5,-=$(!74$947'!1,-&4,)!1-'..%-'!!
G^^! ! G%).'!&-,(.4&!&4+'!
`Xc! ! `,147!'B'!+$@'+'(&!
`HG! ! `'.14-,&$-B!4(7%5&,(5'!1)'&6B.+$:-,16B!!
`cX! ! `,147!+,94)),-B!'91,(.4$(!
`G! ! `'.14-,&$-B!1$)B:-,16B!
#AC!! ! ?=.&-%5&4@'!.)''1!74.$-7'-'7!=-',&64(:!!
#1?*! ! G'-416'-,)!$9B:'(!.,&%-,&4$(!
#`CA! ! #)''1<`'),&'7!C-',&64(:!A4.$-7'-!!
#E#! ! #)$>!>,@'!.)''1!!
^?`#! ! ^-,(.!$-,)!-$=$&45!.%-:'-B!
^#^!! ! ^$&,)!.)''1!&4+'!
IK!! ! I11'-!,4->,B!
IK`#! ! I11'-!,4->,B!-'.4.&,(5'!.B(7-$+'!
IGGG! ! I@%)$1,),&$16,-B(:$1),.&B!
!
!
!
! h!
QR! :0F56525.6)461)B3084/06-0).F)7/00B)157.310301)C3042=56>)56)-=5/1306)
)
4R! ;C723@-2580)7/00B)157.310301)C3042=56>)56)-=5/1306)
!
?=.&-%5&4@'!.)''1!74.$-7'-'7!=-',&64(:!]#AC_! 4.!5),..45,))B!7'D4('7!,.!,!.B(7-$+'!$D!i%11'-!
,4->,B!7B.D%(5&4$(!7%-4(:!.)''1[!56,-,5&'-4F'7!=B!.($-4(:!,(7V$-!4(5-',.'7!-'.14-,&$-B!'DD$-&!
.'5$(7,-B! &$! 4(5-',.'7!%11'-! ,4->,B! -'.4.&,(5'! ,(7!16,-B(:',)! 5$)),1.4=4)4&B! j";! ^6'-'D$-'[!
#AC! .6$%)7! ='! 5$(.47'-'7! ,.! ,! 5$(&4(%%+! 5)4(45,)! .1'5&-%+[! -,(:4(:! D-$+!1-4+,-B! .($-4(:!
]G#_! &$! %11'-! ,4->,B! -'.4.&,(5'! .B(7-$+'! ]IK`#_[! $=.&-%5&4@'! 6B1$@'(&4),&4$(! ]?Q_! ,(7!
D4(,))B!$=.&-%5&4@'!.)''1!,1($',!.B(7-$+'!]?#K#_;!!!
^6'!1-'@,)'(5'!$D!#AC!4.!.$+'>6,&!74DD45%)&!&$!,.5'-&,4(!,.!7'D4(4&4$(.!@,-4'7!$@'-!&4+';!!
G#! 4.! 7'D4('7! ,.! &6'! 1-'.'(5'! $D! 6,=4&%,)! .($-4(:! D$-!+$-'! &6,(! 2! (4:6&.! 1'-!>''T.[! 4(! &6'!
,=.'(5'! $D! -'.14-,&$-B! '@'(&.! ](,+')B! ,1(',.! ,(7! 6B1$1(',._[! .)''1! 74.-%1&4$(! ,(7! :,.!
'956,(:'!,=($-+,)4&4'.;!#4(5'!&6'-'!4.!($!%(4@'-.,))B!,55'1&'7!.&,(7,-7!7'D4(4&4$(!$D!.($-4(:[!
4&.! '9,5&! 1-'@,)'(5'! @,-4'.! ,55$-74(:! &$! &6'! 74DD'-'(&! 1'-5'1&4$(.! $D! >$-7P.!+',(4(:;! K.! ,!
+,&&'-! $D! D,5&[! 74DD'-'(5'.! 4(! )$%7('..! ,(7! D-'O%'(5B! $D! &6'! 16'($+'($(! ]4;';! (%+='-! $D!
(4:6&.!1'-!>''T[!(%+='-!$D!6$%-.!1'-!(4:6&_!6,@'!)'7!&$!74DD'-'(5'.!4(!&6'!'.&4+,&4$(!$D!&6'!
1-'@,)'(5'! $D! G#;! ! ^6'! 1-'@,)'(5'! $D! G#[! :,&6'-'7! @4,! O%'.&4$((,4-'.[! -,(:'.! D-$+! ";bk! &$!
*"k!4(!1,'74,&-45!1$1%),&4$(*! ,55$-74(:! &$! &6'!74DD'-'(&!7'D4(4&4$(.;!Q$>'@'-[! -'5'(&!+'&,<
,(,)B.'.!'.&4+,&'7!,!+'74,(!1-'@,)'(5'!$D!G#!4(!564)7-'(!>$-)7>47'!$D!,-$%(7!""<"*k2[M;!K.!
.%56[!G#!4.!5$++$(!,(7[!.4(5'!4&.!-'1-'.'(&.!&6'!)'..!.'@'-'!D$-+!$D!#AC[!4&!6,.!)$(:!&4+'!=''(!
5$(.47'-'7! ,.! ,! ='(4:(! 74.$-7'-;! Q$>'@'-[! -'5'(&! 7,&,! .%::'.&! ,! 7'5-',.'! $D! 5$:(4&4@'!
D%(5&4$(.!'@'(!4(!564)7-'(!>4&6!G#blh[!-4.4(:!&6'!(''7!D$-!4(5-',.'7!,>,-'('..!-':,-74(:!&6'!
5$(.'O%'(5'.!$D!&6'!>6$)'!.1'5&-%+!$D!#AC;!
IK`#!6,.!=''(!D4-.&)B!7'.5-4='7!4(!"m0*!=B!e%4))'+4(,%)&!'&!,)0!,(7!4.!7'D4('7!,.!&6'!1-'.'(5'!
$D! .($-4(:! ,..$54,&'7! >4&6! D-'O%'(&! .)''1! ,-$%.,).[! =%&! >4&6$%&! -'.14-,&$-B! '@'(&.! $-! :,.!
'956,(:'! ,=($-+,)4&4'.";! ! A'.14&'! &6'! ,=.'(5'! $D! $9B:'(! 7'.,&%-,&4$(.! ,(7! -'.14-,&$-B!
'@'(&.[! IK`#! 6,.! =''(! ,..$54,&'7! &$! 7,B&4+'! ('%-$='6,@4$-,)! .B+1&$+.[! >4&6! ,! 1$.4&4@'!
-'.1$(.'!&$!&-',&+'(&!.4+4),-!&$!&6,&!$D!?#K#;!S'@'-&6')'..[!&6'!'9,5&!1-'@,)'(5'!$D!IK`#!6,.!
('@'-!=''(!-'1$-&'7!4(!)4&'-,&%-'[!,(7!-'5'(&)B!&64.!.B(7-$+'!6,.!=''(!4(5)%7'7!4(!&6'!+$-'!
=-$,7'(! 7'D4(4&4$(! $D! ?#K#! =B! &6'! &64-7! 4(&'-(,&4$(,)! 5),..4D45,&4$(! $D! .)''1! 74.$-7'-.m[!
='5,%.'!$D!&6'!4+1$..4=4)4&B!&$!,(,)B.'!.'1,-,&')B!&6'.'!&>$!'(&4&4'.;!!
?Q! 4.! 7'D4('7! ,.! .($-4(:! >4&6! ,(! ,=($-+,)! 4(5-',.'! $D! '(7<'914-,&$-B! ]G'&3?*_! $-!
&-,(.5%&,('$%.!5,-=$(!74$947'!1,-&4,)!1-'..%-'!]G&53?*_[!>4&6$%&!-'.14-,&$-B!'@'(&.;!S$!7,&,!
! 0!
4.! ,@,4),=)'! $(! &6'! '9,5&! 1-'@,)'(5'! $D!?Q[! .4(5'!+$.&! $D! &6'! .&%74'.! 1%=)4.6'7! .$! D,-! 6,@'!
=''(! D$5%.'7! $(! &6'! 1-'@,)'(5'! $D! ?#K#;! Q?! 4.! D-'O%'(&)B! $=.'-@'7! 4(! 564)7-'(! .4(5'! &6'!
,(,&$+45,)! 56,-,5&'-4.&45.! ,(7! ('%-$)$:45,)! 5$(&-$)! $D! &6'4-! %11'-! ,4->,B.! :'('-,&'! ,(!
4(5$+1)'&'!5$)),1.'!$D!%11'-!,4->,B.[!>4&6!)4&&)'!$-!($!-'1',&'7!-'.14-,&$-B!'@'(&.[!=%&!>4&6!,!
5$(&4(%$%.!D)$>!)4+4&,&4$(!-'.%)&4(:!4(!5,-=$(!74$947'!-'&'(&4$(;!!
?#K#! 4.! &6'!+$.&! .'@'-'! D$-+! $D! #AC! ,(7! 4.! 7'D4('7! ,.! &6'! i-'5%--'(&! 1,-&4,)! $-! 5$+1)'&'!
%11'-! ,4->,B! $=.&-%5&4$(! ]6B1$1(',.[! $=.&-%5&4@'! $-! +49'7! ,1(',._! >4&6! 74.-%1&4$(! $D!
($-+,)! $9B:'(,&4$([! @'(&4),&4$(! ,(7! .)''1! 1,&&'-(j*;! ^6'! 1-'@,)'(5'! $D! ?#K#! 4(! 564)7-'(!
@,-4'.! >47')B! D-$+! /;"! &$! "2kM;! ^64.! @,-4,=4)4&B! 1-$=,=)B! 7'-4@'.! D-$+! &6'! 74DD'-'(&!
7'D4(4&4$(.!,(7!.'@'-4&B! &6-'.6$)7.!%.'7!$@'-! &4+';!Q$>'@'-[! 4&! 4.!%(4@'-.,))B!,55'1&'7! &6,&!
&6'! 1-'@,)'(5'! $D! ?#K#! 4(! 564)7-'(! -,(:'.! ='&>''(! *! &$! Mk"/;! ?#K#! 4.! &6%.! ,! -'),&4@')B!
5$++$(!74.',.'!4(!564)7-'(;!!
?#K#! 4.! 5),..45,))B!,..$54,&'7!>4&6! &$(.4)),-!6B1'-&-$16B! 4(!$&6'->4.'!6',)&6B! 564)7-'([! ,(7!
+$.&!$D!&6'!D4-.&!)4&'-,&%-'!7,&,!5$(5'-('7!&64.!1$1%),&4$(;!Q$>'@'-[!$@'-!&4+'!?#K#!,(7!#AC!
4(!:'('-,)!6,@'!=''(!.&%74'7!4(!$&6'-!1,'74,&-45!1$1%),&4$(.!)4T'!$='.'!564)7-'(!,(7!564)7-'(!
>4&6!5$(:'(4&,)!$-!:'('&45!74.',.'.;!^64.!-'@',)'7!&6,&!?#K#!4.!D,-!+$-'!5$++$(!4(!564)7-'(!
>4&6! ,..$54,&'7! 5$(74&4$(.! )4T'! 5$(:'(4&,)! 5-,(4$D,54,)! +,)D$-+,&4$(.[! ('%-$)$:45,)! ,(7!
('%-$+%.5%),-! 74.',.'.! ,(7! +'&,=$)45! 74.$-7'-.;! ^6'.'! 564)7-'(! ,-'! $D&'(! B$%(:'-! ,(7!
1-'.'(&! ,! +%)&4D,5&$-4,)! 74.$-7'-! &6,&! -'O%4-'.! $=Z'5&4@'! ,..'..+'(&! ,(7! &-',&+'(&! $D! ,))!
%(7'-)B4(:!,=($-+,)4&4'.!&6,&!5$(&-4=%&'!&$!%11'-!,4->,B!$=.&-%5&4$(!7%-4(:!.)''1"";!
K!74.',.'!5),..45,))B!,..$54,&'7!>4&6!%11'-!,4->,B!$=.&-%5&4$(!4.!G4'--'!`$=4(!.'O%'(5';!^6'!
$-4:4(,)! 7'.5-41&4$(! $D! &6'! .'O%'(5'! 5$(.4.&.! $D! ,! &-4,7! $D! +45-$:(,&64,[! :)$..$1&$.4.[! ,(7!
,4->,B!$=.&-%5&4$("*!>4&6!$-!>4&6$%&!5)'D&!1,),&';!H(!&64.!1$1%),&4$([!?#K#!4.!$('!$D!&6'!+$.&!
5$++$(! ,(7! .'@'-'! D',&%-'[! >6456! +,B! (''7! 4(@,.4@'! +,94))$D,54,)! .%-:'-B! $-! '@'(!
&-,56'$.&$+B! ',-)B! 4(! )4D';! ^6'! -'1$-&'7! 1-'@,)'(5'! $D! ?#K#! 4.! ,)+$.&! 0/<m/k"2["M[! >4&6! ,!
:-',&'-!.'@'-4&B!&6,(!4(!$&6'-!D$-+.!$D!4.$),&'7!5)'D&!1,),&'"b;!!
K! .4+4),-! 64:6! 1-'@,)'(5'! $D! ?#K#! 4.! $=.'-@'7! 4(! $&6'-! 5-,(4$D,54,)! +,)D$-+,&4$(."f;! H(!
564)7-'(!>4&6!e$)7'(6,-!.B(7-$+'[!($>!T($>(!,.!$5%)$,%-45%)$@'-&'=-,)!.B(7-$+'[!?#K#!4.!
1-'.'(&!4(!,)+$.&!0/!&$!m/k!$D!&6'!1,&4'(&.!"h;!#49&B!1'-5'(&!$D!1,&4'(&.!>4&6!**O""!7')'&4$(!
.B(7-$+'!,(7!fbk!$D!1,&4'(&.!>4&6!3QK`eX!.B(7-$+'!6,@'!?#K#;!d4D&B!&$!m/k!$D!564)7-'(!
,(7!M"!&$!"//k!$D!,7%)&.!>6$!.%DD'-!D-$+!^-',56'-!3$))4(.!.B(7-$+'!6,@'!?#K#!"0["m;!
3-,(4$.B($.&$.4.!-'1-'.'(&!,!6'&'-$:'('$%.!:-$%1!$D!74.',.'!&6,&!.6,-'!,!1-'+,&%-'!D%.4$(!$D!
$('!$-!+$-'!.T%))!.%&%-'.!&6,&!+,B!5,%.'!D,54,)!7'D$-+4&B;!d$-&B!1'-5'(&!$D!5-,(4$.B($.&$.4.!
,-'! .B(7-$+45[! >4&6! 3-$%F$([! K1'-&! ,(7! GD'4DD'-! ='4(:! &6'! +$.&! 5$++$(;! K)+$.&! b/k! $D!
! m!
,.B+1&$+,&45! 1,&4'(&.! >4&6! ($(<.B(7-$+45! 5-,(4$.B($.&$.4.[! 6,@'! ?#K#*/[! >6'-',.! hM! &$!
0hk!.B(7-$+45!1,&4'(&.!6,@'!?#K#!"f[*/[*"!
?#K#! 4.! ,).$! D-'O%'(&! 4(! 564)7-'(! ,(7! ,7%)&.! >4&6! A$>(! .B(7-$+'! >4&6! ,(! '.&4+,&'7!
1-'@,)'(5'!-,(:4(:!='&>''(!2/!,(7!f/k**l*M[!>6456!-4.'.!&$!mhk*b!>6'(!4(5)%74(:!.($-4(:;!!
364)7-'(!>4&6!G-,7'-!E4))4!.B(7-$+'!,(7!>4&6!,56$(7-$1),.4,!6,@'!,(!4(5-',.'7!-4.T!$D!?#K#[!
>4&6!,!1-'@,)'(5'!$D!,)+$.&!b/k*fl*0!,(7!f/<m/k*m[2/!-'.1'5&4@')B;!Q$>'@'-[!4(!=$&6!$D!&6'.'!
74.',.'.[! 5'(&-,)! ,1(',.! +,B! ,).$! ='! 1-'.'(&;! K! 64:6! 1-'@,)'(5'! $D! ?#K#! 6,.! ,).$! =''(!
-'1$-&'7!4(!74DD'-'(&!.%=&B1'.!$D!+%5$1$)B.,556,-47$.'.2"[2*;!!
S'%-$+%.5%),-!1,&4'(&.!$D&'(!'964=4&!?#K#!4(!,..$54,&4$(!>4&6!($5&%-(,)!6B1$@'(&4),&4$(!7%'!
&$! 1-$:-'..4@'! -'.14-,&$-B!+%.5)'.!>',T('..[!>4&6! ,! 1-'@,)'(5'! $D! fbk22! 4(! 564)7-'(!>4&6!
5$(:'(4&,)!+B$1,&6B!,(7!%1!&$!2/k!4(!,7$)'.5'(&.!>4&6!A%56'(('!7B.&-$16B2M;!X@'(!1,&4'(&.!
>4&6!X6)'-.<A,()$.!.B(7-$+'!+,B!6,@'!?#K#[!>4&6!,!1-'@,)'(5'! -,(:4(:! D-$+!2*! &$!"//k!
2b[2f;!
H(! .%++,-B[! #AC! 4.! O%4&'! 5$++$(! 4(! $&6'->4.'! 6',)&6B! 564)7-'(! =%&! &6'! 1-'@,)'(5'! 4(!
564)7-'(!>4&6!5$(:'(4&,)!,(7!:'('&45!74.',.'.!4.!64:6'-!$D&'(!>4&6!,!+$-'!.'@'-'!D$-+!$D!?#K#;!
d$-! &64.! -,4.$([! :4@'(! &6'! 5%+%),&4@'! 64:6! 1-'@,)'(5'! $D! &6'.'! i$&6'->4.'! -,-'j! 74.',.'.[! ,!
&,4)$-'7!,11-$,56!&$!&6'!74,:($.4.[!,(7!,!5,-'D%)!,(7!.1'54D45!&-',&+'(&!.6$%)7!='!-'.'-@'7!&$!
&6'.'!564)7-'(;!!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
! "/!
^,=)'!";!G-'@,)'(5'!$D!?#K#!4(!74DD'-'(&!5$(:'(4&,)!$-!:'('&45!74.',.'.!$D!564)76$$7!,..$54,&'7!
>4&6!5-,(4$D,54,)!+,)D$-+,&4$(.;!
! #6-5106-0)) *3084/06-0).F);'+'))
3-,(4$D,54,)!,=($-+,)4&4'.!
<! !"#$$#%&'(")%*#+,#)-#%
<! .'/0#)12$%34)0$'5#%
<! 66+7786%0#/#9"')%34)0$'5#%
<! :;<&.=%34)0$'5#%
<! >$#2-1#$%:'//")3%34)0$'5#%
3-,(4$.&'($.4.!
A$>(!.B(7-$+'!
X6)'-<A,()$.!!.B(7-$+'!
G-,7'-!E4))4!.B(7-$+'!
K56$(7-$1),.4,!
c%5$1$)B.,556,-47$.4.!
!
"V0///<"M///!2h[20!
"Vbf//"h!
"VM///2m!
"V0b//M/!
"Vb////M"!
"V*b//M*!
"Vh//M2!
"V"////MM!
"V*b///Mb!
"V*b///Mf!
"Vfb///Mh!
!
0/<m/k"2["M[2h!
0/<m/k"h[M0!
f/kMm!
fbkb/!
b/<m/k"0["m!
hb<m/k"f[*/[*"!
2/<f/k**[*2[*b!
2/<"//k2b[2f!
b/k*fl*0!
f/<m/k*m[2/[b"!
f/<mbk2"[2*[b*!
!
! ""!
CR! :0F56525.6)461)B3084/06-0).F)-06234/)4B6047)56)-=5/1306!
!
K)&6$%:6! #AC! 5),..45,))B! 5$+1-4.'.! ,))! ,=($-+,)! -'.14-,&$-B! '@'(&.[! 4(5)%74(:! &6%.! =$&6!
$=.&-%5&4@'! ,(7! 5'(&-,)! '@'(&.[! $=.&-%5&4@'! -'.14-,&$-B! '@'(&.! ,-'! D,-! +$-'! 5$++$(! &6,(!
5'(&-,)!-'.14-,&$-B!'@'(&.!4(!564)7-'(!]>4&6!&6'!'95'1&4$(!$D!&6'!16B.4$)$:45,)!5'(&-,)!,1(',.!
4(! ('>=$-(.! ,(7! B$%(:! 4(D,(&._;!Q$>'@'-[! 5'(&-,)! .)''1! ,1(',.! ]3#K_!+,B! ='! $=.'-@'7! 4(!
.$+'!564)7-'(!1-'.'(&4(:!.1'54D45!74.$-7'-.;!!!
3'(&-,)! ,1(',.! 4(! 564)7-'(! ,-'! 7'D4('7[! ,55$-74(:! &$! &6'! ),&'.&! K+'-45,(!K5,7'+B!$D! #)''1!
c'7454('! ]KK#c_! -'5$++'(7,&4$(.b2[! ,.! ,! 5'..,&4$(! $D! ,4-D)$>!>4&6$%&! &6$-,5$<,=7$+4(,)!
+$@'+'(&.[! ),.&4(:! ,&! )',.&! *! -'.14-,&$-B! 5B5)'.! 4(! ,..$54,&4$(! >4&6! $9B:'(! 7'.,&%-,&4$([!
,>,T'(4(:.!$-!5$-&45,)!,-$%.,)[!$-!),.&4(:!,&!)',.&!*/!.'5$(7.;!K774&4$(,))B[!4(!4(D,(&.[!5'(&-,)!
,1(',.! 5$%)7! ='! .5$-'7! 4D! ,(! ,1(',[! >4&6$%&! &6$-,5$<,=7$+4(,)! +$@'+'(&.[! $55%-.! ,)$(:!
>4&6!,!7'5-',.'! 4(!6',-&!-,&'!&$! )'..! &6,(!b/!=',&.!1'-!+4(%&'! D$-!,&! )',.&!b!.'5$(7.!$-!)'..!
&6,(!f/!=',&.!1'-!+4(%&'!D$-!"b!.'5$(7.;!H&!4.!4+1$-&,(&!&$!64:6)4:6&!&6,&!=-4'D!5'(&-,)!,1(',.!
,-'!5$++$(!4(!564)7-'([!'.1'54,))B! 4(!,..$54,&4$(!>4&6!+$@'+'(&.[!=%&! &6'B!,-'!%.%,))B!($&!
,..$54,&'7!>4&6!,!7'.,&%-,&4$(!$-!,(!,-$%.,);!^6%.[!.5$-4(:!.6$%)7!='!1'-D$-+'7!=B!,!-',7'-!
>6$! 6,.! ,! O%,)4D45,&4$(! ,(7! '91'-&4.'! 4(! 1'74,&-45! .)''1! 4(! $-7'-! &$! ($&! $@'-'.&4+,&'! &6'!
(%+='-!$D!5'(&-,)!,1(',.;!!
H(! ,7%)&.[! 3#K! 4.! O%4&'! 5$++$(! 4(! .$+'! 74.$-7'-.;! 3#K! ,-'! 1-'.'(&! 4(! ,)+$.&! 2b<M/k! $D!
1,&4'(&.!>4&6!6',-&! D,4)%-'!,(7!,! )'D&! @'(&-45%),-! D-,5&4$(!$D! )'..! &6,(!MbkbM;! H74$1,&645!3#K!
]H3#K_[! (,-5$&45<4(7%5'7! 5'(&-,)! ,1($',[! $='.4&B! 6B1$@'(&4),&4$(! .B(7-$+'! ]?Q#_[! ,(7!
36'B('<#&$T'.!=-',&64(:!]3#C_!,-'!$&6'-!>'))!7'.5-4='7!D$-+.!$D!5'(&-,)!,1($',!4(!,7%)&.bb;!
E64)'! &6'! 1-'54.'! 1-'5414&,&4(:!+'56,(4.+.! 4(@$)@'7! 4(! &6'! @,-4$%.! &B1'.! $D! 3#K!+,B! @,-B!
5$(.47'-,=)B[! %(.&,=)'! @'(&4),&$-B! 7-4@'! 7%-4(:! .)''1! -'1-'.'(&! ,! 5$-('-.&$('! %(7'-)B4(:!
D',&%-';!
H(!564)7-'([!5'(&-,)!,1(',.!,-'!5$++$(!7%-4(:!&6'!('$(,&,)!1'-4$7[!'.1'54,))B! 4(!1-'+,&%-'!
('>=$-(.!,(7!+,B!='!$=.'-@'7!,.!4.$),&'7!,1(',.!$-!,.!,(!%(.&,=)'!1'-4$745!=-',&64(:bf[bh;!
^64.! '(&4&B! 4.! 5,))'7! ,1(',.! $D! &6'! 1-'+,&%-'! ,(7! &6'! +'56,(4.+! %(7'-)B4(:! 3#K! 4(! &6'!
('>=$-(!1-$=,=)B!4(@$)@'.!,(!4++,&%-'!56'+$<-'.1$(.4@'('..!&$!5,-=$(!74$947'!]3?*_!,(7!
$9B:'(! ]?*_[! :4@'(! &6'! .1$(&,('$%.! -'.$)%&4$(! ='&>''(! 2f! &$! M2!>''T.! $D! :'.&,&4$(! ,:'bf;!
E4&6! &6'! 1-$:-'..4@'! =-,4(! +,&%-,&4$([! 5'(&-,)! ,1(',.! 7'5-',.'! 16B.4$)$:45,))B! >4&6!
4(5-',.4(:!,:'b0[bm!=%&!+,B!1'-.4.&!4(!564)7-'(!>4&6!5$(:'(4&,)!$-!,5O%4-'7!74.$-7'-.!4+1,4-4(:!
@'(&4),&$-B! 7-4@';! ?('! $D! &6'! ='.&! '9,+1)'! $D! &64.! +'56,(4.+! 4.! 5$(:'(4&,)! 5'(&-,)!
6B1$@'(&4),&4$(! .B(7-$+'! ]33Q#_[! ,! -,-'! :'('&45! 74.$-7'-! $D! -'.14-,&$-B! 5$(&-$)!
! "*!
56,-,5&'-4.'7!=B!,(!,%&$($+45!('-@$%.!.B.&'+!7B.-':%),&4$(!,(7!,(!4+1,4-'7!7'@')$1+'(&!
$D!('%-,)! 5-'.&<7'-4@'7!5')).! ]('%-$5-4.&$1,&6B_f/;! !^64.!74.$-7'-! 4.! 5,%.'7!=B!,!1$)B,),(4('!
-'1',&!'91,(.4$(!+%&,&4$(!]GK`c._!$D!&6'!GQ?n*C!:'('f"!,(7!)',7.!4(!4&.!5),..45,)!D$-+!&$!,!
5$+1)'&'!7'1'(7'(5B!$(!@'(&4),&$-B!.%11$-&!7%'!&$!3#K!,(7!6B1$@'(&4),&4$(;!Q$>'@'-!&64.!
74.',.'! 4.!@'-B! -,-'f*! ,(7!$()B! )4+4&'7!7,&,!6,@'! =''(!1%=)4.6'7!$(!$&6'-! 5,%.'.!$D!3#K! 4(!
564)7-'(!$@'-!$('!B',-!$D!,:';!^6'!'.&4+,&'7!1-'@,)'(5'!$D!3#K!4(!564)7-'(!4.!($&!T($>([!=%&!
1%=)4.6'7!7,&,! 4(745,&'! &6,&!$()B!bk!$D! 564)7-'(! -'D'--'7! D$-!,! .)''1! .&%7B!6,@'! .4:(4D45,(&!
4(5-',.'7! 5'(&-,)! ,1(',.f2;! A4.',.'.! ,..$54,&'7! >4&6! =-,4(.&'+! 5$+1-'..4$(! $-! 5'(&-,)!
('-@$%.!.B.&'+! 4++,&%-4&B!.%56!,.!K-($)7l364,-4!+,)D$-+,&4$(fM[!+%5$1$)B.,556,-47$.4.2*!
$-!,56$(7-$1),.4,b"!+,B!='!5,%.'!3#K;!c$-'$@'-[!3#K!6,.!=''(!7'.5-4='7! 4(!$&6'-!74.',.'.!
.%56! ,.! G-,7'-lE4))4*f! .B(7-$+'! ,(7! 6B1$&6B-$474.+fb;! H&! 6,.! &$! ='! ($&'7! &6,&! 4(! .$+'! $D!
&6'.'!.B(7-$+'!?#K#!,(7!3#K!5$%)7!5$'94.&!7%'!&$!&6'!1-'.'(5'!$D!%11'-!,4->,B.!$=.&-%5&4$(!
,(7! &$!,!7'D454'(&!@'(&4),&$-B! 5$(&-$);! H(7''7[! 4(.&,(5'.!>6'-'=B!5'(&-,)! -'.14-,&$-B!'@'(&.!
)',7! &$!$=.&-%5&4@'! -'.14-,&$-B!'@'(&.! 4(!1,&4'(&.!>4&6!@%)('-,=)'!16,-B(:',)! ,(,&$+B[! ,(7!
@45'!@'-.,[! ,-'!$=.'-@'7! 4(! .$+'!.)''1!,1(',! 1,&4'(&.;!^6'!$@'-),1!='&>''(!3#K! ,(7!?#K#!
.%::'.&.!&6,&!5$++$(!+'56,(4.&45!&-,4&.!,-'!)4T')B!4(@$)@'7ff;!^B145,))B[!3#K!4.!5$(.47'-'7!&$!
='! &6'! 1-4+,-B! 74,:($.4.! >6'(! o! b/k! $D! ,1(',.! ,-'! .5$-'7! ,.! 5'(&-,)! 4(! $-4:4([! >6'-',.!
5$+1)'9! ,1(',! .B(7-$+'! 4.! 5$(.47'-'7! >6'(! 5'(&-,)! ,1(',.! ,-'! )'..! &6,(! b/k! $D! &6'!
-'.14-,&$-B! '@'(&.fh;! Q$>'@'-[! .%56! &6-'.6$)7.! ,-'! 5)',-)B! ,-=4&-,-B! ,(7! 7'-4@'! D-$+! ,7%)&!
.)''1!.&%74'.!1'-D$-+'7!+$.&)B!4(!1,&4'(&.!>4&6!6',-&!D,4)%-';!
!
! "2!
SR! *40154235-);'+')B=06.2PB07)
 
e4@'(! &6'! 74DD'-'(&! 5)4(45,)! +,(4D'.&,&4$(.! ,(7! 16B.4$1,&6$)$:45,)! .1'54D454&4'.[! &6'! 5),..45!
5)4(45,)!?#K#!4(!564)7-'(!74DD'-.!+,-T'7)B!D-$+!?#K#!.''(!4(!,7%)&.;!Q$>'@'-[!.4(5'!&6'!4(4&4,)!
7'.5-41&4$(! =B! e%4))'+4(,%)&! 4(! "mhf[! &6'! 5$+1-'6'(.4$(! $D! #AC! 4(! 564)7-'(! ,(7! 4&.!
16B.4$1,&6$)$:B!6,.!1-$:-'..4@')B!'@$)@'7;!^6'!-$)'!$D!,7'($&$(.4)),-!6B1'-&-$16B!,11',-'7!
1-'7$+4(,(&! 4(! &6'! D4-.&! 7'.5-41&4$(! $D! &6'! 74.',.';! A%-4(:! &6'! ),.&! &6-''! 7'5,7'.[! &6'!
'147'+45!$D!564)76$$7!$='.4&B!6,7!5$(&-4=%&'7!&$!&6'!'+'-:'(5'!$D!,!('>!16'($&B145!@,-4,(&!
$D!?#K#! 4(! 564)7-'(;! H(7''7[!?#K#!>,.! D$%(7! &$! ='! 64:6)B! 1-'@,)'(&! 4(! 564)7-'(!>4&6! .$+'!
%(7'-)B4(:!74.',.'.!,DD'5&4(:!&6'!%11'-!,4->,B;!^6'.'! D4(74(:.!)'7!&$!,!('>!5),..4D45,&4$(!$D!
#AC!4(!564)7-'(!4(&$!&6-''!5)4(45,)!16'($&B1'.!f0!;!364)7-'(!>4&6!&B1'!"!?#K#!,-'!($-+,))B!1-'<
.56$$)!,:'7[!($&!$='.'[!&6'B!7$!($&!1-'.'(&!7,B&4+'!.$+($)'(5'!=%&!,-'!-,&6'-!6B1'-,5&4@';!
^6'B! %.%,))B! 6,@'! ,7'($&$(.4)),-! 6B1'-&-$16B[! &6'B! ,-'!+$-'! 1-$('! &$! -'5%--'(&! ',-[! ($.'!
,(7!&6-$,&!4(D'5&4$(.!,(7!)'..!1-$('!&$!7'@')$1!+'&,=$)45!,(7!5,-74$@,.5%),-!+$-=474&4'.;!^6'!
KQH!4.!%.%,))B!+$7'-,&')B!')'@,&'7;!K7'($&$(.4))'5&$+B!-'1-'.'(&.!&6'!D4-.&!)4('!&-',&+'(&!$D!
?#K#!&B1'!"!,(7!4.!:'('-,))B!,=)'!&$!5%-'!&6'!?#K#;!!^B1'!*!?#K#!4.!5),..45,))B!.''(!4(!$='.'!
564)7-'([! 1,-&45%),-)B! 4(! &6$.'! >4&6! +,-T'7! &-%(5,)! $='.4&B;! ^6'.'! 564)7-'(! 6,@'! $D&'(! ,(!
4+1$-&,(&!7,B&4+'!.)''14('..[!('%-$5$:(4&4@'!,(7!+$$7!74.&%-=,(5'.!,(7!,-'!+$-'!1-$('!&$!
5,-74$@,.5%),-! ,(7! +'&,=$)45! 5$+1)45,&4$(.;! K)&6$%:6! 6B1'-&-$16B! $D! &6'! ,7'($47.! ,(7!
&$(.4).!.&4))!1),B.!,!1-'7$+4(,(&!-$)'!4(!?#K#!$(!$='.'!564)7-'(!,(7!-'1-'.'(&.!&6'!D4-.&!)4('!
&-',&+'(&!,D&'-!>'4:6&!)$..[!&6'!'DD45,5B!$D!%11'-!,4->,B!.%-:'-B!4.!)'..!'DD'5&4@'!&6,(!&6'!&B1'!
"! ?#K#fm;! ! ^6'! &64-7! ?#K#! 16'($&B1'! 4.! -'1-'.'(&'7! =B! 564)7-'(! >4&6! 5$(:'(4&,)!
+,)D$-+,&4$([!:'('&45!74.',.'.!$-!4(!:'('-,)!>4&6!,(B!%(7'-)B4(:!74.',.'!&6,&!+,B!5$(&-4=%&'!
&$!&6'!1,&6$:'('.4.!$D!?#K#;!^64.!.$<5,))'7!i5$+1)'9!?#K#j!74DD'-.!D-$+!&6'!&B1'!"!,(7!*!D$-!
.'@'-,)! -',.$(.;!d4-.&!$D! ,))[! ($!,:'!74.&-4=%&4$(! 4.!1-'.'(&! 4(! &64.!:-$%1;!364)7-'(!+,B!6,@'!
?#K#!,&!,(B!,:'[! D-$+!4(D,(5B!&$!),&'!,7$)'.5'(5'[!,55$-74(:!&$!&6'!%(7'-)B4(:!74.',.';!^64.!
6,.! =''(! 5)',-)B! 7'+$(.&-,&'7! 4(! G-,7'-!E4))4! .B(7-$+'[!A$>(! .B(7-$+'[! ,56$(7-$1),.4,[!
^-',56'-! 3$))4(.! ,(7! $&6'-! 74.',.'."m[**[*h[*0;! ^6'! .'@'-4&B! $D! &6'! ?#K#! 4.! %.%,))B!
4(5-',.'7"b[*b[2/[M*! ,(7! &6'! 1,&6$:'('.4.! 4.! D,-! +$-'! 5$+1)'9! &6,(! .$)')B! ,7'($&$(.4)),-!
6B1'-&-$16B!,(7V$-!$='.4&B;!^6'-'D$-'[!&-',&+'(&!,11-$,56!4.!,).$!@'-B!74DD'-'(&!D-$+!?#K#!
&B1'!"!,(7!*[!.4(5'!,7'($&$(.4))'5&$+B!4.!+$-'!)4T')B!&$!='!4(.%DD454'(&!&$!5%-'!?#K#;!C'5,%.'!
$D! &6'!1-'.'(5'!$D!5$+$-=474&4'.[! &6'!('%-$)$:45,)!,(7!5,-74$@,.5%),-!5$(.'O%'(5'.!$D!?#K#!
,-'!74DD45%)&!&$!'@,)%,&'[!=%&!.$+'!'@47'(5'.!'94.&!-':,-74(:!&6'!-$)'!$D!?#K#!4(!&6'!4(&'))'5&%,)!
7'D454&!$D!.$+'!$D!&6'.'!1,&4'(&.h/;!c$-'$@'-[!&6'!5$+1)'94&B!$D!5)4(45,)!1-'.'(&,&4$(!&'(7.!&$!
! "M!
5$+1)45,&'! &6'! '@,)%,&4$(! $D! .B+1&$+.! 4(! &6'.'! 564)7-'(;! ^64.! '91),4(.! >6B! $=Z'5&4@'!
+',.%-'!&$!,.5'-&,4(!&6'!.'@'-4&B!$D!?#K#!,-'!'@'(!+$-'!4+1$-&,(&!4(!&B1'!2!?#K#!&6,(!4(!&6'!
$&6'-!&>$!:-$%1.;!!
H(! 5$(5)%.4$(!?#K#! ,11',-.! ,.! ,! 5$+1)'9! 74.',.'! 4(! 564)7-'([!>4&6! &6'! 1-'.'(5'! $D! ,&! )',.&!
&6-''!74.&4(5&!16'($&B1'.[!>6456!74DD'-!D-$+!&6'!16B.4$1,&6$)$:B!&$!&6'!5)4(45,)!+,(4D'.&,&4$(!
,(7!+$-'! 4+1$-&,(&! &$! &6'! &-',&+'(&!,11-$,56!>6456!.6$%)7!='! &,4)$-'7!$(! &6'!%(7'-)B4(:!
74.',.'!4(!&B1'!2!?#K#;!d%-&6'-+$-'[!+$.&!$D!&6'!.&%74'.!$(!1'74,&-45!?#K#!6,@'!D$5%.'7!$(!
&B1'!"!1,&4'(&.!>4&6!)'..!4(D$-+,&4$(!$(!&6'!$&6'-!&>$!:-$%1.;!
!
^,=)'!*;!A4DD'-'(&!5)4(45,)!'(&4&4'.!$D!#AC!4(!564)7-'(!
) (PB0)Q) (PB0)S) (PB0)T)
+>0)157235C@25.6) G-'<.56$$)!,:'! #56$$)!,:'[!
,7$)'.5'(&.!
K(B!,:'!:-$%1!
*30157B.756>)
F4-2.37)
K7'($<&$(.4)),-!
6B1'-&-$16B!
^-%(5,)!$='.4&B! e'('&45V5$(:'(4&,)!
+,)D$-+,&4$(.!!
'080352P)) c4)7!&$!+$7'-,&'! c$7'-,&'! #'@'-'!
G0=485.@34/)461)
-.>652580)7PDB2.D7)
QB1'-,5&4@4&B! #$+($)'(5'[!
7'1-'..4$(!
A4DD45%)&!&$!7'&'-+4('!
,(7!1$$-)B!'@,)%,&'7!
]1-'.'(5'! $D!
5$+$-=474&4'._!
<4315.847-@/43)
-.670?@06-07)
J4&&)'!$-!($('! #B.&'+45!
6B1'-&'(.4$(!
G$$-)B! '@,)%,&'7[!
4(5-',.'7! -4.T! $D!
1%)+$(,-B!
6B1'-&'(.4$(!
A024C./5-)
4/203425.67)
J4&&)'!$-!($('! K..$54,&'7! +'&,=$)45!
.B(7-$+'!!
S$&!'@,)%,&'7!
! "b!
TR! *=P75.B42=./.>P)461)357U)F4-2.37)F.3);'+')56)-=5/1306)
!
^6'! %11'-! ,4->,B! 5$(.4.&.! $D! &6'! ($.'[! 16,-B(9[! ),-B(9[! ,(7! '9&-,&6$-,545! &-,56',;! ^6'!
16,-B(9! 4.! ,! 5$)),1.4=)'! .':+'(&! >6456! 4.! %(7'-! &6'! =,),(5'7! 5$(&-$)! $D! 74),&$-! ,(7!
5$(.&-45&$-!+%.5)'.;!A%-4(:!>,T'D%)('..[!.4:(4D45,(&! -'7%5&4$(!$D! &6'!,4->,B!1,&'(5B! 4.! -,-'!
'@'(! 4(! 4(74@47%,).!>4&6!+,-T'7)B! '(),-:'7! &$(.4).[! $='.4&B[! 5-,(4$D,54,)! ,($+,)4'.[! ,(7V$-!
,=($-+,)!('%-$+%.5%),-! &$(';!^64.! 4.! '91),4('7!=B! &6'!,=4)4&B!$D! &6'!16,-B(:',)!74),&$-.! &$!
5$+1'(.,&'!D$-!>6,&'@'-!D,5&$-.!&6,&!+4:6&!)',7!&$!%11'-!,4->,B!5$)),1.';!A%-4(:!.)''1[!&6'!
('%-$+%.5%),-! &$('! $D! &6'! 16,-B(:',)! 74),&$-.[! ,(7! &6'4-! 5$$-74(,&4$(!>4&6! &6'! 4(.14-,&$-B!
1%+1! +%.5)'.[! 4.! 7'5-',.'7! .$! &6,&! &6'B! ,-'! )'..! ,=)'! &$! 5$+1'(.,&'! D$-! &64.! ,4->,B!
5$)),1.,=4)4&B;!G6,-B(:',)!74),&$-!+%.5)'.!,5&4@4&B!7'5-',.'.!7%-4(:!($(<-,147!'B'!+$@'+'(&!
]S`Xc_!.)''1! 4(! 564)7-'(!,(7!7'5-',.'.! D%-&6'-!7%-4(:! -,147!'B'!+$@'+'(&! ]`Xc_!.)''1h";!
S'%-$+%.5%),-! 5$(&-$)! $D! %11'-! ,4->,B! 1,&'(5B! 4.! ,DD'5&'7! =B! 5'(&-,)! @'(&4),&$-B! 7-4@'[!
,-$%.,)!-'.1$(.'.!&$!-'.14-,&$-B!$55)%.4$(!],-$%.,)!&6-'.6$)7_[!,(7!%11'-!,4->,B!-'D)'9'.h*;!
3'(&-,)!@'(&4),&$-B!7-4@'!4.!4(5-',.'7!7%-4(:!564)76$$7!,(7!7'5)4('.!:-,7%,))B!>4&6!,:'h2[hM;!!
^6'-'! 4.! ,! 16B.4$)$:45,)! 7'5-',.'! 4(! ,)@'$),-! @'(&4),&4$(! 7%-4(:! `Xc! .)''1! ='5,%.'! )%(:!
@$)%+'.!,-'! )$>'-[! 4(&'-5$.&,)!+%.5)'.!7$!($&! .%=.&,(&4,))B! 5$(&-4=%&'! &$! 4(.14-,&$-B!'DD$-&[!
,(7!&6'!16,-B(:',)!74),&$-.!,-'! )'..!'DD'5&4@'!&6,(!7%-4(:!S`Xc!.)''1;! H(!1,&4'(&.!>4&6!#AC!
&6'.'!,)&'-,&4$(.!)',7!&$!,!.)''1!&-,54(:!4(!>64568!
−! `Xc! 1'-4$7.! ,-'! $D&'(! ,..$54,&'7! >4&6! 6B1$@'(&4),&4$(! ,(7! .4:(4D45,(&! $9B:'(!
7'.,&%-,&4$(.!
−! S`Xc!.&,:'!S2!].)$><>,@'!.)''1_!4.!-'),&4@')B!1-$&'5&'7!>4&6$%&!7'.,&%-,&4$(.!
−! S`Xc!.&,:'!S*!.6$>.!+$7'.&!7'.,&%-,&4$(.!
^6'.'! ,)&'-,&4$(.! ,-'! '91),4('7! =B! &6'! ,&&'+1&! $D! &6'! 564)7! &$! 5$+1'(.,&'! D$-! &6'! 74DD'-'(&!
,)&'-,&4$(.!$D!,4->,B!5$(&-$)!7%-4(:!.)''1;!K&!.)''1!$(.'&[!&6'!&$('!$D!&6'!16,-B(:',)!74),&$-.!
7'5-',.'.[! )',74(:! &$! ,! 7'5-',.'! 4(! ,4->,B! 5,)4='-;! I11'-! ,4->,B! -'.4.&,(5'! 4(5-',.'.!
5$(.'O%'(&)B[! -'.%)&4(:! 4(! ,! 7'5-',.'! 4(! &6'! 4(&-,)%+4(,)! 1-'..%-'! 4(! &6'! 16,-B(9;! ^6'!
7'5-',.'7! ,4-D)$>[! 4(5-',.'7! (':,&4@'! 1-'..%-'[! ,(7! &6'! 4(5-',.'! 4(! 3?*! .&4+%),&'! &6'!
16,-B(:',)! +'56,($-'5'1&$-.! &$! 4(5-',.'! 16,-B(:',)! 74),&$-! 5$(&-,5&4$(.hb;! H(! ,! 564)7!
>4&6$%&!#AC[!&64.!16B.4$)$:45,)!-'.1$(.'!+,4(&,4(.!,4->,B!1,&'(5B;!
H(! 564)7-'(! >4&6! #AC[! &64.! -'.1$(.'! 4(! 4(.%DD454'(&! ,(7! ($&! ,=)'! &$! 1-'@'(&! %11'-! ,4->,B!
5$)),1.';!H(!&6'!+4)7'.&!D$-+!$D!#AC[!,!+$7'.&!7'5-',.'!4(!&6'!5,)4='-!$D!&6'!16,-B(:',)!,4->,B!
)',7.! &$! ,! &%-=%)'(&! ,4-D)$>! 5,%.4(:! @4=-,&4$(! $D! &6'! .$D&! 1,),&'! ,(7! .($-4(:;! K.! &6'! %11'-!
,4->,B!$=.&-%5&4$(!>$-.'(.[!6B1$@'(&4),&4$(!7'@')$1.[! -'D)'5&'7!=B! ,! -4.'! 4(!G3?*! ,(7V$-!,!
"f
7'5-',.'!4(!,-&'-4,)!$9B:'(!.,&%-,&4$(;!^64.!D%-&6'-!.&4+%),&'.!&6'!16,-B(:',)!74),&$-.!,(7!&6'!
-'.14-,&$-B!1%+1!+%.5)'.;!H(!+,(B!564)7-'(!>4&6!?#K#[!&64.!-'.1$(.'!%.%,))B!4.!.%DD454'(&!&$!
+,4(&,4(!,!1,-&4,))B!$1'(!16,-B(:',)! ,4->,B! D$-! )$(:!1'-4$7.!$D! .)''1!>4&6$%&!'91'-4'(54(:!
$=.&-%5&4@'! ,1('45! '@'(&.;! CB! 5$(&-,.&[! ,7%)&.! >4&6! ?#K#! ,-'! +$-'! )4T')B! &$! 6,@'! ,5%&'!
$=.&-%5&4@'! ,1('45! '@'(&.[! )',74(:! &$! ,-$%.,).[! ='5,%.'! &6'! 16,-B(:',)! 74),&$-.! ,-'! )'..!
'DD'5&4@'!,(7V$-!&6'!16,-B(9!4.!+$-'!5$)),1.4=)'!,.!5$+1,-'7!&$!564)7-'(;!^64.!4(5-',.'7!7-4@'!
7%-4(:!.)''1!,55$%(&.!D$-!&6'!4(5-',.'7!%11'-!,4->,B!-'D)'9'.!,(7!&$('!4(!564)7-'([!-'.%)&4(:!
4(!,!&'(7'(5B!&$!5$)),1.'!,&!+$-'!(':,&4@'!1-'..%-'!&6,(!,7%)&.hf;!?(!&6'!$&6'-!6,(7[!564)7-'(!
>4&6!?#K#!1-'.'(&!,!5-4&45,)!%11'-!,4->,B!5)$.%-'!1-'..%-'!5)$.'!&$!1$.4&4@'!@,)%'.hh[!>6456!
7$'.!($&!-'&%-(!&$!($-+,)!,D&'-!,7'($&$(.4))'5&$+Bh0;!^6'.'!D4(74(:.!.%::'.&!,(!4+1,4-+'(&!
4(!+,4(&,4(4(:!,(!,7'O%,&'!16,-B(9!74),&$-!+%.5)'.!&$('!4(!564)7-'(!>4&6!?#K#;!^6%.[!:4@'(!
&64.!4(5-',.'!4(!@'(&4),&$-B!7-4@'[!564)7-'(!6,@'!,!.1'54D45!=-',&64(:!1,&&'-(!$D!?Q!-,&6'-!&6,(!
&6'!74.5-'&'[!5B5)45!$=.&-%5&4@'!,1(',.!1,&&'-(!&6,&!4.!5$++$()B!.''(!4(!,7%)&!#AChm;!
H(!$-7'-!&$!,55$%(&!D$-!,))!&6'!D,5&$-.!1),B4(:!,!-$)'!4(!?#K#!4(!564)7-'([!c,-5%.0/!1-$1$.'7!,!
+$7')!&$!'91),4(!&6'!16B.4$1,&6$)$:B!$D!?#K#!,.!&6'!-'.%)&!$D!,!5$+=4(,&4$(!$D!%11'-!,4->,B!
(,--$>4(:[! ,=($-+,)! %11'-! ,4->,B! ('%-$+$&$-! &$('! ,(7! $&6'-! D,5&$-.! )4T'! :'('&45!
7'&'-+4('7!5$(&-$)!$D!&6'!%11'-!,4->,B.!$-!.%=&)'!,(,&$+45,)!,($+,)4'.;!^64.!+$7')!'91),4(.!
&6'!+%)&4D,5&$-4,)!$-4:4(!$D!?#K#!4(!564)7-'(!,(7!64:6)4:6&.!&6'!(''7!D$-!,!&,4)$-'7!,11-$,56'7!
&$!&64.!74.',.';!!
!
d4:%-' ";!G,&6$16B.4$)$:B!$D!$=.&-%5&4@'!.)''1!,1(',;!
K==-'@4,&4$(.8!IK8!%11'-!,4->,B[!K^Q8!,7'($&$(.4)),-!6B1'-&-$16B[!?#K#8!$=.&-%5&4@'! .)''1!
,1(',;!?"@,$#%A$'5%$#A#$#)-#%BC;!
! "h!
!
K7'($&$(.4)),-!6B1'-&-$16B!4.!%(4@'-.,))B!,55'1&'7!,.!&6'!+$.&!5$++$(!,(7!4+1$-&,(&!-4.T!
D,5&$-! D$-!?#K#!564)7-'(!>4&6!&B1'!"!1-$D4)';!K7'($47!,(7!&$(.4).!:-$>!1-$:-'..4@')B!7%-4(:!
564)76$$7hf[0"[!=%&!,&!,!D,.&'-!-,&'!&6,(!&6'!.T')'&,)!=$%(7,-4'.!$D!&6'!%11'-!,4->,B.;!C'&>''(!
&6'!,:'.!$D!2!,(7!0!B',-.[!&6'!&$(.4).!,(7!,7'($47.!,-'!),-:'.&!4(!-'),&4$(!&$!&6'!%11'-!,4->,B.!
.4F';! H(! 1-'.56$$)! 564)7-'(!>4&6!?#K#[! ,! -'5$(.&-%5&4$(! $D! &6'! %11'-! ,4->,B.! @4,! 5$+1%&'7!
&$+$:-,16B! ]3^_! 7'+$(.&-,&'7! &6,&! +$.&! 564)7-'(! 6,7! ,! (,--$>'-! @$)%+'! ,(7! 5-$..<
.'5&4$(,)! ,-',! ,&! &6'! 4(&'-.'5&4$(! ='&>''(! &$(.4).! ,(7! ,7'($47.! &6,(! 6',)&6B! 5$(&-$).[!
5$(D4-+4(:!&6'!1-4+,-B!-$)'!$D!)B+16$47!&4..%'.!4(!&B1'!"!?#K#!1,&6$:'('.4.0*;!S'@'-&6')'..[!
,.! ,(&4541,&'7[! ,7'($&$(.4)),-! 6B1'-&-$16B! 4.! ($&! &6'! $()B! D,5&$-! 5,%.4(:! ?#K#! 4(! 564)7-'(;!
d4-.&!$D!,))[!&6'-'!4.!),5T!$D!5$--'),&4$(!='&>''(!&6'!&$(.4).!,(7!,7'($47.!.4F'!,(7!&6'!.'@'-4&B!
$D!?#K#02;!#'5$(7)B[!4D!,7'($&$(.4)),-!6B1'-&-$16B!>,.!&6'!$()B!7'&'-+4(,(&!$D!?#K#[!4&!>$%)7!
='! 74DD45%)&! &$! '91),4(! &6'! 64:6! -,&'! $D! 1'-.4.&'(&!?#K#! ,D&'-! ,7'($&$(.4))'5&$+B0M[0b;! #%=&)'!
5-,(4$D,54,)!,=($-+,)4&4'.!+,B!&6'-'D$-'!4(5-',.'!&6'!-4.T!$D!?#K#!4(!($(<.B(7-$+45!564)7-'(;!
K!+'&,<,(,)B.4.! 47'(&4D4'7!,!-'&-%.4@'!564([!,!.&''1!+,(74=%),-!1),('[! ,!@'-&45,)!74-'5&4$(!$D!
5-,(4$D,54,)!:-$>&6!,(7!,!&'(7'(5B!&$>,-7!5),..!HH!+,)$55)%.4$(!&$!='!-'),&'7!&$!&6'!1-'.'(5'!
$D!?#K#0f;!!!
#$+'! '@47'(5'.! .%::'.&! ,).$! D,+4)4,)! 5)%.&'-.! $D! ?#K#;! H(! 1,-&45%),-[! ,! 64.&$-B! $D! 1,-'(&,)!
,7'($&$(.4))'5&$+B0h[00! $-! ?#K#0m! 4(5-',.'.! &6'! -4.T! $D! ?#K#! 4(! .4=)4(:.;! H&! 6,.! =''(!
.1'5%),&'7! &6,&! .$+'! :'('&45! D,5&$-.[! 4(@$)@'7! 4(! 5-,(4$D,54,)! 7'@')$1+'(&! ,(7! 16,-B(:',)!
+%.5)'.!5$(&-$)[!+,B!,).$!1),B!,!-$)'!4(!&6'!1,&6$:'('.4.!$D!?#K#;!!
?='.4&B!-'1-'.'(&.!&6'!6,))+,-T!$D!&B1'!*!?#K#!4(!564)7-'(!,.!4(!,7%)&.;!^6'!.'@'-4&B!$D!?#K!
5$--'),&'.!&$!&6'!7':-''!$D!$='.4&B[!.%56!&6,&!D$-!'@'-B!"!T:V+*!4(5-'+'(&!4(!=$7B!+,..!4(7'9!
]CcH_!='B$(7! &6'!+',(!CcH! D$-!,:'! ,(7!:'(7'-[! &6'! -4.T!$D!?#K#! 4(5-',.'.!=B!"*km/;! H(! ,!
1-$.1'5&4@'!.&%7B[!?#K#!>,.!74,:($.'7!4(!Mk!$D!,7$)'.5'(&.!]"f!&$!"m!B',-.!$D!,:'_!,(7!+$.&!
$D! &6'+! 6,7! ($! .4:(.! $-! .B+1&$+.! $D! ?#K#! 7%-4(:! +47<564)76$$7m"[! ='D$-'! 7'@')$14(:!
$='.4&B;! K)&6$%:6! $='.4&B! 4.! ($&! ,.! 5$++$(! 4(! 564)7-'(! ,.! 4&! 4.! 4(! ,7%)&.[! 4&.! 1-'@,)'(5'! 4.!
4(5-',.4(:!>$-)7>47'[!4(!1,-&45%),-!4(!,7$)'.5'(&.m*lmM;!C'5,%.'!&6'!1-'@,)'(5'!,(7!.'@'-4&B!$D!
$='.4&B!4(!564)7-'(!4.!4(5-',.4(:[!4&!4.!)4T')B!&$!='5$+'!,(!4+1$-&,(&!5,%.'!$D!1'74,&-45!#AC!4(!
&6'! D%&%-'[! 1,-&45%),-)B! 4(! ,7$)'.5'(&.! ,(7! B$%(:! ,7%)&.m*lmM;! d,&! 1,7! 4(D4)&-,&4$(! $D! %11'-!
,4->,B! '91),4(.! &6'! 4(5-',.'7! ?#K#! 4(! $='.4&BM[m/[mblmh;! ?='.4&B! 5$(&-4=%&'.! &$! ,4->,B!
(,--$>4(:! 4(! .'@'-,)! >,B.[! 4(5)%74(:! D,&&B! 4(D4)&-,&4$(! $D! ,-',.! .%--$%(74(:! &6'! ,4->,B[!
&$(:%'[!$-!D,&!1,7.!),&'-,)!&$!&6'!,4->,B;!H+1$-&,(&)B[!+,:('&45!-'.$(,(5'!.&%74'.!.6$>'7!&6,&!
%11'-! ,4->,B! )B+16$47! &4..%'! 4.! .4:(4D45,(&! 4(5-',.'! 4(! $='.'! 564)7-'(! >4&6! ?#K#m0[mm;!
! "0!
H(5-',.'7!,741$.'!&4..%'!4(!&6'!,=7$+4(,)!>,))!,(7!5,@4&B!,.!>'))!,.!.%--$%(74(:!&6'!&6$-,9!
4(5-',.'.! &6'! :)$=,)! -'.14-,&$-B! )$,7[! -'7%54(:! 4(&-,&6$-,545! @$)%+'! ,(7! 74,16-,:+!
'95%-.4$([!1,-&45%),-)B!4(!&6'!.%14('!1$.4&4$([!)',74(:!&$!6B1$@'(&4),&4$("//!
364)7-'(! >4&6! &B1'! 2! ?#K#! 6,@'! ,(! 4(5-',.'7! 1-'@,)'(5'! $D! ?#K#! >6$.'! 16B.4$1,&6$)$:B!
),-:')B!7'1'(7.!$(!&6'!%(7'-)B4(:!74.',.';!!
H(!G4'--'!`$=4(!.'O%'(5'[!,4->,B!$=.&-%5&4$(!6,.!=''(!)$(:<&4+'!5$(.47'-'7!&$!='!'95)%.4@')B!
-'),&'7!&$!:)$..$1&$.4.;!Q$>'@'-[!+$-'!-'5'(&!7,&,!.%::'.&!,&!)',.&!D$%-!74.&4(5&!+'56,(4.+.!
$D! ?#K#;! ! H(! &B1'! "! +'56,(4.+[! ]&6'! +$.&! 5$++$()B! .''(! 4(! G4'--'! `$=4(! .'O%'(5'_! &6'!
7$-.%+!$D! &6'! &$(:%'!+$@'.! &$! &6'!1$.&'-4$-!16,-B(:',)!>,));! H(! &B1'!*[! &6'! &$(:%'!+$@'.!
1$.&'-4$-)B! ,(7! 5$+1-'..'.! &6'! .$D&! 1,),&'! $-! &6'! 5)'D&! 1,),&,)! &,:.! ,:,4(.&! &6'! 1$.&'-4$-!
16,-B(:',)! >,));! H(! &B1'! 2[! &6'! ),&'-,)! 16,-B(:',)! >,)).! +$@'! +'74,))B! ,(7! $11$.'! $('!
,($&6'-p!,(7!4(!&B1'!M[!&6'!16,-B(9!5$(.&-45&.!4(!,!54-5%),-!+,(('-"/";!?&6'-!'@47'(5'.!.%::'.&!
,).$!,!7B.D%(5&4$(!$D! &6'! )4(:%,)! ,(7!16,-B(:',)!+$&$-!$-:,(4F,&4$(!>4&6$%&!,(B! .&-%5&%-,)!
4+1,4-+'(&! 4(! =-,4(.&'+! (%5)'4! ,(7! 1,&6>,B."M;! 364)7-'(! >4&6! A$>(! .B(7-$+'! 6,@'!
(%+'-$%.!D,5&$-.!5$(&-4=%&4(:!&$!&6'!7'@')$1+'(&!$D!#AC!.%56!,.!+47D,5'!6B1$1),.4,[!,!64:6<
,-56'7!1,),&'[!+,5-$:)$..4,[!5-,(4,)!=,.'!,($+,)4'.[!6B1$&$(4,[!),-B(:$+,),54,!,(7!'(),-:'7!
,7'($47."/*;! #AC! 4.! ,).$! 5$++$(! 4(! 1,&4'(&.! >4&6! ,56$(7-$1),.4,;! c,94)),-B! 6B1$1),.4,[!
+45-$:(,&64,[! ,(7! ,! 7'1-'..'7! (,.,)! =-47:'! 5,%.4(:! (,--$>! 56$,(,)! .4F'[! ,7'($&$(.4)),-!
6B1'-&-$16B[! 64:6! 1,),&'! ,(7! ,4->,B! +%.5)'.! 6B1$&$(4,! 4(! 4(D,(5B! ,-'! ,))! -4.T! D,5&$-.!
5$(&-4=%&4(:!&$!&6'!64:6!1-'@,)'(5'!$D!?#K#!4(!&6'.'!1,&4'(&."/2;!
^6'!+$.&! 5$++$(! ('%-$+%.5%),-! 1-$=)'+.! 5$(&-4=%&4(:! &$! #AC! ,-'! ,)&'-,&4$(.! 4(!+%.5)'!
&$('! ]'4&6'-! 6B1$&$(4,! $-! 6B1'-&$(4,_;! e4@'(! &6'! ),-:'! 6'&'-$:'('4&B! $D! &6'.'! 74.',.'.[!
4(@$)@4(:! @4-&%,))B! ,(B! 1,-&! $D! &6'! ('-@'! ,(7! +%.5)'[! &6'! 1,&6$16B.4$)$:B! $D! #AC! @,-4'.!
),-:')B! ,55$-74(:! &$! &6'! 74DD'-'(&! 1,&6$)$:45,)! ,)&'-,&4$(;! d$-! 4(.&,(5'[! 74.$-7'-.! >4&6!
1-$+4('(&! 5-,(4,)! ('-@'.! 4(@$)@'+'(&! +,B! )',7! &$! %11'-! ,4->,B.! 5$)),1.'! >4&6! ,!
1-'7$+4(,(&! 1,&&'-(! $D! ?#K#[! >6'-',.! 4(@$)@'+'(&! $D! &6'! -'.14-,&$-B! +%.5)'.! +,B! 5,%.'!
($5&%-(,)! ,)@'$),-!6B1$@'(&4),&4$(! 4(! &6'!,=.'(5'!$D!$=.&-%5&4@'!'@'(&.;!^6'!($-+,)! )$..!$D!
+%.5)'! &$('!7%-4(:!`Xc!.)''1!7'5-',.'.! &6'! -4=! 5,:'! 5$(&-4=%&4$(!&$! &6'! &47,)! @$)%+'! &$!q!
"mk[!5$+1,-'7!&$!&6'!q!M/k!$=.'-@'7!7%-4(:!>,T'D%)('..!,(7!O%4'&!.)''1"/M;!#%.5'1&4=4)4&B!
$D! &6'! 74DD'-'(&! -'.14-,&$-B! +$&$-! ('%-$(.! &$! `Xc! ,&$(4,! @,-4'.! >47')B[! >4&6! &6'! )',.&!
7'1-'..4$(!$D!-'.14-,&$-B!+%.5)'!$%&1%&!D$%(7!4(!&6'!16-'(45!('-@'!,(7!&6'!+$.&!.%11-'..4$(!
4(! 4(.14-,&$-B! ),-B(:',)[! '914-,&$-B! 16,-B(:',)[! ,(7! 4(.14-,&$-B! ,(7! '914-,&$-B! 4(&'-5$.&,)!
('-@'!,5&4@4&4'."/b;!^6'-'D$-'[!&6'!56'.&!>,))!'95%-.4$(!4(!`Xc!.)''1!7'1'(7.!1-'7$+4(,(&)B!
$(! &6'! 1-'.'-@'7! 74,16-,:+! D%(5&4$("/f;! ^6%.[! 74.',.'.! >4&6! ,! 1-$+4('(&! 74,16-,:+,&45!
! "m!
4(@$)@'+'(&!+,(4D'.&!>4&6!1-'7$+4(,(&!`Xc!.)''1!6B1$@'(&4),&4$(;!d4(,))B[!56-$(45!56,(:'.!
4(!+%.5)'!&$('!+,B!6,@'!.4:(4D45,(&!'DD'5&.!$(!:-$>&6!,(7!7'@')$1+'(&!$D!&6'!D,54,)!.T')'&$([!
&6'-'=B!,DD'5&4(:!%11'-!,4->,B!1,&'(5B!,(7!&6%.!?#K#;!
d4(,))B[! ,(&6-$1$+'&-45! ,(7! 7'+$:-,1645! @,-4,=)'.! ,-'! ,).$! 5$--'),&'7! &$!?#K#! 4(! 564)7-'(;!
c,)'!.'9!6,.!=''(!-'1$-&'7!,.!,!1-'74.1$.4(:!D,5&$-!D$-!?#K#!=B!&>$!'147'+4$)$:45,)!.&%74'.[!
>6'-',.! $&6'-! '@47'(5'.! .%::'.&! ,! .4+4),-! 1-'@,)'(5'! 4(! =$&6! .'9'."/h["/0;! X@'(! 4D! &64.!
4(5-',.'7!1-'@,)'(5'! 4(!=$B.!4.!($&!5$(D4-+'7!.$! D,-[!,!.&-$(:!5$--'),&4$(!='&>''(!+,)'!.'9!
,(7! 1'-.4.&'(&! ?#K#! ,D&'-! ,7'($&$(.4))'5&$+B! 6,.! =''(! 5)',-)B! 7'+$(.&-,&'70b["/m;! ! K).$[!
'&6(454&B!1-'74.1$.'!&$!&6'!7'@')$1+'(&!$D!?#K#!>4&6!KD-45,(!K+'-45,(!6,@4(:!,!64:6'-!-4.T!
$D!?#K#!5$+1,-'7!&$!3,%5,.4,(!,(7!K.4,(!'&6(454&4'.""/;!
!
%
%
%
%
%
%
%
! */!
VR! </565-4/)D465F072425.67).F)':G)
!
3)4(45,)!+,(4D'.&,&4$(.! $D! #AC! 4(! 564)7-'(! 74DD'-! D-$+! ,7%)&.;! 364)7-'(! &'(7! &$!6,@'! ,!+%56!
+$-'! @,-4'7! 5$(.&')),&4$(! $D! .B+1&$+.[! $D&'(! 74DD45%)&! &$! -'5$:(4F';! H(! 5$(&-,.&! &$! ,7%)&.[!
($-+,)!564)7-'(!.($-'! 4(D-'O%'(&)B;!^64.! 4.!5$(.4.&'(&!>4&6!&6'!='&&'-!1-'.'-@,&4$(!$D!%11'-!
,4->,B!1,&'(5B!4(!5,.'!$D!.%=,&+$.16'-45!1-'..%-';!X95'..4@'!7,B&4+'!.)''14('..[!>6456!4.!,!
6,))+,-T!$D!1$$-! .)''1!O%,)4&B! 4(!,7%)&.[! 4.! -,-')B!$=.'-@'7! 4(! 564)7-'(!>4&6!#AC""";!`,&6'-[!
564)7-'(! &'(7! &$! ='! 6B1'-,5&4@';! K).$[! .B+1&$+.! '@$)@'! ,(7! 56,(:'! >4&6! ,:'! ,.! .6$>(! 4(!
^,=)'!2;!#$+'!.B+1&$+.!,-'!$=.'-@'7!,&!,(B!,:'[!.%56!,.!(4:6&<&4+'!,>,T'(4(:.[!>64)'!$&6'-!
.B+1&$+.!,-'!+$-'!5$++$(!4(!.$+'!,:'!:-$%1.;!!
#($-4(:! 4.!%.%,))B!($&!1-'.'(&! 4(! 4(D,(&.[!=%&! 1,-'(&.! -'1$-&! D-'O%'(&)B!,! i($4.Bj!=-',&64(:[!
.($-&4(:!$-!:,.14(:;!G$$-!.%5T4(:!$-!74DD45%)&!D''74(:!+,B!='!-'),&'7!&$!6B1$&$(4,[!>6456!4.!,!
-4.T! D,5&$-! D$-! #AC! 4(! &64.! B$%(:'-! ,:'! :-$%1;! #&-47$-! $-! :,.14(:! 4.! $D&'(! -'1$-&'7! 4(! &6'!
1-'.'(5'! $D! ),B(:$+,),54,! $-! @$5,)! 5$-7! 1,-,)B.4.;! K! 64.&$-B! $D! =-4'D! -'.$)@'7[! %('91),4('7!
'@'(&.!+,B!='!,..$54,&'7!>4&6!&6'!1-'.'(5'!$-!&6'!7'@')$1+'(&!$D!?#K#"";!
H(! &$77)'-.[!.($-4(:!+,B! 4(4&4,))B!$55%-! 4(! &6'!.%14('!1$.4&4$([!=%&!,.! &6'! .'@'-4&B!$D! ,4->,B!
$=.&-%5&4$(! 4(5-',.'.[! .($-4(:! +,B! ='! $=.'-@'7! 4(! ,(B! .)''14(:! 1$.4&4$(;! H(! &64.! ,:'[! &6'!
1,-'(&.!+,B!-'1$-&!,1(',.!,(7!74DD45%)&!=-',&64(:[!$D&'(!7'.5-4='7!,.!1,-,7$945,)!+$@'+'(&.!
$D! &6$-,545! 5,:'! 7%-4(:! 4(.14-,&4$(! ,)$(:! >4&6! -'&-,5&4$(.;! K=($-+,)! .)''1! 1$.4&4$([! >4&6!
6B1'-'9&'(.4$(!$D! &6'!('5T[!+$%&6!=-',&64(:[!,:4&,&4$(!7%-4(:!.)''1!,(7!'95'..4@'!.>',&4(:!
,-'! ,).$! -'1$-&'7;! d4(,))B[! 1,-'(&.! +,B! ,5T($>)'7:'! .&,B4(:! ,>,T'! 7%-4(:! &6'! (4:6&! &$!
+$(4&$-! &6'! =-',&64(:! $D! &6'4-! 564)7[! 4(! $-7'-! &$! .&4+%),&'! 64+V6'-! 7%-4(:! .)''1! 4(! 5,.'! $D!
,=($-+,)!=-',&64(:;!!
H(!1-'<.56$$)!564)7-'([!.B+1&$+.!$D!#AC!,-'!.4+4),-!&$!&6$.'!$=.'-@'7!4(!&$77)'-.;!Q$>'@'-[!
,.!&6'!564)7-'(!.&,-&!T4(7'-:,-&'(!,(7!(''7!&$!,7,1&!&$!,!.)''1!-$%&4('[!74DD45%)&!,>,T'(4(:.!
7%'! &$! .)''14('..! ='5$+'! +$-'! ,11,-'(&;! H(! &64.! ,:'[! .'5$(7,-B! '(%-'.4.! (''7.! &$! ='!
4(@'.&4:,&'7;!
H(!.56$$)<,:'!564)7-'([!.($-4(:[!(4:6&!,>,T'(4(:.!,(7!+$%&6!=-',&64(:!,-'!5$++$(;!J',-(4(:!
74DD45%)&4'.! .'5$(7,-B! &$! 1$$-! 5$(5'(&-,&4$(! ,(7! 4+1,4-'7! .6$-&<&'-+! +'+$-B! ='5$+'!
,11,-'(&;!A,B&4+'!.B+1&$+.!+,B!4(5)%7'!(,.,)!$=.&-%5&4$([!+$%&6!=-',&64(:!$-!$&6'-!.4:(.!
$D!,7'($&$(.4)),-!6B1'-&-$16B[!>6456!5$(D4:%-'!&6'!.$<5,))'7!i,7'($47<D,54'.j!]d4:%-'!*_;!!!
H(!,7$)'.5'(&.!,(7!B$%(:!,7%)&.[!,(!i,7%)&j!1-'.'(&,&4$(!>4&6!.($-4(:!,(7!7,B&4+'!.)''14('..!
4.!5$++$(;!c$-'$@'-[!+$$7!74.&%-=,(5'.!.%56!7'1-'..4$(!,(7!,(94'&B!+,B!$55%-!,(7!,DD'5&!
O%,)4&B!$D!)4D';!
! *"!
#B+1&$+.!$D! #AC!,-'!+$-'!74DD45%)&! &$!7'&'5&! 4(! 564)7-'(!>4&6! &B1'!2!?#K#;!G$$-! D''74(:! 4.!
%.%,))B!1-'.'(&!,&!=4-&6!4(!G-,7'-!E4))4!.B(7-$+'!,(7!G4'--'!`$=4(!.'O%'(5'!4--'.1'5&4@')B!$D!
&6'!1-'.'(5'!$-!&6'!.'@'-4&B!$D!&6'!%11'-!,4->,B!$=.&-%5&4$(;!#)''1!,:4&,&4$(!,(7!,>,T'(4(:.!
,-'! 5$++$(! 4(! 564)7-'(!>4&6!('%-$)$:45,)!74.',.'.! .%56!,.!'14)'1.B;!A,B&4+'!,:4&,&4$(!,(7!
4(&'))'5&%,)! 74.,=4)4&B! ,-'! 1-'.'(&! 4(! .'@'-,)! :'('&45! 74.',.'.! .%56! ,.! A$>(! .B(7-$+'! ,(7!
G-,7'-!E4))4!.B(7-$+'!>6456!64(7'-.!&6'!'@,)%,&4$(!$D!&6'!.1'54D45!4+1,5&!$D!.)''1!,1(',.!4(!
&6'.'!564)7-'(;!!
E64)'!+$.&!564)7-'(!>4&6!?#K#!6,@'!,!($-+,)!16B.45,)!'9,+4(,&4$(!4(!&B1'!"!?#K#[!.'@'-,)!
5)4(45,)! ,=($-+,)4&4'.! +,B! ='! $=.'-@'7;! ^6'.'! +,B! 1-$@47'! 74-'5&! $-! 4(74-'5&! '@47'(5'! $D!
4(5-',.'7!%11'-!,4->,B!-'.4.&,(5'!,(7!:%47'!&6'!74,:($.4.!,(7!&6'!1$&'(&4,)!5$+1)45,&4$(.!$D!
#AC;!
^6'!564)7r.!6'4:6&!,(7!>'4:6&!.6$%)7!='!1)$&&'7!$(!,!.&,(7,-7!:-$>&6!56,-&!='5,%.'!D,4)%-'!&$!
&6-4@'!+,B!='!$=.'-@'7!4(!.$+'!564)7-'(!>4&6!.'@'-'!?#K#;!C$7B!+,..!4(7'9!]CcH_!.6$%)7!='!
5,)5%),&'7! ,(7! '@,)%,&'7! D$))$>4(:! .1'54D45! ,:'<-'),&'7! 1'-5'(&4)'.[! .4(5'! $@'->'4:6&! ,(7!
$='.4&B!,-'!,(! 4+1$-&,(&! -4.T! D,5&$-! D$-!?#K#;!C)$$7!1-'..%-'!.6$%)7!='!+',.%-'7!,&! '@'-B!
16B.45,)!'9,+4(,&4$(!,.!?#K#!-'1-'.'(&.!,!-'5$:(4F'7!-4.T!D,5&$-!D$-!.B.&'+45!6B1'-&'(.4$(;!
I11'-!,4->,B!,(,&$+B!.6$%)7!='!5,-'D%))B!'@,)%,&'7!.',-564(:!D$-!5-,(4$D,54,)!,=($-+,)4&4'.!
)4T'!+47D,5'!6B1$1),.4,[!-'&-$:(,&64,!,(7V$-!+45-$:(,&64,;!c$%&6!=-',&64(:[!i,7'($47j!D,54'.[!
(,.,)! ,4-D)$>! $=.&-%5&4$(! $-! 6B1$(,.,)! .1''56! +,B! ='! D',&%-'.! $D! ,7'($47,)! 6B1'-&-$16B[!
>6456!+,B!5$(&-4=%&'!&$!$-!5,%.'!?#K#;!c%5$.,)!$-!&%-=4(,&'!.>'))4(:!.%::'.&.!56-$(45!(,.,)!
5$(:'.&4$([!>6456!+,B!='!,))'-:45;!#'1&,)!7'@4,&4$(!.6$%)7!,).$!='!,5&4@')B!.',-56'7;!!
K=($-+,)! +,94))$+,(74=%),-! 7'@')$1+'(&! )4T'! ,! 64:6<,-56'7! ,(7! (,--$>! 6,-7! 1,),&'[! ,!
5-$..=4&'[! $@'-),114(:! 4(54.$-.[! ,(7! .4:(4D45,(&! $@'-=4&'! .6$%)7! ='! ($&'7;! c,5-$:)$..4,[! ,.!
$=.'-@'7! 4(!A$>(!.B(7-$+'[!E4'7'+,((!C'5T>4&6! .B(7-$+'! ,(7!+%5$1$)B.,556,-47$.'.[!
+,B!-'7%5'!&6'!5,)4='-!$D!&6'!%11'-!,4->,B;!#4(5'!&$(.4)),-!6B1'-&-$16B!4.!,!+,Z$-!5$(&-4=%&$-!
&$!#AC!4(!564)7-'([!&$(.4).!.4F'!.6$%)7!='!'@,)%,&'7!>4&6!&6'!c,)),+1,&4!5),..4D45,&4$(!,(7!&6'!
d-4'7+,(!.5$-'!]d4:%-'!2_;!!
3)4(45,)!'9,+4(,&4$(!4.!,).$!4+1$-&,(&!4(!&B1'!*!,(7!2!?#K#!:-$%1.;!Q$>'@'-[!4(!&6'.'!5,.'.!,!
+$-'!5$+1-'6'(.4@'!>$-T<%1!4.!>,--,(&'7;!d$-!4(.&,(5'[!.$+'!$D!&6'.'!564)7-'(!5$%)7!6,@'!
&%-=4(,&'! $-! )4(:%,)! &$(.4).! 6B1'-&-$16B[! $-! ,..$54,&'7! ),-B(:',)! $-! &-,56',)!+,)D$-+,&4$(.!
&6,&!-'O%4-'7!,(!'(7$.5$145!$-!-,74$)$:45,)!'@,)%,&4$(;!!
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! ""!
#$%&'!()!*+,-./,0!/1!0&''-!230/42'4'2!%4'$.5367!36!853&24'6!%+!$7'!
!"#$"%&'()*+,'-."%/&0' 1.22345&'(+*)'650' 754*&8/..3'()*9'650' :8/..3'(9*+;'650'
-! 9/30+!%4'$.5367!
-! :3.6'00'2!$-6'$0!
-! ;4'<='6.!$4/=0$&0!
-! >31138=&.!%4'$.5367!!
-! ?/=.5!%4'$.5367!
-! 9/8.=46$&!0@'$.367!
-! ;$3&=4'!./!.543A'!
-! 9$0$&!8/67'0.3/6!
-! B+-'4'C.'62'2!6'8D!!
-! E//4!0=8D367!
-! *.432/4!
-! F4'$.55/&2367!0-'&&0!
-! *6/4367!
-! :3.6'00'2!$-6'$0!
-! ;4'<='6.!$4/=0$&0!
-! >31138=&.!%4'$.5367!!
-! ?/=.5!%4'$.5367G24+!,/=.5!
-! 9/8.=46$&!0@'$.367!
-! ;$3&=4'!./!.543A'!
-! 9$0$&!8/67'0.3/6!
-! B+-'4'C.'62'2!6'8D!
-! H'0.&'00!0&''-!!
-! *&''-!.'44/40!
-! I/61=03/6$&!$4/=0$&!
-! J443.$%3&3.+!!
-! >$+.3,'!0&''-36'00!!
-! *6/4367!
-! :3.6'00'2!$-6'$0!
-! ;4'<='6.!$4/=0$&0!
-! ?/=.5!%4'$.5367G24+!,/=.5!
-! 9/8.=46$&!0@'$.367!
-! ;$3&=4'!./!.543A'!
-! 9$0$&!8/67'0.3/6!
-! B+-'4'C.'62'2!6'8D!!
-! *&''-!.'44/40!
-! I/61=03/6$&!$4/=0$&!
-! *&''-@$&D367!
-! >$+.3,'!0&''-36'00G!-'4030.'6.!6$-0!
-! H'0.&'00!0&''-!
-! K6=4'030!
-! B+-'4$8.3A3.+L!36$..'6.3/6!!
-! >31138=&.+!@$D367!=-!36!,/46367!
-! ?/46367!5'$2$85'!
-! *&''-!36!D6''M85'0.!-/03.3/6!
-! *6/4367!
-! :3.6'00'2!$-6'$0!
-! ;4'<='6.!$4/=0$&0!
-! ?/=.5!%4'$.5367G24+!,/=.5!
-! 9/8.=46$&!0@'$.367!
-! ;$3&=4'!./!.543A'!
-! 9$0$&!8/67'0.3/6!
-! B+-'4'C.'62'2!6'8D!!
-! 9375.,$4'0!
-! *&''-.$&D367!
-! I/61=03/6$&!$4/=0$&!
-! *&''-@$&D367!
-! >$+.3,'!0&''-36'00!
-! H'0.&'00!0&''-!
-! K6=4'030!
-! B+-'4$8.3A3.+L!36$..'6.3/6!!
-! >31138=&.+!@$D367!=-!36!,/46367!!
-! ?/46367!5'$2$85'!
-! J60/,63$!
-! N'$46367!231138=&.3'0!
-! >'&$+'2!-=%'4.+!
-! ?//2!230/42'40!
-! B+-'4.'603/6!
'
'
<2$=%42'#5.-'54#454"84'++,>'
'
! "#!
$%&'()!"*!+,%-.!/%0,!1!023%41-!51.)67%.8!914%)8:*!!
!
;70)!0,)!3()8)64)!79!61((7/!3%64,).!6780(%-8<!73)6!=7'0,<!)>)(0).!'33)(!-%3!16.!0,)!-788!79!
6187-1?%1-!97-.8*!!
!"#$%&"'()*+')&(&)&,-&'../'
!
!
!
!
!
!
!
!
!
!
"@
!
$%&'()!#*!A768%-8!&(1.%6&!?2!0,)!B1--1=310%!847()!
!
A768%-!8%C)!%8!&(1.).!76!1!841-)!9(7=!D!07!EF!
D!G A768%-8!1()!)60%()-2!/%0,%6!0,)!0768%--1(!3%--1(<!H7(!3()>%7'8-2!()=7>).!?2!8'(&)(2I*!
JK!G! A768%-8! 744'32! -)88! 0,16! "E! 3)(4)60! 79! 0,)! -10)(1-! .%=)68%76! 79! 0,)! 7(73,1(26L<! 18!
=)18'().!?)0/))6!0,)!160)(%7(!0768%--1(!3%--1(8!H87-%.!2)--7/!1((7/I*!
"K!G!A768%-8!744'32!"M!07!ED!3)(4)60!79!0,)!-10)(1-!.%=)68%76!79!0,)!7(73,1(26L*!
#K!G!A768%-8!744'32!EJ!07!NE!3)(4)60!79!0,)!-10)(1-!.%=)68%76!79!0,)!7(73,1(26L*!
@K!G!A768%-8!744'32!=7()!0,16!NE!3)(4)60!79!0,)!-10)(1-!.%=)68%76!79!0,)!7(73,1(26L*!
!"#$%&"'()*+')&(&)&,-&'..0*!
!
!
!
!
!
"E
!
$%&'()!@F!O(1.%6&!79!0,)!3,1(26&)1-!8314)!?2!0,)!$(%).=16!847()*!!
!
!"#$%&"'()*+')&(&)&,-&'..1'
!
!
!
!
!
!
! "M!
"#! $%&'()*(&+('!%,!-./!0&!+10234(&!
!
A,)!4768)P')64)8!79!QRS!%6!4,%-.()6!1()!='-0%914)0).*!T9!'60()10).<!7(!1-0)(610%>)-2!%9!0()10).!
-10)<! 3).%10(%4! QRS!=12! 41'8)! 8'?80160%1-!=7(?%.%02! 0,10! 199)408!='-0%3-)! 01(&)0! 7(&168! 16.!
8280)=8*! T=37(0160-2<! 87=)! .)-)0)(%7'8! 4768)P')64)8! 7?8)(>).! %6! 4,%-.()6! =12! 670! ?)!
47=3-)0)-2! ()>)(8%?-)! )>)6! 190)(! 133(73(%10)! 0()10=)60*! U?80('40%>)! QRS! %6! 4,%-.()6! 416!
47=3(7=%8)!87=10%4!&(7/0,<!-)1.!07!6)'(747&6%0%>)!.%80'(?164)8<!-)1(6%6&!.)9%4%08<!%=31%().!
?),1>%7'(<! 41(.%7>184'-1(! 16.!=)01?7-%4!=7(?%.%02<! 16.! .)4()18).! P'1-%02! 79! -%9)*!V7/)>)(<!
670!1--!4,%-.()6!/%--!=16%9)80!1--!0,)!4768)P')64)8!79!QRS*!T0!%8!0,)()97()!()18761?-)!07!188'=)!
0,10! %6! 1..%0%76! 07! 0,)! 8)>)(%02! 79! 0,)! '6.)(-2%6&! 8-))3! .%87(.)(<! 87=)! &)6)0%4! 16.!
)6>%(76=)601-! 91407(8! =12! 3-12! 1! 4(%0%41-! (7-)! %6! 0,)! 8'84)30%?%-%02! 07! )6.W7(&16! %6X'(2*!
B7()7>)(<! 4768)P')64)8! 79! QRS!,1>)! ?))6!/)--!.)84(%?).! %6! 023)! J!UQYQ! ?'0!='4,! -)88! %6!
4,%-.()6!79! 0,)! 023)!"!16.! 023)!#!UQYQ!&(7'38*!A,)8)! 4,%-.()6!790)6!3()8)60! 47=7(?%.%0%)8!
.)(%>%6&! 9(7=! 0,)%(! '6.)(-2%6&! .%8)18)*! A,)()97()<! 0,)! )L140! (7-)! 79! UQYQ! ()-10).!
4768)P')64)8! 16.!=780! %=37(0160-2<! 0,)%(! ()>)(8%?%-%02!/%0,! 0()10=)60<! ()3()8)60! 0,)!=1%6!
4764)(6!97(!0,)8)!0/7!&(7'38!79!310%)608*!!
!
2&3)*$45-6*7*89-#7'#,"'-*8,9%9:&'$)*;7&+4'#44*-9#%&"'<9%6'=>?'
'
A,)! ?),1>%7'(1-! 16.! 141.)=%4! 4768)P')64)8! 79! 8-))3! 9(1&=)6010%76<! %64-'.%6&! %6100)60%76<!
,23)(140%>%02<! %=3'-8%>%02<! 16.! %((%01?%-%02<! =12! ?)! 0,)! 3(%=1(2! 3()8)60%6&! 47=3-1%608! %6!
4,%-.()6!/%0,!QRS<!/,10)>)(!0,)!8)>)(%02<!%64-'.%6&!ZQ*!!
UQYQ!%6!4,%-.()6!,18!?))6!18874%10).!/%0,!6)'(7?),1>%7(1-!82=307=8!?2!=162!1'0,7(8JJM[J"D*!
\]L0)(61-%C%6&\! ?),1>%7'(8! 1()! 31(0%4'-1(-2! 9()P')60<! %64-'.%6&! 1&&()88%>%02<! %=3'-8%>%02<!
,23)(140%>%02<! 73378%0%761-! ?),1>%7'(<! 16.! 476.'40! 3(7?-)=8J"J<J""*! U3378%0%761-W.)9%160!
.%87(.)(! 16.! 476.'40! .%87(.)(8! 7(! ()-10).! .%8('30%>)! ?),1>%7'(8! 8'4,! 18! ?'--2%6&! 1()! 1-87!
47==76! 4768)P')64)8! 79! 3).%10(%4! QRSJ"#<J"@*! U0,)(! 1-0)(10%768! %64-'.)! )=70%761-!
.28()&'-10%76! 16.! \%60)(61-%C%6&\! ?),1>%7'(8! 8'4,! 18! %((%01?%-%02<! =77.! %6801?%-%02<! -7/!
9('80(10%76! 07-)(164)<! .)3()88%76^16L%)02<! 874%1-! /%0,.(1/1-<! 16.! %64()18).! 87=10%4!
47=3-1%608*!\+-188%4\!82=307=8!79!)L4)88%>)!.120%=)!8-))3%6)88!H)*&*<!.%99%4'-02!/1_%6&!%6!0,)!
=7(6%6&<! 91--%6&!18-))3!10! %6133(73(%10)! 0%=)8<!7(! %64()18).!6133%6&I!1()! 47==76! %6!1.'-08!
/%0,!UQYQ!?'0! 0)6.! 07!?)! -)88!7?>%7'8! %6! 4,%-.()6<! )L4)30! %6!1.7-)84)608<!7?)8)! 4,%-.()6!7(!
0,78)!/%0,!8)>)()!QRS*!!
! "N!
A,)! )>%.)64)! ()&1(.%6&! 0,)! )99)40! 79!UQYQ! 76! 47&6%0%76! %8! -)88! (7?'80! 0,16! 97(! ?),1>%7'(1-!
=16%9)8010%768*! Y! 6'=?)(! 79! 80'.%)8! ,1>)! 8'&&)80).! 16! 18874%10%76! ?)0/))6! UQYQ! 16.!
%=31%().!)L)4'0%>)! 9'640%768! 8'4,!18! 018_8! %6>7->%6&!()140%76! 0%=)<! >%&%-164)<! 16.! 8'801%6).!
16.! 8)-)40%>)! 100)60%76<! %6! 70,)(/%8)! ,)1-0,2! 4,%-.()6JJM<JJN! 16.! %6! 0,78)! /%0,! '6.)(-2%6&!
6)'(747&6%0%>)!.)9%4%08!8'4,!18!R7/6!826.(7=)ND<J"N*!V7/)>)(<!70,)(!1()18!79!%=31%(=)60!1()!
670!4768%80)60!14(788!80'.%)8*!B780!80'.%)8!,1>)!91%-).!07!9%6.!1!.78)W.)3)6.)60!()-10%768,%3!
?)0/))6! 3).%10(%4! UQYQ! 8)>)(%02! 16.! 0,)! .)&())! 79! 47&6%0%>)! H7(! ?),1>%7'(1-I! %=31%(=)60*!
Q7=)!47&6%0%>)!.)9%4%08<!8'4,!18! -16&'1&)!.)-12!16.! %=31%(=)60! %6!>%8'1-!3)(4)30%76<!=707(!
9'640%76<!16.!=)=7(2<!,1>)!?))6! %.)60%9%).! %6!>)(2!27'6&!4,%-.()6!/%0,!76-2!=%-.!QRS*!$7(!
)L1=3-)<!%691608!/%0,!3)(8%80)60!,1?%0'1-!867(%6&!,1>)!?))6!97'6.!07!,1>)!-7/)(!847()8!76!1!
8016.1(.%C).!=)18'()!79!%69160^07..-)(!.)>)-73=)60!HS12-)2!847()8IJ"`*!
V7/)>)(<! %0! %8! -%_)-2! 0,10! 0,)! 18874%10%76! ?)0/))6! UQYQ! 16.! ?),1>%7'(1-! 7(! 47&6%0%>)!
.289'640%76! =12! ,1>)! ?))6! 47697'6.).! ?2! 70,)(! 91407(8! 0,10! 1-87! %64()18)! 0,)! (%8_! 79!
47&6%0%>)!%=31%(=)60<!%64-'.%6&!47=7(?%.!476.%0%768!H3()=10'(%02<!'6.)(-2%6&!.%87(.)(8!16.!
47W744'(()64)!/%0,!70,)(!8-))3!.%87(.)(8Ia!)6>%(76=)601-!16.!874%74'-0'(1-!%69-')64)8!H8,7(0!
8-))3!.'(10%76<!)L378'()!07!)6>%(76=)601-!8=7_)<!16.!)4767=%4!.%81.>1601&)Ia!16.!&)6)0%4!
8'84)30%?%-%02*!
!
@&%#;*79-'-*,4&A3&,-&4'
!
T68'-%6!()8%80164)<!.28-%3%.1)=%1<!,23)(0)68%76<!16.!7?)8%02!()3()8)60!1!4-'80)(!79!476.%0%768!
%64-'.).! %6! 0,)! .)9%6%0%76! 79! 5=)01?7-%4! 826.(7=):*! U?)8%02! %8! 1! (%8_! 91407(! 79! =)01?7-%4!
826.(7=)!)>)6!%6!0,)!31).%10(%4!373'-10%76<!8%64)!)>)(2!D*E!'6%0!%64()=)60!%6!SBT!H476>)(0).!
07! 1! b! 847()I! %64()18)8! 0,)! (%8_! 79! =)01?7-%4! 826.(7=)! ?2! 6)1(-2! EDc130*! UQYQ! ,18! ?))6!
%.)60%9%).! 18! 16! %=37(0160! (%8_! 91407(! 97(! 0,)! 744'(()64)! 79! =)01?7-%4! 826.(7=)! %6! 1.'-0!
310%)608J#D<J#J! ?'0! 670! %6! 4,%-.()6J#"<J##*! V7/)>)(<! 8%=%-1(! 07! 1.'-08!/,)6! 7?)8%02! 16.! UQYQ!
47%64%.)!%6!4,%-.()6<!0,)8)!0/7!476.%0%768!4760(%?'0)!07!%6.'4)!=)01?7-%4!.%80'(?164)8J#@<J#E*!
+769-%40%6&!.101!)L%80!76!0,)!(7-)!79!UQYQW.(%>)6!%69-1==10%76!%6!0,)!41(.%7>184'-1(!=7(?%.%02!
79!UQYQ!%6!4,%-.()6*!Q)('=!'(%4!14%.<!1!()-%1?-)!=1(_)(!79!7L%.10%>)!80()88<!/18!97'6.!)-)>10).!
%6!1!&(7'3!79!7>)(/)%&,0!4,%-.()6<!/%0,!1!8%&6%9%4160!()-10%768,%3!?)0/))6!0,)!8)>)(%02!79!UQYQ!
16.! 8)('=! '(%4! 14%.! -)>)-8J#M<! 16.! 1! 67(=1-%810%76! 79! '(%4! 14%.! 190)(! 0()10=)60J#N*! Y6!
%6.)3)6.)60! %60)(140%76!?)0/))6!6740'(61-! %60)(=%00)60!,237L%1!16.! %64()18).!/,%0)!?-77.!
4)--! 16.! 6)'0(73,%-! -)>)-8! %6! 7>)(/)%&,0! 16.! 7?)8)! 4,%-.()6! 16.! 1.7-)84)608! ,18! 1-87! ?))6!
.)=7680(10).J#`*!
! "`!
;)>)(0,)-)88!+W()140%>)!3(70)%6! H+dZI<! 1!=1(_)(!79! 8280)=%4! %69-1==10%76!790)6!)-)>10).! %6!
1.'-08!/%0,!UQYQ<!/18!97'6.!07!?)!67(=1-!%6!0,)8)!4,%-.()6*!
!
B#)"9*:#4-37#)'-*+*);9"9%9&4'
'
+1(.%7>184'-1(! 47=3-%410%768! 1()! 1! =1X7(! UQYQ! =7(?%.%02! %6! 1.'-08*! T6! 4,%-.()6<! .101! 1()!
841(4)<! 16.! 0,)! -76&W0)(=! )99)408!79!UQYQ! 1()!.%99%4'-0! 07! 188)88! &%>)6! 0,)! -14_! 79! -76&! 0)(=!
97--7/W'3*!V7/)>)(<!4,%-.()6!/%0,!8)>)()!'60()10).!UQYQ<!.)9%6).!18!16!YVT!79!=7()!0,16!E!
)>)608^,<!,1>)!16!%64()18).!3()>1-)64)!79!8280)=%4!,23)(0)68%76!/%0,!16!7..!(10%7!79!#*e!97(!
82807-%4!16.!#*#!97(!.%1807-%4!,23)(0)68%76J#e*!T60)()80%6&-2<!%6!1!&(7'3!79!JDJ!4,%-.()6<!1&).!M!
07!J#!2)1(8<!8)>)()!UQYQ!H.)9%6).!18!16!YVT!,%&,)(!0,16!E!)>)608^,I!/18!18874%10).!/%0,!1!
-7/)(!(%&,0!>)60(%4'-1(!)X)40%76! 9(140%76<! %64()18).! -)90! >)60(%4'-1(!.%1807-%4!.289'640%76!16.!
41(.%14! ()=7.)-%6&! /%0,! -1(&)(! %60)(>)60(%4'-1(! 8)301-! 0,%4_6)88! %6.)L! 76! 0,)!
)4,741(.%7&(1=<! %6.)3)6.)60! 79! 0,)! 3()8)64)! 79! 7?)8%02J@D*! $'(0,)(=7()<! 87=)! 79! 0,)!
41(.%7>184'-1(!47=7(?%.%0%)8!18874%10).!/%0,!UQYQ!0)6.!07! %=3(7>)!/%0,!0()10=)60*! T6.)).<!
0,)!()&'-1(!'8)!79!+ZYZ!97(!M!=760,8!%6!4,%-.()6!/%0,!UQYQ!/18!1?-)!07!8%&6%9%4160-2!().'4)!
82807-%4!3()88'()J@J*!+764)(6%6&!0,)!3788%?-)!4760(%?'0%76!79!UQYQ!07!41(.%7>184'-1(!.%8)18)8<!
%0! ,18! ?))6! 8,7/6! 0,10! -%3%.! 3)(7L%.10%76! -)>)-8! 47(()-10).!/%0,! 0,)! .)&())! 79! %60)(=%00)60!
,237L%1! %6! 4,%-.()6J@"<! 3788%?-2! 4760(%?'0%6&! 07! )6.70,)-%1-! .289'640%76J@#<J@@! 16.! 07! -10)(!
41(.%7>184'-1(!=7(?%.%02*!
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a b s t r a c t
Objectives: The accuracy of respiratory polygraphy (RP) is limited because of the absence of electroen-
cephalography (EEG). Pulse wave amplitude (PWA) reduction has been shown to be a marker of auto-
nomic activation during arousal, and may represent a substitute for obstructive respiratory-related
cortical arousal (RRCA). This study tested the hypothesis that PWA could be a surrogate for RRCA in
detecting obstructive hypopnea (OH) in a pediatric population.
Materials and methods: Two experienced readers scored 30 consecutive polysomnographies (PSG) using
standard scoring rules. Automatic software detected every 20e90% reduction in PWA. A second scoring
of respiratory events using PWA reduction as a surrogate for RRCA was performed (RP with PWA) for
each percentage of PWA reduction. The ﬁnal analysis consisted of determining the concordance between
the two methods of detecting OH.
Results: A total of 987 episodes of !30% ﬂow reduction were analyzed: 330 with RRCA only, 205 with
desaturation (DS) only, 134 with both, and 318 without RRCA or DS. As the percentage of reduction in
PWA increased, the sensitivity of PWA as a substitute for RRCA decreased, but the speciﬁcity increased.
For a decrease in PWA of 60% or 70%, the sensitivities of PWA as a substitute for RRCA were 79% and 57%,
and the speciﬁcities 51% and 76%, respectively.
Conclusion: Pulse wave amplitude reduction lacks sensitivity and speciﬁcity to be used as a surrogate for
RRCA to detect OH in children. Polysomnography remains the gold standard for the diagnosis of sleep
disordered breathing in children.
© 2017 Elsevier B.V. All rights reserved.
1. Introduction
Overnight polysomnography (PSG) represents the gold standard
for diagnosing obstructive sleep apnea syndrome (OSAS) in chil-
dren and adults [1e3]. However, due to practical and economic
reasons, limited channel recordings without electroencephalog-
raphy (EEG) (respiratory polygraphy (RP), or type III recordings) are
increasingly used in adults [4,5]. RP has been shown to underesti-
mate the apneaehypopnea index (AHI) in childrenwhen compared
to PSG [6], mainly because of an incorrect estimation of total sleep
time (TST). However, sleep and wakefulness can be accurately
determined in children by using cardiorespiratory and videotape
recordings [7], which reduce this discrepancy between PSG and RP.
A second major problem when scoring obstructive respiratory
events with RP is the absence of EEG, which precludes the detection
of respiratory-related cortical arousals (RRCA) for the scoring of
obstructive hypopneas. According to the American Academy of
Sleep Medicine (AASM), obstructive hypopneas (OH) are deﬁned in
children as a drop of at least 30% of respiratory ﬂow, lasting at least
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two breaths, associated with a !3% oxygen desaturation (DS) and/
or a RRCA [8]. Therefore, in the absence of EEG tracings, hypopneas
not associated with DS are not scored, which may underestimate
the AHI [8].
Arousals cause central autonomic activation, which leads to
increased sympathetic activity and peripheral vasoconstriction [9].
Pulse wave amplitude (PWA) reduction has been shown to reﬂect
sympathetic activation during sleep [10e12] in adults, but also to
improve the diagnostic value of conventional PSG in obstructive
sleep apnea syndrome (OSAS) by better detecting respiratory
events and RRCA [13]. However, studies in children and studies
assessing PWA as a surrogate for RRCA for respiratory event
detection are still lacking.
The aim of the present study was to verify if PWA reduction
could be a surrogate for RRCA for the scoring of OH in children
referred to a sleep laboratory for suspected OSAS.
2. Material and methods
2.1. Polysomnography
The PSG of 50 consecutive children who were referred to the
sleep unit of Necker University Hospital in Paris for a suspicion of
OSAS, between March 2014 and March 2015, were analyzed. PSG
was performed using CID 102* (Cidelec, Saint Gemmes sur Loire,
France). The recorded data included airﬂow (nasal pressure trans-
ducer and oronasal thermistance), body position, bodymovements,
thoracic and abdominal movements assessed with inductance
belts, pulse oximetry (SpO2), and PWA using the Nonin pulse ox-
imeter (Nonin Medical, Inc., Plymouth, MN) with a sampling fre-
quency of 64 Hz. The EEG recordings were based on the
international 10e20 system, which includes the placement of
electrodes in positions F1-A2, F2-A1, C3-A2, C4-A1, O1-A2, O2-A1,
recording of eye movements, electromyography of the chin and
electrocardiogram. Sleep stages were obtained manually using
standard criteria [14]. Sleep arousals were deﬁned as an abrupt shift
in EEG frequency, including a theta-alpha pattern and/or a fre-
quency >16 Hz lasting!3 s with!10 s of stable sleep preceding the
event. Respiratory events were scored according to the AASM
manual and following update [8,14]. Oxygen desaturation index
(ODI) was deﬁned as the number of DS per hour of PSG recording.
2.2. Data analysis
PSG was analyzed using the Cidelec 2.2.2 software; they were
retained for analysis if sleep time lasted at least 4 h of TST and if
there were no artifacts in the EEG, PWA, and respiratory ﬂow
tracings.
A ﬁrst standard PSG scoring using the AASM scoringmanual [14]
was performed by two experienced readers: the ﬁrst reader scored
the PSG and the second validated the analysis. Percentage of PWA
reduction was added by mean of speciﬁc software developed by
Cidelec (GB), which scored each 20%e90% reduction in PWA.
Maximal PWA percentage reduction was calculated according to
the baseline amplitude of the signal within the previous 5 s. Each
PWA reduction was graphically represented with corresponding
bars on the PSG tracing (Fig. 1a). Only reductions in PWA occurring
at the time of a respiratory event or during the 5 s following the
event were retained for analysis. All the reductions in PWA caused
by artifacts of the pulse wave signal were discarded.
The second scoring, performed in a random order, consisted of a
“blind” RP scoring, without the EEG tracings but with the graphical
representation of the decrease in PWA. The two readers were thus
aware of the different percentages of reduction in PWA (from 20% to
90%). Every!30%decreaseof airﬂow(nasal pressure transducer)was
scored as an OH if it was associated with DS and/or a reduction in
PWA. Decreases in airﬂow,!30% but<90%, not associatedwith DS or
PWA reduction, were marked as respiratory events. The ﬁrst reader
scored the RP scoring and the second validated the analysis (Fig. 1b).
Lastly, the two scorings were integrated in the same tracing
(Fig. 2). A third reader, who was unaware of the results of the ﬁrst
two scorings, performed a manual comparison between the two
scorings for each percentage of maximal reduction in PWA.
The protocol was approved by the local ethical committee (CPP
Ile de France II, n# 2014-03-09 SC).
2.3. Statistical analysis
Data were presented as median and range. The sensitivity and
speciﬁcity of every percentage level of PWA reduction to detect
AASM hypopnea were calculated according to the following
formulas:
Sensitivity¼ [true positives]/[true positivesþ false negatives] * 100
Speciﬁcity ¼ [true negatives]/[true negatives þ false
positives] * 100
Table 1 shows the process for the calculation of the sensitivity
and speciﬁcity of PWA as a surrogate for a RRCA to score OH. The
same table was completed by the third reader, for each percentage
of maximal reduction in PWA from 20 to 90%.
3. Results
3.1. Polysomnographies
Thirty out of the 50 PSGs were retained for analysis, due to the
presence of artifacts or insufﬁcient sleep time (TST<4 h) in 20 PSGs.
Clinical and demographic characteristics of the patients (16 males)
are shown in Table 2. Mean age was 11.9 ± 4.6 years old. The most
frequent diagnosis was PradereWilli syndrome (14/30). Thirty
percent of patients were obese, with a bodymass index (BMI)!95%
centile [15]. None of the patients were using drugs that could have
effect on the EEG or PWA results. The results of the PSG are shown
in Table 3. The total number of OH retained for analysis from the 30
PSGs was 669, with 3145 RRCA and 1160 DS.
The total number of !30% decreases in respiratory ﬂow was
987: 134 events were associated with a DS and RRCA, 205 events
were associated with a DS only, 330 events were associated with
RRCA only, and 318 events were not associated with a DS nor with a
RRCA (Table 4). The distribution of these 318 “respiratory events”
not associated with RRCA or DS, but only with a decrease in PWA
(“false positives”) is shown in Fig. 3.
3.2. Analysis of the agreement between pulse wave amplitude and
respiratory-related cortical arousal
Figs. 4 and 5 show the sensitivity and speciﬁcity values for every
given level of PWA reduction to predict an RRCA for OH scoring,
with and without DS. During episodes of !30% respiratory ﬂow
reduction with RRCA and no DS (which deﬁnes hypopnea not
detected on RP), as the percentage of decrease in PWA increased,
the sensitivity of PWA to substitute for RRCA decreased, but the
speciﬁcity increased (Fig. 4). The best compromise of sensitivity and
speciﬁcity values were found for a decrease in PWA between 60%
and 70%. The sensitivities of PWA to predict RRCA were 79% and
57%, respectively, and the speciﬁcities 51% and 76%. Comparable
results were observed for episodes of !30% respiratory ﬂow
reduction with RRCA and DS (Fig. 5).
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As an example, Table 5 shows the difference between the HI
obtained on PSG and RP according to the different levels of re-
ductions of PWA as a surrogate for RRCA. This table shows that the
HI ranged from 1.9 events/hour for a 90% reduction in PWA to 3.9
events/hour for a 20% reduction in PWA. BlandeAltmann plots for
the HI corresponding to a 60% and 70% reduction in PWA, which
were associated with the best sensitivity and speciﬁcity, are shown
in Fig. 6a and b, respectively. As compared to a 60% reduction in
Fig. 1. Examples of the procedures. 1a. An example of the graphical presentation of % of reduction in PWA. 1b. An example of the scoring of PWA reduction related events. Ab-
breviations: Abdo, abdomen; HR, heart rate; OH, obstructive hypopnea; PWA, pulse wave amplitude; SpO2, peripheral oxygen saturation.
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PWA, a 70% reduction in PWA seemed to have a better agreement
with the RRCA scoring.
4. Discussion
This study is the ﬁrst to compare OH scoring using PWAvs RRCA,
and shows that the reduction in PWA reduction lacks sensitivity
and speciﬁcity to be used as a surrogate for RRCA in a pediatric
population referred for OSAS. Indeed, an inverse relationship be-
tween sensitivity and speciﬁcity was observed for the ability of
PWA to substitute for RRCA, with increasing levels of PWA reduc-
tion. For the scoring of hypopneas in children, PSG remains the gold
standard.
The results show that the percentage of decrease in PWA cannot
be used as a reliable surrogate for RRCA in children. Indeed, an
Fig. 2. Example of integration of the two scores. Black bar (OH) represents a respiratory event scored according to AASM scoring rules (PSG ﬁrst scoring); Gray bar (OH) represents a
respiratory event scored according to PWA reduction scoring (second scoring). Abbreviations: AASM, American Academy of Sleep Medicine; Abdo, abdomen; HR, heart rate; OH,
obstructive hypopnea; PWA, pulse wave amplitude; PSG, polysomnography; SpO2, peripheral oxygen saturation.
Table 1
Calculation of sensitivity and speciﬁcity of pulse wave amplitude as a surrogate for
respiratory-related cortical arousal.
RRCA No RRCA
Decrease in PWA With a DS
¼hypopnea
¼true positive
With a DS
¼hypopnea
¼false positive
Without a DS
¼hypopnea
¼true positive
Without a DS
¼no hypopnea
¼false positive
No decrease in PWA With a DS
¼hypopnea
¼false negative
With a DS
¼hypopnea
¼true negative
Without a DS
¼hypopnea
¼false negative
Without a DS
¼no hypopnea
¼true negative
DS, !3% oxygen desaturation; PWA, pulse wave amplitude; RRCA, respiratory-
related cortical arousal.
Table 2
Clinical and demographic characteristics of the patients (n ¼ 30).
Age, years (median and range) 13 (4e19.5)
Female to male ratio 16/14
BMI (centile) 62 (±38)
Underweight (<5th percentile) 17%
Obese (!95th percentile) 30%
Diagnosis PradereWilli syndrome 14
Non co-morbid OSAS 2
Bronchopulmonary dysplasia 2
Polymalformative syndrome 2
Spinal muscular atrophy type 2 2
Vocal cord palsy 2
Rett syndrome 1
Cerebral tumor 1
Duchenne muscular dystrophy 1
Sickle cell disease 1
Silver-Russell syndrome 1
Neuroﬁbromatosis type 1 1
BMI, Body mass index (Kg/m2); OSAS, obstructive sleep apnea syndrome.
Table 3
Sleep study data (n ¼ 30). Data are expressed as mean and standard deviation.
TST, minutes (median, range) 480.5 (332e681)
Sleep stage duration, minutes (median, range)
N1 35 (0e91)
N2 227 (161e764)
N3 101 (32e186)
REM 91 (8e167)
Arousal index, events/hour (median, range) 11 (5e34)
Respiratory events, events/hour (median, range)
AHI 3.6 (1e46)
OAI 0.2 (0e5)
CAI 0 (0e46)
Mean SpO2%, (mean ± SD) 96 (±1.3)
Minimal SpO2%, (mean ± SD) 89 (±4.4)
ODI events/hours, (mean ± SD) 4.5 (±6.2)
AHI, apneaehypopnea index; CAI, central apnea index; OAI, obstructive apnea in-
dex; ODI, oxygen desaturation index; REM, rapid eye movements; SpO2, pulse ox-
imetry; TST, total sleep time.
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inverse trend was observed between sensitivity and speciﬁcity for
every level of PWA reduction. Table 5 shows the potential changes
in the AHI according to a given PWA threshold. As children usually
have low AHI, even a small change in the AHI may thus potentially
impact the therapeutic decision [3].
Vat and colleagues [16] compared four different deﬁnitions for
scoring hypopnea in adults, using 3% or 4% desaturation associated
or not with a PWA reduction. Using a PWA reduction of at least 30%,
they found an increase in the estimation of the HI, but a lack of
speciﬁcity due to poor correlation between EEG arousal and PWA
drops. Delessert and colleagues [12] analyzed !20% decreases of
PWA and associated changes in EEG power density and cortical
activity during sleep in an adult population. They found a sensi-
tivity of 64.7% and a predictive value of 70.9% of PWA reduction to
predict an arousal. By performing an EEG power density analysis,
they observed that a reduction in PWA was associated with an
arousal, but also to subtle EEG power changes in all bands. These
ﬁndings, along with other experiences [17,18], suggest that
increased power density with an autonomic reaction such as a PWA
drop may represent a central nervous system mechanism to pre-
vent arousal and promote sleep continuity. It can thus be
Table 4
Total number of !30% decreases in respiratory ﬂow retained for the study.
Number
!30% decrease in
respiratory ﬂow with 3%DS
With RRCA 134 “AASM”
hypopneas
Without RRCA 205
!30% decrease in
respiratory ﬂow without 3%DS
With RRCA 330
Without RRCA 318 No “AASM”
hypopneas
Abbreviations: 3%DS, !3% oxygen desaturation; AASM, American Academy of Sleep
Medicine; RRCA, respiratory-related cortical arousal.
Fig. 3. Number of respiratory events with !30% decrease in respiratory ﬂow, associated with pulse wave amplitude reduction, but without a respiratory-related cortical arousal or
!3% oxygen desaturation. Abbreviations: DS, oxygen desaturation; PRRCA, respiratory-related corcial arousal; PWA, pulse wave amplitude.
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Fig. 4. Sensitivity and speciﬁcity level for every % of pulse wave amplitude reduction with desaturation. Abbreviations: PWA, pulse wave amplitude; sens, sensitivity; spec,
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speculated that PWA changes represent a more subtle analysis of
sleep fragmentation; they are able to detect autonomic activations
not necessarily followed by cortical arousal. Even if these auto-
nomic activations had been linked to deleterious consequences on
daytime functions [19], they are currently not taken into account
for the scoring of arousal during respiratory events that still rely on
classical EEG ﬁndings [14]. This observation may contribute to an
explanation of the poor concordance between RRCA and PWA
changes in the present study. Moreover, in another study of adults
treated by noninvasive ventilation, a 30% reduction in PWA was
found to have a 87% positive predictive value for detecting EEG
arousals [20]. As in the present study, the speciﬁcity was low
(40.7%), but the sensitivity was higher (89%). It could therefore be
speculated that these results highlight the extreme sensitivity of
PWA changes for “sub-cortical” arousals that are not recorded by
conventional EEG, but only by spectral analysis. Finger PWA could
probably be more sensitive in detecting autonomic arousals than
standard EEG, and therefore does not represent the ideal parameter
to substitute EEG-scored arousals [21]. Moreover PWA itself could
offer additional information regarding the effects of upper airway
obstruction on the central nervous and cardiovascular systems.
More recently, Karmakar and colleagues [10] proposed a complex
arousal detection model derived from ﬁnger photo-
plethysmography, taking into account PWA and areaearea under
peak. They found 68% sensitivity and 95% speciﬁcity of this model
to detect respiratory arousals in a group of 10 adult patients with
sleep-disordered breathing.
The present study had some limitations. For instance, it was a
single-center study with the majority of children having
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Table 5
Comparison of the hypopnea index on polysomnography and respiratory polyg-
raphy, according to the different levels of reductions of pulse wave amplitude as a
surrogate for respiratory-related cortical arousal.
HI on PSG
(events/hour)
HI on RP, according to the different levels of reduction in
PWA (events/hour)
90% 80% 70% 60% 50% 40% 30% 20%
2.8 1.9 2.1 2.7 3.2 3.6 3.7 3.8 3.9
HI, hypopnea index; PSG, polysomnography; PWA, pulse wave amplitude; RP,
respiratory polygraphy.
Fig. 6. BlandeAltman plots between the hypopnea index (HI) corresponding to a 60% reduction in pulse wave amplitude (PWA) (a), the HI corresponding to a 70% reduction in PWA
(b) and the HI scored on a polysomnography (PSG). The thin lines represent the limits of agreement and the continuous bold line represents the bias (mean of the difference).
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PradereWilli syndrome, which was due to the presence of a Pra-
dereWilli reference center at the hospital. This may have affected
the results, since it has been shown that these patients may have
some alterations of sleep architecture [22] and autonomic dys-
functions [23] with imbalanced sympathetic and parasympathetic
activity. However, childrenwith PradereWilli are routinely referred
to a sleep laboratory due to high prevalence of OSAS. This study did
not analyze the accuracy of the PWA according to the different
sleep stages. Indeed, PWA reductions not associated with RRCA are
more frequent during REM sleep [11,12,17,18,24], which is the most
vulnerable sleep stage for obstructive respiratory events. It could be
argued that PWA could perform better in predicting RRCA during
NREM sleep stages. Nevertheless, the aim of the present study was
to evaluate if RP could be used instead of PSG, and thus EEG, by
using other noninvasive surrogates of RRCA. Since the scoring of
sleep stages relies on EEG signals, as it is for arousals, this data seem
non-relevant when searching for a parameter that could be used
instead of EEG tracings.
However, an important strength of the study was the use of an
automated analysis of the reduction in PWA, the dual PSG scoring,
and the ﬁnal analysis by an independent reader. Great care was
taken to use the same pulse oximeter sensor for all recordings. It is
well known that pulse oximetry accuracy varies from one manu-
facturer to another [25], especially during hypoxemia.
In conclusion, this study showed that PWA reduction is not a
reliable surrogate for RRCA, and therefore could not substitute EEG
tracings for scoring OH. Future studies should aim at improving
comprehension of the relationship between other markers of
autonomic activation and deleterious consequences of sleep
disordered breathing in children.
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Abstract
Purpose The characte r iza t ion of apneas dur ing
polysomnography (PSG) as obstructive or central is a key ele-
ment of a sleep study. Pulse transit time (PTT) has demonstrat-
ed its potential as a noninvasive surrogate marker for inspira-
tory efforts. The aim of the study was to assess the ability of
PTT to classify apneas as central or obstructive, as compared to
respiratory inductance plethysmography (RIP) in children.
Methods Overnight PSG with simultaneous PTT recording
was performed on 11 consecutive children (mean age
8.9 years, range 1–18.2 years). The same observer scored
the apneas using two blinded configurations: (1) the RIP
scoring used the nasal pressure, thermistors, thoracic and ab-
dominal movements, and pulse oximetry signals: (2) the PTT
scoring used PTT in combination with all the other signals
without the thoracic and abdominal movements.
Results One hundred fourteen apneas out of a total of 520
respiratory events were analyzed. With RIP, 58 (51%) apneas
were scored as obstructive and 56 (49%) as central. Using
PTT, 77 (68%) of the apneas were scored as obstructive and
37 (32%) as central. When using PTT, 30 apneas scored as
central by RIP were scored as obstructive. PTT was highly
sensitive (81%) but poorly specific (46%) in scoring 58
apneas as obstructive. PTTwas less sensitive (46%) but highly
specific (81%) to score 56 apneas as central.
Conclusion PTT may be used as an additional tool to RIP to
improve the scoring of apneas as obstructive or central in
children. The high percentage of artifact is a limitation of PTT.
Keywords Pulse transit time . Polysomnography .
Respiratory inductance plethysmography . Apneas . Child
Introduction
The characterization of respiratory events during sleep as ob-
structive or central is a key element of a sleep study, as mis-
classification can lead to inappropriate treatment. Increased
respiratory effort is a sign of obstructive sleep-disordered
breathing and may be recorded from mechanical, electrical,
and electromechanical signals [1].
The measurement of swings in esophageal pressure (Pes)
by means of an esophageal catheter is the current gold stan-
dard technique for detecting changes in inspiratory effort.
However, the placement of an esophageal catheter is uncom-
fortable and difficult to accept especially in children.
Moreover, it may modify the upper airway dynamics and in-
duce sleep disruption [2]. According to the 2012 recommen-
dations of the American Academy of Sleep Medicine
(AASM), respiratory inductance plethysmography (RIP) can
be used as an alternative method to detect respiratory efforts
[3]. RIP is a noninvasive, well-tolerated, and reproducible
method. However, this technique is difficult to standardize
as variation may occur with body position, sleep stage, and
the degree of obesity. Obstructive events may thus be
underestimated by RIP [4–6].
Pulse transit time (PTT) is a measure of respiratory effort
and arousal that has shown promise in the diagnosis of sleep-
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disordered breathing in adults [7–9] and children [10]. PTT is
the time period the pulse wave takes to travel between the
aortic valve and the vessels in the finger and is calculated as
the interval between the R wave of the ECG and the arrival of
the photoplethysmographic pulse at the finger [11]. Several
studies have shown a good correlation between the PTT and
the Pes swings in adult patients [9, 12, 13],
Few studies have evaluated PTT in children [10, 14–17].
The majority of these studies, including one study which used
Pes [14], evaluated the usefulness of PTT to improve the de-
tection of arousals associated with respiratory events [14–17].
Only one study assessed the usefulness of PTT with a stand-
alone system to classify respiratory events as central or ob-
structive, with encouraging results [10].
The aim of the present study was to assess the ability of
PTT, recorded with an automated integrated software, to clas-
sify apneas as central or obstructive, as compared to RIP,
which is the recommended scoring by the American
Academy of Sleep Medicine (AASM) [3] in patients referred
to a pediatric university hospital sleep unit.
Material and methods
Population
This study was conducted at the Noninvasive Ventilation and
Sleep Unit of Necker University Pediatric Hospital in Paris.
Consecutive children with sleep-disordered breathing, who
were referred for a scheduled PSG, were enrolled. All proce-
dures performed in studies involving human participants were
in accordance with the ethical standards of the institutional
and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable
ethical standards. The study was approved by the local ethical
committee (CPP Ile de France II, no. 2014-03-09 SC).
Informed consent was obtained from all parents and patients
>6 years included in the study.
Polysomnography
All the children underwent a full-night polysomnography.
Continuous recordings were performed using an electroenceph-
alogram (EEG) with electrode positions C3/A2-Cz/O1 of the
International 10–20 Electrode Placement System, electrooculo-
gram, chin electromyogram, and electrocardiogram (ECG).
Thoracic and abdominal movements were recorded by RIP.
Airflow was measured by means of nasal pressure, associated
with the sum of buccal and nasal thermistor signals. Pulse oxim-
etry (SpO2) was also measured. All the recordings were per-
formed with the PSG system Alice 6 LDxS (Philips
Respironics, Carquefou, France). Sleep studies were scoredman-
ually using standard techniques and criteria of the AASM [3].
Method of PTT measurement
PTT was recorded simultaneously from the automated
integrated software of the Alice 6 LDxS (Philips
Respironics, Carquefou, France). The PTT refers to the
time period the pulse wave takes to travel between two
arterial sites, from the moment the pulse leaves the aortic
valve, identified by the R wave on the ECG, to the time
when it reaches the vessels in the finger, identified by
the pulse wave detected by the SpO2 sensor. The speed
at which this arterial pressure wave travels is directly
proportional to blood pressure. An acute rise in blood
pressure causes vascular tone to increase, and hence,
the arterial wall becomes stiffer causing the PTT to
shorten. Conversely, when blood pressure falls, vascular
tone decreases and PTT increases [18]. PTT can quantify
respiratory effort by detecting changes in the blood pres-
sure oscillations associated with pleural swings (“pulsus
paradoxus”) [15]. PTT was calculated as the interval be-
tween the ECG R wave and the point corresponding to
50% of the height of the maximum value on the pulse
wave form detected by photoplethysmography at the fin-
ger level. PTT values are available with every heartbeat
and are measured with an accuracy of 2 ms. The signal
is typically oversampled at 5 Hz to ensure no values are
neglected. Normal PTT is approximately 200 to 300 ms
when using the finger probe.
Procedure
The analysis was only done on apneas. Hypopneas and respi-
ratory events occurring during the time period of artifacts on
the ECG, RIP, or SpO2 signals were discarded.
The study was designed as a blinded PSG study:
patients underwent an overnight multichannel PSG with
simultaneous PTT recording. The same observer scored
the PSG respiratory events using two scoring configura-
tions. The RIP scoring used the nasal pressure, therm-
istors, thoracic and abdominal movements, and SpO2
signals. The PTT scoring, blinded to the first scoring,
used PTT in combination with all the other signals
without the thoracic and abdominal movements.
Obstructive apnea (OA) was defined as the absence of
nasal airflow for at least two breaths, with continued
chest wall and abdominal movements on the RIP
scoring or an increase in PTT on the PTT scoring.
(Fig. 1) Central apnea (CA) was defined as the absence
of airflow lasting more than 20 s or of shorter duration
and associated with an arousal and/or a 3% oxygen
desaturation with the cessation of respiratory effort on
the RIP scoring or (no change) near disappearance/
reduction in PTT on the PTT scoring [10].
Sleep Breath
Statistical analysis
Statistical calculations were performed using the Excel 2010
(Microsoft Corp, Seattle, WA) program. The sensitivity and
specificity of PTT to detect obstructive or central respiratory
events, compared to RIP (considered as the reference method)
were calculated according to the following formulas:
Sensitivity = [true positives]/[true positives + false nega-
tives]*100; Specificity = [true negatives]/[true negatives +
false positives]*100. Positive predictive value was calculated
as [true positives]/[true positives + false positives]*100.
Negative predictive value was determined as [true nega-
tives]/[true negatives + false negatives]*100.
Results
Patient population
Eleven children (four boys) were included in the study
(Table 1). Mean age was 8.9 years (range 1–18.2 years).
All the patients had an underlying disease: Prader-Willi
syndrome (n = 4), achondroplasia (n = 3), Bardet Biedl
syndrome (n = 1), Down’s syndrome (n = 1), Fallot
tetralogy (n = 1), and juvenile polyarthritis (n = 1).
The mean apnea-hypopnea index (AHI) was 6.9 events/
h (range 2.5 to 11.3 events/h) and the mean apnea index
(AI) 2.5 events/h (range 0 to 7.4 events/h).
Fig. 1 One-minute sections of PSG tracingswith pulse transit time (PTT)
and RIP (THO-ABD) in four different patients. a Concordance in
obstructive apneas: the apneas can clearly be seen on both signals with
a pattern of increase in the PTT swings and phase opposition on RIP. b
Concordance in central apneas: determination of a central event is made
from the near disappearance of the PTT swings or the respiratory
movements on RIP. c Misclassification of a central apnea by the PTT:
there is an obvious pattern of increase in the PTTswings whereas there are
no respiratory oscillations on RIP. d Misclassification of an obstructive
apnea by the PTT: there are no PTT oscillations whereas there are still
respiratory movements on RIP
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Respiratory events
Fivehundred twenty respiratory eventswere scoredusing the
RIP. Among these events, 180were apneas and 340were ob-
structive hypopneas. Among the 180 apneas detected using
RIP, 66 (37%) apneas were excluded because of artifacts on
the ECG,RIP, or SpO2 signals. One hundred fourteen apneas
remained available for a comparison of scoring between RIP
andPTT.
Accuracy of PTT for distinguishing central
and obstructive apneas
With RIP, 58 (51%) apneas were scored as obstructive and 56
(49%) as central (Table 2). Using PTT, 77 (68%) of the apneas
were scored as obstructive and 37 (32%) as central. When
using PTT, 30 apneas scored as central by RIP were scored
as obstructive. An agreement for obstructive and central ap-
neas was observed in only 73 (64%) of the 114 apneas. When
RIP was taken as the reference scoring, PPT was highly sen-
sitive (81%) and poorly specific (46%) in scoring 58 apneas as
obstructive (Table 2). The positive predictive value was 61%
and the negative predictive value was 70%. PTT was less
sensitive (46%) but highly specific (81%) to score 56 apneas
as central. The positive predictive value was 70% and the
negative predictive value was 61% (Table 2).
Discussion
Our results show that a scoring of apneas with PTT (without
RIP) on the automated integrated software of a commercial
PSG device, led to a greater number of obstructive apneas as a
scoring based on RIP, as recommended by the AASM.
However, 37% of the apneas could not be used for analysis
because of artifacts.
The aim of the studywas to evaluate the ability and accuracy
of PTT to classify apneas as obstructive or central in children.
Because we were not able to compare PTT to Pes which is the
gold standard, we compared PTT to RIP, which is used to
assess respiratory efforts in routine care [3]. However, it is well
known that RIP may underestimate respiratory effort, because
chest and abdominal wall movements may be influenced by
lung volume and posture. The sensor bands on the chest and the
abdomen may move up or down during the night, leading to an
overestimation of central sleep apnea events. RIP may also be
unreliable when the amplitude of the chest wall movements is
small, as may be observed in very young children or in older
children with obesity. Similarly to studies that used Pes or
diaphragmatic EMG, we found more obstructive apneas with
a PTT scoring (68%) as compared to a RIP scoring (51%) [5,
6]. PTT has been compared to Pes in three adult studies [9, 12,
13] and one pediatric study [14]. All these studies demonstrated
an excellent correlation between the changes in Pes and PTT.
Indeed, the analysis of 177 respiratory events by Argod et al.
Table 1 Characteristics of the
population Gender Age (years) Pathology AHI (events/h) AI (events/h)
Patient 1 F 8.3 Prader-Willi 9.6 1.7
Patient 2 F 7.8 Prader-Willi 3.9 1.5
Patient 3 F 8.9 Prader-Willi 10.3 7.1
Patient 4 F 9.4 Prader-Willi 2.5 1
Patient 5 M 8.2 Achondroplasia 11.3 7.4
Patient 6 F 8.2 Achondroplasia 3.9 0.6
Patient 7 F 7.9 Achodronplasia 3.6 0.7
Patient 8 M 14.9 Bardet Biedl syndrome 11 0
Patient 9 M 4.8 Fallot tetralogy 10.8 2
Patient 10 M 18.2 Juvenile polyarthritis 6 4.3
Patient 11 F 1.0 Down syndrome 4 0.9
F female, M male, AHI apnea-hypopnea index, AI apnea index
Table 2 Comparison of the classification of apneas (n = 114) by respiratory inductance plethysmography (RIP) technique (comprising RIP, nasal
pressure, thermistors, and pulse oximetry) and pulse transit time (PTT) technique (comprising nasal pressure, thermistors, and pulse oximetry without
RIP)
RIP technique
Obstructive apneas (RIP) Central apneas (RIP)
PTT
technique
Obstructive apneas (PTT) 47 30
Central apneas (PTT) 11 26
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showed that PTT had a 93% specificity and a 100% sensitivity
for the detection of central apneas, and a 99% specificity and a
85% sensitivity for the detection of obstructive apneas as com-
pared to a Pes scoring [12]. Katz et al. performed a
polysomnography with Pes and PTT in 24 symptomatic chil-
dren and 10 normal controls to assess if PTTcould increase the
detection of respiratory arousals [14]. They observed also a
good correlation between the change in Pes and PTT. Foo
et al. performed a study quite similar to ours in 33 children
comparing a scoring of respiratory events by RIP and PTT
[10]. They found that PTT had a 90% sensitivity and 82%
specificity to detect obstructive events and a 90% sensitivity
and 80% specificity to detect central events. The main limita-
tion was the effect of motion artifacts with only 334 events out
of 993 (34%) events being considered as valid for the PTT
analysis. We can thus reasonably assume that PTT may be
useful to “correct” the scoring of some central apneas by RIP
as obstructive apneas and that PTT is more sensitive than RIP
for the scoring of obstructive apneas.
Despite these results, the PTT is not used on a routine basis
for the scoring of respiratory events during sleep. The main
limitation of PTT is artifact [10, 18, 19]. This is mostly due to
interference with the photoplethysmographic signal at the fin-
ger, or chest wall movements which disturb the ECG leads.
There is also a significant variation in PTT between individ-
uals as a result of differences in blood pressure and vascular
compliance [19]. This may partially explain why 11 apneas
scored as obstructive by the RIP scoring were scored as cen-
tral by the PTTscoring in the present study (Table 2). Artifacts
are more likely to occur during rapid eye movement sleep
(REM) as this sleep state is associated with large variations
in respiratory drive. This is particularly troublesome as REM
sleep is a period associated with an increased incidence of
respiratory events. REM sleep is also associated with a labile
hemodynamic state, with an increase in sympathetic activity
causing fluctuations in pulse rate and blood pressure, affecting
the stability of the PTT signal. Finally, PTT cannot be consid-
ered as a quantitative measure as a PTT recording is only
available with each cardiac cycle; measurement may thus fall
on either side of the peak or trough of the blood flow pressure
oscillation associated with respiratory effort, resulting in a
tendency to undersample. The change in PTT may therefore
not represent the real value of the change in respiratory effort.
Our study has several limitations. The major limitation is
the lack of comparison with the gold standard, i.e., Pes. Such a
study would be difficult to perform in our population of chil-
dren with severe underlying diseases for which repeated and
often invasive procedures are commonly required. A second
limitation is the small number of apnea events. This is ex-
plained by the fact that the study was performed in children,
in whom the number of apneas is generally lower than in
adults. We did not compare the scoring of hypopneas because
our patients had only obstructive hypopneas. Finally, PTT
analysis was performed by an automated integrated software
of a commercially available equipment whereas most previous
studies used a standalone system [9, 10, 12, 17]. We found
only one study in children using the Alice software, but the
aim of this study was to evaluate the usefulness of PTT for the
detection of respiratory-related arousal [14]. Part of the high
variability of the PTT signals may indeed be explained by the
quality of the recorder data processor device.
Conclusion
Scoring of apneas with PTT (without RIP) on the automated
integrated software of a commercial PSG device, led to a
greater number of obstructive apneas as a scoring based on
RIP. As previous studies using Pes have shown that PTT can
be used as an accurate semi-quantitative estimate of respirato-
ry effort, PTT could be used as an additional tool with RIP to
improve the scoring of apneas as obstructive or central in
children. However, the high percentage of artifact is a limita-
tion of PTT. Finally, a study validating PTTagainst Pes would
definitely be able to confirm the value of PTT in children.
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U
pper airway obstruction is a hallmark in 
neonates with Pierre Robin sequence.1–4 
Noninvasive continuous positive airway 
pressure has been shown to be an effective treat-
ment for severe upper airway obstruction in 
Pierre Robin sequence.5 The aim of this study was 
to evaluate a standardized protocol using nonin-
vasive continuous positive airway pressure as first-
line treatment for upper airway obstruction in 
neonates with Pierre Robin sequence.
PATIENTS AND METHODS
The medical records of all neonates with Pierre 
Robin sequence evaluated between September of 
2013 and September of 2014 were analyzed. Four 
groups were identified. The severe upper airway 
obstruction group comprised the neonates who 
were not able to breathe spontaneously without a 
tracheal tube or noninvasive continuous positive 
airway pressure without immediate desaturation 
(pulse oximetry <80 percent) and hypercapnia 
(transcutaneous carbon dioxide >60 mmHg). 
Neonates with less severe upper airway obstruc-
tion underwent daytime nap polygraphy, scored 
according to the American Academy of Sleep 
Medicine guidelines,6 in the prone position and 
classified as those with abnormal (moderate upper 
airway obstruction group) or normal polygraphic 
(mild upper airway obstruction group) findings. 
The moderate upper airway obstruction group 
was started on noninvasive continuous positive 
Disclosure: The authors have no financial rela-
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funding.Copyright © 2016 by the American Society of Plastic Surgeons
DOI: 10.1097/01.prs.0000475799.07597.23
Alessandro Amaddeo, M.D.
Veronique Abadie, M.D., 
Ph.D.
Christel Chalouhi, M.D.
Natacha Kadlub, M.D., Ph.D.
Annick Frapin, M.S.N.
Alexandre Lapillonne, 
M.D., Ph.D.
Nicolas Leboulanger, M.D., 
Ph.D.
Erea Noel Garabédian, 
M.D., Ph.D.
Arnaud Picard, M.D., Ph.D.
Brigitte Fauroux, M.D., Ph.D.
Paris, France
Summary: The aim of the study was to evaluate noninvasive continuous posi-
tive airway pressure as first-line treatment for upper airway obstruction in 
neonates with Pierre Robin sequence. Forty-four neonates were enrolled 
and classified in 4 groups: ventilator-dependent patients (severe upper air-
way obstruction group), patients with clinical upper airway obstruction, an 
abnormal (moderate upper airway obstruction group) or normal polygraphy 
(mild upper airway obstruction group), and those with no clinical upper 
airway obstruction (no upper airway obstruction group). Five neonates in 
the severe upper airway obstrction group (n = 9) were successfully man-
aged by noninvasive continuous positive airway pressure and 4 required a 
tracheotomy. The moderate upper airway obstruction group (n = 4) was suc-
cessfully managed by noninvasive continuous positive airway pressure and 
the other patients by prone positioning. Continuous positive airway pres-
sure represents an effective treatment of upper airway obstruction in Pierre 
Robin sequence and may be recommended in selected patients. (Plast. 
Reconstr. Surg. 137: 609, 2016.)
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
From the Pediatric Noninvasive Ventilation and Sleep Unit, 
General Pediatric Department, National Reference Center for 
Pierre Robin Sequence, Pediatric Plastic and Maxillofacial 
Surgery Department, Neonatology Department, and Pediat-
ric Head and Neck Surgery Department, AP-HP, Hôpital 
Necker-Enfants Malades; and Paris Descartes University.
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Continuous Positive Airway Pressure for  
Upper Airway Obstruction in Infants with 
Pierre Robin Sequence
IDEAS AND INNOVATIONS
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airway pressure on the basis of the following cri-
teria: apnea-hypopnea index greater than 10 per 
hour and/or oxygen desaturation index greater 
than 15 per hour and/or minimal pulse oximetry 
less than 90 percent and/or maximal transcutane-
ous carbon dioxide greater than 50 mmHg.
Continuous positive airway pressure was used 
continuously in the severe upper airway obstruc-
tion group with the aim of decreasing continu-
ous positive airway pressure use to sleep periods 
only over a 1- to 2-week period.7–9 The moderate 
upper airway obstruction group was treated with 
noninvasive continuous positive airway pressure 
during sleep periods only. Intensive care unit 
ventilators or home continuous positive airway 
pressure devices with industrial nasal masks were 
used. The initial noninvasive continuous positive 
airway pressure level was set at 6 cmH
2
O and rap-
idly increased to the maximal tolerated continu-
ous positive airway pressure level.9 A tracheotomy 
was proposed in case of continuous ventilator-
dependence or noninvasive continuous posi-
tive airway pressure failure. Patients admitted 
for nutritional problems only and those seen 
as outpatients comprised the no upper airway 
obstruction group.
The continuous positive airway pressure devices 
were either intensive care unit ventilators in the 
neonatal intensive care unit, or home continuous 
positive airway pressure devices on the neonatol-
ogy ward: Infant Flow SiPAP system (CareFusion, 
Hoechberg, Germany), Trilogy 100 or BiPap A40 
(Philips Respironics, Murrysville, Pa.), and S9 
(ResMed, Saint Priest, France). Industrial nasal 
masks were used: Infant Flow (Fisher & Paykel, 
Auckland, New Zealand) in the neonatal intensive 
care unit, and Soft Baby (Air Liquide Medical Sys-
tems, Antony, France) or Nonny (AG Industries, 
St. Louis, Mo.) in the neonatology ward. The pro-
tocol was approved by the local ethical committee 
(Comité de Protection des Personnes Ile de France 
II, no. 2014-03-09 SC).
RESULTS
Forty-four patients were evaluated, 37 as inpa-
tients (26 with isolated and 11 with associated/
syndromic Pierre Robin sequence) and seven 
as outpatients (two patients with 22q11 and five 
Fig. 1. Flowchart of the patients. PRS, Pierre Robin sequence; UAO, upper airway obstruction; NICU, neonatal intensive care unit; 
CPAP, continuous positive airway pressure.
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isolated Pierre Robin sequence) (Fig. 1). Five (four 
isolated and one associated/syndromic Pierre 
Robin sequence) of the nine patients of the severe 
upper airway obstruction group were successfully 
managed by noninvasive continuous positive airway 
pressure and four (three isolated and one Stickler 
syndrome) required a tracheotomy (Table 1).
Eleven neonates underwent polygraphy, 
which was normal in seven (mild upper airway 
obstruction group: five with isolated and two with 
associated/syndromic Pierre Robin sequence) 
and abnormal in four (moderate upper airway 
obstruction group: two with isolated and two with 
associated/syndromic Pierre Robin sequence) 
with an apnea-hypopnea index between 19 and 
42 per hour, an oxygen desaturation index 
between 18 and 137 per hour, a minimal pulse 
oximetry value between 78 and 90 percent, and 
a maximal transcutaneous carbon dioxide value 
between 41 and 55 mmHg. These four patients 
were managed successfully by noninvasive contin-
uous positive airway pressure (Table 1).
All nine noninvasive continuous positive air-
way pressure patients were successfully discharged 
to home after a median hospital stay of 1 month 
(range, 20 to 40 days). Objective compliance 
with noninvasive continuous positive airway pres-
sure 1 month after discharge was greater than 
8 hours per 24 hours. The four patients who were 
tracheotomized were discharged to home after a 
median hospital stay of 2 months (range, 6 weeks 
to 4 months).
The mild upper airway obstruction group 
comprised seven neonates having normal poly-
graphic findings in the prone position. The 
17 hospitalized patients with no symptoms of upper 
airway obstruction and only feeding problems and 
the seven nonhospitalized patients comprised the 
no–upper airway obstruction group. These two 
groups experienced an uneventful course.
In conclusion, during a 1-year period, 
44 neonates with Pierre Robin sequence were 
evaluated in our reference center before the age 
of 1 month; seven patients (16 percent) were seen 
as outpatients and 37 (84 percent) were seen as 
inpatients. Four patients (9 percent) required 
a tracheotomy and nine (20 percent) were suc-
cessfully managed by noninvasive continuous 
positive airway pressure, with the remaining 31 
patients (70 percent) having no significant upper 
airway obstruction and being managed by prone 
positioning.
DISCUSSION
This study shows that noninvasive continuous 
positive airway pressure is an effective treatment 
for moderate and severe upper airway obstruction, 
Table 1. Patient Characteristics, Continuous Positive Airway Pressure Initiation Criteria, and Evolution of the 
Patients
Patient Sex
Pierre Robin 
Sequence  
Form
Age at  
CPAP  
Initiation
Weight at 
CPAP  
Initiation (kg)
CPAP  
Indication
CPAP  
Pressure 
(cmH
2
O)
CPAP  
Duration 
(mo)
Criteria of CPAP  
Withdrawal
1 F Isolated At birth 3.7 Weaning failure 7 1 Normal PG (AHI 4/hr) 
and gas exchange
2 M Isolated At birth 3.5 Weaning failure 6 2 Normal gas exchange
3 M Associated At birth 3.3 Weaning failure 6 2.5 Normal PG (AHI 3/hr) 
and gas exchange
4 F Isolated At birth 3.2 Weaning failure 7 5.5 Normal gas exchange
5 M Isolated At birth 4.0 Weaning failure 7 4 Still on CPAP
6 F Isolated 7 days 2.6 AHI, 19/hr; ODI, 18/hr 
SpO
2
 min, 90%; % time 
with SpO
2
 <90%, 0%; 
PtcCO
2
 max, 43 mmHg
7 1 Normal gas exchange
7 F Isolated 10 days 3.5 AHI, 32/hr; ODI, 19/hr; 
SpO
2
 min, 78%; % time 
with SpO
2
 <90%, 0%; 
PtcCO
2
 max, 52 mmHg
8 1.2 Normal gas exchange
8 F Associated 15 days 3.0 AHI, 42/hr; ODI, 32/hr; 
SpO
2
 min, 82%; % time 
with SpO
2
 <90%, 16%; 
PtcCO
2
 max, 55 mmHg
7 4 Still on CPAP
9 F Associated 2 mo 4.2 AHI, 37/hr; ODI, 137/hr; 
SpO
2
 min, 82%; % time 
with SpO
2
 <90%, 4%; 
PtcCO
2
 max, 41 mmHg
7 4 Still on CPAP
CPAP, continuous positive airway pressure; F, female; M, male; PG, polygraphy; AHI, apnea-hypopnea index; ODI, oxygen desaturation index; 
SpO
2
, pulse oximetry; PtcCO
2
, transcutaneous carbon dioxide.
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assessed objectively by polygraphy, in neonates 
with Pierre Robin sequence.5 As such, noninva-
sive continuous positive airway pressure may be 
recommended in selected neonates before more 
invasive procedures. Duration of noninvasive con-
tinuous positive airway pressure ranged from 4 
weeks to more than 4 months, showing that non-
invasive continuous positive airway pressure is 
necessary only during a critical window of a maxi-
mum of 6 months in most patients. This relatively 
short period restricts the potential side effects of 
long-term noninvasive continuous positive airway 
pressure such as facial flattening and maxillary 
retrusion.10 However, the major advantage of non-
invasive continuous positive airway pressure is that 
this treatment is noninvasive and can be applied on 
demand. Indeed, tracheotomy is associated with 
significant morbidity and mortality, with a mean 
duration in our center of 1 year.11 Surgical proce-
dures are associated with wound dehiscence, lip 
scar contracture for tongue-lip adhesion,12 pin tract 
infection, or damage to the mandibular branch 
of the trigeminal or facial nerve for mandibular 
distraction.13 These surgical treatments relieve 
only one obstacle, whereas some patients may 
have an upper airway obstruction at different lev-
els.12 Uncertainties exist also about long-term out-
come. Moreover, these procedures do not respect 
the spontaneous improvement of the functional 
and anatomical anomalies of children with Pierre 
Robin sequence.14 For that reason, we reserve neo-
natal mandibular distraction for only a selected 
group of patients with Pierre Robin sequence.
We have previously reported the physiologic 
and clinical benefit of noninvasive continuous 
positive airway pressure in seven infants with Pierre 
Robin sequence and severe upper airway obstruc-
tion.5 The extension of noninvasive continuous 
positive airway pressure as routine care was possi-
ble because of the availability of well-adapted, well-
tolerated industrial nasal masks for this age group, 
enabling this technique to be used on a larger scale.
CONCLUSIONS
Noninvasive continuous positive airway pres-
sure represents an effective, safe, noninvasive 
treatment of moderate and severe upper air-
way obstruction in selected neonates with Pierre 
Robin sequence. Continuous positive airway pres-
sure reduces the need for a tracheotomy and may 
represent an interesting alternative to other sur-
gical procedures. Systematic sleep studies should 
be part of the respiratory management in Pierre 
Robin sequence.
Brigitte Fauroux, M.D., Ph.D.
Pediatric Noninvasive Ventilation and Sleep Unit
AP-HP, Hôpital Necker-Enfants Malades
149 rue de Sèvres
Paris F-75015, France
brigitte.fauroux@aphp.fr
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Pediatric Pulmonology
Long Term Continuous Positive Airway Pressure (CPAP)
and Noninvasive Ventilation (NIV) in Children:
Initiation Criteria in Real Life
A. Amaddeo, MD,1,2,3 J. Moreau, MD,1,4 A. Frapin, MSN,1 S. Khirani, PhD,1,5 O. Felix, MD,1,6
M. Fernandez-Bolanos, MSc,1 A. Ramirez, MSc,1,7 and B. Fauroux, MD, PhD1,2,3*
Summary. Introduction: Long term noninvasive continuous positive airway pressure (CPAP) and
noninvasive ventilation (NIV) are increasingly used in children but limited information is available
on the criteria and conditions leading to the initiation of these treatments. The aim of the study is to
describe the objective overnight respiratory parameters and clinical situations that led to the
initiation of CPAP/NIV in a pediatric NIVunit. Material and Methods: Retrospective analysis of the
data of all the children discharged on home CPAP/NIV over a 1 year period. Results: Seventy-six
patientswere started onCPAP (n¼64) or NIV (n¼12). CPAP/NIVwas initiated because of CPAP/
NIV weaning failure (Acute group) in 15 patients. None of these patients had an overnight gas
exchange or sleep study before CPAP/NIV initiation. In 18 patients, CPAP/NIV was initiated on
abnormal nocturnal gas exchange alone (Subacute group). These patients had a median of three
of the following five overnight gas exchange abnormalities: minimal pulse oximetry (SpO2)<90%,
maximal transcutaneous carbon dioxide (PtcCO2) >50mmHg, time spent with SpO2 <90% or
PtcCO2 >50mmHg "2% of recording time, oxygen desaturation index >1.4/hr. In the last 43
patients, CPAP/NIV was initiated after an abnormal sleep study (Chronic group) on amean of four
of the aforementioned criteria and an apnea-hypopnea index >10/hr. Conclusion: In clinical
practice, CPAP/NIV was initiated in an acute, subacute and chronic setting with most patients
having an association of several abnormal gas exchange or sleep study parameters. Future
studies should evaluate the effectiveness and benefits of CPAP/NIV according to the clinical
situation and initiation criteria. Pediatr Pulmonol. ! 2016 Wiley Periodicals, Inc.
Key words: noninvasive ventilation; continuous positive airway pressure; children;
polygraphy; sleep apnea; gas exchange.
Funding source: Association Francaise contre les Myopathies (AFM); Assistance
Publique-Ho^pitaux de Paris; Universit!e Paris Descartes—Paris V; INSERM; ADEP
Assistance; ASV Sant!e; IP Sant!e Domicile.
BACKGROUND
Long term noninvasive ventilation (NIV) and continu-
ous positive airway pressure (CPAP) are increasingly
used in children.1–8NIV represents nowadays the first line
treatment of chronic hypercapnic respiratory failure due
to neuromuscular,9,10 lung,11 or chest wall disorders in
children.12 CPAP is an effective treatment for severe
upper airway obstruction and in particular for persistent
obstructive sleep apnea syndrome (OSAS) after adeno-
tonsillectomy (AT)13 or occurring in children with
underlying disorders or conditions such as obesity,
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storage disorders or complex craniofacial malforma-
tions.14–18 Although the spectrum of indications for NIV
and CPAP in children is widening, few information is
available on the criteria and conditions in which these
treatments are initiated. In patients with Duchenne
muscular dystrophy, NIV is recommended when a
combination of signs and symptoms of hypoventilation
and gas exchange abnormalities are met.19 In the absence
of stronger evidence from randomized trials, these
parameters have been extended and adapted for the
respiratory care of paediatric neuromuscular patients.20
Moreover, these criteria are often extrapolated and
applied to patients with chest wall or lung disease,
without any evidence to support this assumption.
Validated criteria to start CPAP are also lacking, since
the degree of severity of OSAS at which a respiratory
support treatment should be started has not been
established. Clinicians must therefore deal with uncer-
tainty when deciding when to start NIV or CPAP. In
clinical practice, given the lack of definite cut-off values,
a combination of clinical situations, gas exchange, and
polysomnographic data are often used. In a recent study
analyzing 68 children who were started on CPAP because
of severe OSAS, CPAP was started “electively” in 62% of
the patients and in an “acute” setting in 38%.18 But the
authors did not give any information on the objective
parameters that led to the decision of CPAP. Finally, the
heterogeneity of the pediatric population which may
require CPAP/NIV, with regard to age and underlying
disease, represents a supplemental challenge. Information
on the objective criteria and clinical conditions, in terms
of underlying diseases and sleep study results that justify
the initiation of CPAP/NIV is important because this may
potentially influence outcome, effectiveness, and adher-
ence to treatment.
The aim of this retrospective study was to describe the
sleep exams performed to assess the need for CPAP/NIV,
the objective abnormalities found on these exams and to
analyze the settings that led to the initiation of long term
CPAP/NIV in a pediatric NIV unit at a tertiary care
hospital over a 1-year period.
MATERIALS AND METHODS
We retrospectively reviewed the clinical charts of all
the patients started on long term CPAP or NIV, defined as
the need for CPAP or NIV for more than 2 months after
hospital discharge, fromOctober 2013 to September 2014
in the NIV and sleep unit at Necker Children’s Hospital.
This hospital is a tertiary pediatric university hospital,
with a capacity of almost 500 beds comprising all the
pediatric medical and surgical subspecialties. The NIVand
sleep unit consists in a three beds unit exclusively dedicated
to sleep studies with a mobile unit capable of performing
sleep studies andNIVinitiation in every unit of the hospital.
Almost 450 polysomnography (PSG)/polygraphy (PG) and
900 gas exchange studies are performed per year.
For each patient, the spontaneous breathing overnight
gas exchange and/or PG or PSG abnormalities, as well as
the clinical situation at CPAP/NIV initiation was
analyzed. The data were extracted from the electronic
database of the NIV unit and there was no missing data.
PSG or PG were performed using CID 102# (Cidelec,
Angers, France). For the patients younger than 6 months,
a daytime (nap) sleep PG was performed as an alternative
to overnight study if the patient slept for more than 1 hr
during the study period. Due to equipment and staff
limitation, in our center PSG is usually reserved to
patients with non-respiratory sleep problems (such as
insomnia or parasomnias) whilst the majority of patients
with sleep disordered breathing (SDB) undergo a simple
PG. The recorded data included airflow, body position,
body movements, thoracic and abdominal movements
assessed with inductance belts for the CID 102#, pulse
oxymetry (SpO2). For PSG, the electroencephalographic
(EEG) recordings were based on the international 10–20
system, which includes the placement of electrodes in
positions F1-A2, F2-A1, C3-A2, $C4-A1, $O1-A2, O2-
A1, the recording of eye movements, the electromyogra-
phy of the chin and the electrocardiogram. Sleep stages
were obtained manually using standard criteria.22,23
Respiratory events were scored according to the Ameri-
can Academy of Sleep Medicine (AASM) manual and
following update21,22 OSAS was considered as moderate
when the apnea-hypopnea index (AHI) was between 5
and 10 events/hr and severe when the AHI was >10
events/hr. Oxygen desaturation was defined as a fall in
peripheral oxygen saturation (SpO2) of at least 3% and the
oxygen desaturation index (ODI) was defined as the
number of oxygen desaturation per hour of PSG/PG
recording. Nocturnal hypoxia was defined as the presence
of a SpO2 %90% for at least 2% of night time
23 and the
ODI was considered as abnormal when >1.4/hr.24
Overnight gas exchange study consists on combined
SpO2 and transcutaneous carbon dioxide (PtcCO2)
recordings, performed with the SenTec Digital Monitor
(SenTec Inc, Therwil, Switzerland). Mean, maximal
PtcCO2, and the percentage of night-time spent with a
PtcCO2 greater than 50mmHg were recorded.
25 Noctur-
nal hypercapnia was defined as a PtcCO2 "50mmHg for
at least 2% of night time.25
The protocol was approved by the local ethical
committee (CPP Ile de France II, n8 2014-03-09 SC).
Statistical Analysis
All the data are presented as median and range. The
difference in median was evaluated with Mann–Whitney
Rank Sum Test. A P-value less than 0.05 was considered
statistically significant.
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RESULTS
During the study period, 374 PSGs or PGs and 684
overnight gas exchange studies were performed. Subse-
quently, 76 patients were started on long term CPAP
(n¼ 64) or NIV (n¼ 12). CPAP was initiated because of
isolated OSAS, while NIV was initiated in patients
presenting with alveolar hypoventilation alone or associ-
ated with OSAS. The majority of the patients were
referred from the genetic, neurology, metabolic disease,
and otolaryngology and maxillo-facial surgery depart-
ments of the hospital. The patients were subdivided into
three groups according to clinical scenarios under which
long term respiratory support were initiated:
& Fifteen (20%) patients were started on CPAP/NIV
without any spontaneous breathing overnight gas
exchange or PG/PSG recording. Indeed, the respiratory
status of this group was too unstable and did not allow
an overnight spontaneous breathing recording. All
these patients were hospitalized in the intensive care
unit (ICU) because of the inability to be weaned from
noninvasive ventilatory support after an acute respira-
tory failure requiring an acute initiation of CPAP/NIV
or an endotrachaeal intubation. All of these patients had
arterial blood gases analysis as a part of their clinical
follow up but no datawere collected about these exams.
This group was designated the Acute group. The
median age of this group was 0.3 (0.1–13.5) years with
a predominance of infants with Pierre Robin syndrome
(6 patients out of 15, Table 1) due to the recruitment of
our hospital.
& Eighteen (24%) patients were started on CPAP/NIV
after a variable association of overnight gas exchange
abnormalities alone. None of these patients had a PG/
PSG. These patients were hospitalized for 1) an acute
moderate respiratory exacerbation that did not require
an ICU admission or 2) a scheduled hospitalization for
their underlying disease during which the presence of
SDB symptoms justified an overnight gas exchange
recording. These patients had amean of three of the five
aforementioned overnight gas exchange abnormalities
(Tables 1, 2, and 3, variables 1–5, and Figs. 1 and 2).
This group was designated the Subacute group. The
median age of these patients was 0.6 (0.2–18.2) years.
& In the last 43 (56%) patients, CPAP/NIV was initiated
after an overnight PSG (n¼ 4) or PG (n¼ 28), or a nap
study (n¼ 11). These patients were referred to the NIV
TABLE 1—Clinical and Demographics Characteristics of the Patients According to the Three Study Groups (total n¼76)
Acute group n¼ 15 Subacute group n¼ 18 Chronic group n¼ 43
Median age, years (interquartile
range)
0.3 (0.1–13.5) 0.6 (0.2–18.2) 1.6 (0.1–19.5)
Female to male ratio (F/M) 7/8 8/10 22/21
Diagnosis Pierre Robin syndrome 6 Laryngomalacia 4 Pierre Robin syndrome 5
Laryngomalacia 3 Prader Willi syndrome 1 Down syndrome 5
Polymalformative
syndrome
2 Pierre Robin syndrome 1 Mucopolysaccharidosis
type 1
3
Kabuki syndrome 1
Bronchopulmonary dysplasia 1
Charge syndrome 3
Cystic fibrosis 1
Crouzon syndrome 1
Laryngomalacia 3
Bronchopulmonary
dysplasia
1
Treacher Collins syndrome 1
Polymalformative
syndrome
3
Neuromuscular disorder 1
Vocal cord palsy 1
Treacher Collins syndrome 2
Down syndrome 1
Achondroplasia 2
Mucopolysaccharidosis type 2 1
Prader Willi syndrome 2
Duchenne muscular dystrophy 1
Bronchopulmonary
dysplasia
2
Immunodeficiency with lymphoid tissue
hyperplasia
1
Congenital myasthenia 1
Craniofacial malformation 1
Nemaline myopathy 1
Generalised dystonia 1
Mucopolysaccharidosis
type 2
1
Achondroplasia 1
Myhre syndrome 1
Tracheomalacia 1
Spinal muscular atrophy 1
Rett syndrome 1
Goldenhar syndrome 1
Hanhart syndrome 1
Beckwith Wiedemann
syndrome
1
Loeys Dietz syndrome 1
Ossificant fibrodysplasia 1
Idiopathic OSAS 1
OSAS, obstructive sleep apnea syndrome.
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and sleep unit by the other medical and surgical
departments of the hospital. CPAP/NIV was initiated
after a scheduled PSG/PG that showed a mean of four
out of six criteria (made up by the five overnight gas
exchange abnormalities aforementioned and the addi-
tion of an AHI >10/hr) (Tables 2 and 3 and Figs. 1
and 2). These patients did not have overt symptoms of
SDB, based on parents’ reports. This group was
designated as the Chronic group. A combination of
several abnormal gas exchange or PSG/PG data was
observed in most of the patients. In this group, the four
patients with a normal AHI and SpO2 had an ODI of 5,
12, 16, and 38/hr, respectively.
Clinical and demographic characteristics of the three
groups are shown in Table 1. The median age of the
patients in the Acute group was significantly lower as the
other two groups (P¼ 0.009). The Acute group was
characterized by the unavailability of any abnormal
overnight gas exchange or PG/PSG criteria whereas the
median number of criteria in the Subacute and Chronic
group were three and four, respectively.
Figure 2 shows the number of patients with abnormal
criteria for the Subacute and Chronic group. In the
Subacute group the most common alterations were a
minimal SpO2 %90% and an abnormalODI. Themajority
of patients in the Chronic group were hypoxemic
(minimal SpO2 %90% and abnormal ODI) and had a
high AHI. On the other hand hypercapnia, defined as a
PtcCO2 "50mmHg for at least 2% of night time and as a
maximal PtcCO2 "50mmHg, was seen in almost half of
our cohort.
Table 3 shows the overnight gas exchange and sleep
study results in the Subacute and Chronic group. No
TABLE 2—Respiratory Variables Used for Continuous
Positive Pressure or Noninvasive Ventilation Initiation
1. Minimum SpO2 <90%
2. Maximal PtcCO2 >50mmHg
3. Time spent with a SpO2 <90% "2% of recording time
4. Time spent with a PtcCO2 >50mmHg "2% of recording time
5. Oxygen desaturation index >1.4 events/hr
6. AHI >10 events/hr
SpO2, pulse oximetry; PtcCO2, transcutaneous carbon dioxide; AHI,
apnea-hypopnea index.
TABLE 3—Nocturnal Gas Exchange and Sleep Study Results in the Subacute Group and the Chronic Group
Subacute group n¼ 18 Chronic group n¼ 43 P
Nocturnal gas exchange
Minimal SpO2 (%) 79 (68–90) 80 (57–92) 0.65
Time spent with SpO2 <90% (%) 2 (0–13) 1 (0–89) 0.99
Oxygen desaturation index (number/hr) 16 (0–48) 21 (2–88) 0.22
Maximal PtcCO2 (mmHg) 53 (41–83) 51 (38–70) 0.20
Time spent with PtcCO2 >50mmHg (%) 7 (0–100) 0 (0–93) 0.08
AHI (events/hr) NA 23 (0–159)
Data are given as median and range.
AHI, apnea hypopnea index; NA, not available; PtcCO2, transcutaneous carbon dioxide; SpO2, pulse oximetry.
Fig. 1. Percentage of patients having one or more abnormal criteria that led to the initiation of
CPAP or NIV in the Subacute (n¼18) and Chronic group (n¼43).
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significant differences were observed between these two
groups regarding overnight gas exchange. Median SpO2
and PtcCO2were also comparable for the two groups with
a median SpO2 of 95% (89–97%) and 94% (86–100%) for
the Subacute and Chronic group, respectively (P¼ 0.97),
and a median PtcCO2 of 46mmHg (41–83mmHg) and 51
(38–70mmHg) for the Subacute and Chronic group,
respectively (P¼ 0.37).
DISCUSSION
This study is the first to analyze the objective overnight
respiratory parameters and the clinical situations that led
to the initiation of CPAP or NIV in a large pediatric
population. Our results show that CPAP or NIV was
initiated in three different situations namely an acute,
subacute, or chronic setting, with the majority of the
patients in the two latter groups having an association of
several abnormal objective respiratory parameters such as
SpO2, PtcCO2, and/or AHI.
Long term CPAP/NIV was started in an acute setting
after a respiratory exacerbation or as transition from
invasive ventilation in 20% of our patients but also in 38%
of the patients presenting severe complex OSAS in a
Portuguese pediatric center.18 In this Acute group, the
clinical respiratory status of the patients was too unstable
to allow any spontaneously breathing overnight gas
exchange or PG/PSG recording. Due to the specific
recruitment of our hospital, which concentrates numerous
national reference centers, including the national refer-
ence center for Pierre Robin Sequence, the patients in this
group were younger than those of the two other groups.15
The Subacute group comprised patients referred by a
subspecialist during a hospital admission, either for a
moderate acute respiratory exacerbation or a scheduled
hospitalization for the follow up for their underlying
disease. Since the number of PGs and PSGs that may be
performed is strongly limited by the availability of sleep
equipments, we usually apply a shortcut in order to
overcome the inevitable delay for a sleep study in clinical
practice. Such practice is also reported by other centers
with only 49% of the patients being started on CPAP/NIV
being evaluated by a PG.18 Patients in whom the clinical
presentation was considered severe enough based on
clinical examination and age, usually underwent only an
overnight gas exchange study. On the contrary, patients
with a suspected SDB but in a stable condition underwent
a PG or a PSG along with an overnight gas exchange
study, in order to quantify the degree of severity of their
SDB. The decision of performing either a gas exchange or
a PSG/PG was taken by the medical staff of the NIVunit.
Based on these premises, we expected to find a higher
degree of severity in the Subacute group as compared to
the Chronic group. But we did not observe any important
difference between the two groups regarding the severity
of gas exchange abnormalities or general characteristics
such as age. Some patients with the same underlying
disease (such as Prader Willi syndrome or achondropla-
sia) could belong to different groups. This may be
explained by the presence of more overt SDB symptoms
in patients in the Subacute as compared to the Chronic
group. However, the poor correlation between symptoms
and objective assessments of SDB is well known in
children. In summary, as patients in the present Subacute
and Chronic group had similar gas exchange abnormali-
ties, it may seem justified to join these two groups for
future studies.
It is known that nocturnal SpO2, if evaluated by a
skilled physician, could effectively identify children with
OSAS26 or with SDB due to neuromuscular disease.27
Fig. 2. Number of patients having an abnormal nocturnal parameter in the Subacute (n¼18)
and Chronic group (n¼43). SpO2, pulse oximetry; ODI, oxygen desaturation index; PtcCO2,
transcutaneous carbon dioxide; AHI, apnea-hypopnea index.
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Moreover, the addition of overnight capnography enables
the diagnosis of nocturnal hypoventilation.28 One can
therefore speculate that, since a gas exchange study may
effectively identify which patient has severe SDB, a
complete sleep study may be superfluous for some
children requiring CPAP/NIV. On the contrary, PSG
remains the gold standard for children with suspected
SDB, as it allows to assess the severity of SDB and to
identify subtle alterations that can not detected by a
simple gas exchange monitoring or a PG, in particular
for patients with mild to moderate abnormalities
(1<AHI<10 events/hr).29 However, the patients in our
study had profound abnormalities on their PSG or PG
with a median AHI of 23 (0–159) events/hr, which
may suppose that the performance of a PSG instead of
a PG would not have changed the decision of CPAP or
NIV.
Another important finding of our study is that the
initiation of CPAP or NIV was usually based on a
combination of several severely abnormal physiological
parameters, with very few patients having only one or two
abnormalities. Obviously, some abnormalities are clearly
related to each others, like minimal SpO2 and the time
spent with SpO2 <90% or ODI and AHI, but this
observation highlights the importance of identifying a
“core” of objectives measurements that could coherently
identify which child will benefit most from long term
ventilatory support.
The most frequent gas exchange abnormality was
hypoxia, in particular pathological minimal SpO2% and
ODI. This data could possibly reflect the high prevalence
of patients with OSAS due to upper airwaymalformations
in our cohort.
This study has several limitations. Our data come from
a single specialized center in pediatric NIV and may not
be applicable to other centers. Secondly, our recruitment
may also differ from other centers with a majority of
patients having complex genetic disorders. However, the
pathologies presented by our patients are comparable to
that of other pediatric centers in Europe.18,30 Thirdly, we
arbitrarily selected a core of major criteria routinely used
to initiate CPAP/NIV at our center. We voluntary omit
some criteria that may be taken into account when
deciding to start CPAP/NIV such as clinical symptoms of
SDB, sleep quality and quality of life,31 lung function
tests, and the rate of unscheduled hospital admissions20 as
for neuromuscular patients. Since these criteria are
difficult to be standardized in order to create a univocal
set of objective measures, we decided not to add them in
the analysis of CPAP/NIV initiation criteria. However,
these criteria may be taken into account on an individual
basis when deciding for a PSG/PG. Besides these
considerations it has to be said that every patient in our
cohort had at least one pathological criterion.
In conclusion, our main results are that the initiation of
CPAP/NIVin children occurred in three different settings;
that is, an acute, subacute and chronic setting with the
majority of the patients of the Subacute and Chronic
groups presenting an association of severely abnormal gas
exchange or PG parameters. Future studies evaluating the
effectiveness and benefits of CPAP/NIV should take in
account the clinical situation and initiation criteria.
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Abstract  
Introduction 
Current guidelines recommend initiating continuous positive airway pressure (CPAP) in children 
during an overnight in-hospital titration study. Due to a shortage of hospital beds and economic 
constraints, we started an outpatient initiation of CPAP in selected children with obstructive sleep 
apnea (OSA). 
Methods 
Objective CPAP compliance and efficacy were evaluated in consecutive children enrolled in an 
outpatient CPAP program when they fulfilled the following criteria: persistent OSA, age > 6 months, 
stable condition, family living in the Parisian area and agreeing with a regular follow-up. 
Results 
Thirty-one children, median (range) age 8.9 years (0.8-17.5), were included in the program. The most 
common diagnoses were Down syndrome (n=7), achondroplasia (n=3) and obesity (n=3). Median 
baseline obstructive apnea-hypopnea index (OAHI) was 12.5 events/h (5-100). Median duration of 
follow-up was 12.3 months (2.2-25.2). Four subjects (3 adolescents with Down syndrome) were not 
compliant at 2-month follow-up with a compliance <4 h/night. In the other 27 subjects, median 
compliance was 08:21 h:min/night (05:45-12:20), with a median number of night use per month of 
25 (18-30). CPAP efficacy at the end of follow-up was excellent in the compliant subjects with a 
median AHI of 2 events/h (0-4) and normal gas exchange with CPAP therapy. Three subjects were 
successfully weaned from CPAP treatment during the study period. 
Conclusion 
Initiating CPAP in an outpatient setting in children is feasible and effective in selected subjects. A 
high rate of compliance can be achieved as well as a correction of OSA. 
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Obstructive sleep apnea (OSA) 
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Pulse oximetry (SpO2)  
Transcutaneous carbon dioxide (PtcCO2) 
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Brief summary 
 
Study rationale 
- Current guidelines recommend that continuous positive airway pressure (CPAP) should be 
initiated in a hospital setting during a titration overnight polysomnography (PSG).  
- Due to the shortage of hospital beds and the increasing number of children who need CPAP 
an outpatient initiation program should be preferred.   
  
Study impact 
- Initiation of CPAP in an outpatient setting is feasible and effective in selected pediatric 
subjects.  
- A high rate of compliance can be achieved as well as a correction of obstructive sleep apnea 
syndrome (OSAS).  
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Introduction 
 Continuous positive airway pressure (CPAP) is increasingly used in children with persistent 
obstructive sleep apnea (OSA) despite optimal medical and/or surgical management 1–3. CPAP has 
proven its efficacy for treating OSA in children with various underlying disorders such as Down 
syndrome, congenital bone diseases, metabolic diseases, Prader Willi syndrome, and craniofacial 
malformations 1,4–8.  
 Current guidelines recommend a CPAP initiation in an hospital setting with an overnight 
supervised polysomnography (PSG) titration study 9. However, this approach is not always feasible 
in real life because of shortage of hospital beds, limited access to PSG, and economic constraints. 
Moreover, repeated hospitalizations may be stressful for children with chronic conditions who spent 
already a large amount of time in hospital. Hospitalizations are associated with school and parent’s 
work loss, and a risk of nosocomial infection, particularly during the winter season. In addition, with 
regard to comfort and quality of life, subjects and families inevitably prefer outpatient versus in 
patient care 10. Moreover, there have been dramatic improvements in the technology of home CPAP 
devices over last decade. The in-built software of CPAP devices can now provide a large amount of 
data regarding treatment compliance and efficacy, even in young children 11. For all these reasons, 
initiation of CPAP in an outpatient setting within a strict protocol may constitute an alternative to an 
inpatient initiation. Some experience has been reported on the initiation of mechanical ventilation in 
an outpatient or home setting in adult subjects, but experience in children is scarce 12,13. 
 The aim of the present study was to evaluate the objective compliance and efficacy of CPAP 
initiated through an outpatient CPAP program in selected children with OSA. 
 
Methods 
Selection and description of participants  
 The study was conducted between Mars 2015 and January 2017 at the noninvasive ventilation 
(NIV) and sleep unit of Necker Children’s Hospital. All consecutive children who underwent an 
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overnight polysomnography (PSG) or polygraphy (PG)  in our sleep laboratory and who presented 
persistent OSA defined as an obstructive apnea-hypopnea index (OAHI) > 5 events/hour despite 
optimal surgical and/or medical treatment, were included in an outpatient CPAP initiation program if 
they fulfilled the following inclusion criteria: 1) stable medical condition, 2) age > 6 month of age, 
3) French-speaking family living in the Parisian area and agreeing with regular follow-up visits.  
The protocol was approved by the local ethical committee (CPP Ile de France II, n° 2014-03-09 SC). 
 
Outpatient initiation program 
 The program consisted of an individual approximately 2-hours outpatient visit. During the first 
30 minutes, the results of the sleep study and the principles of CPAP treatment were explained to the 
patient (if age > 2 – 3 years) and the parents by a paediatric pulmonologist and a nurse specialized in 
NIV and educational intervention, by means of specific age-adapted educational tools. These tools 
associated educational boards and cartoons, a booklet explaining CPAP, and a teddy bear breathing 
with a CPAP device (online Figures 1 and 2). 
 The choice of the ventilator was made according to manufacturers’ recommendations, i.e. based 
on a minimal weight 14–17. This choice was made in order to avoid an underestimation of objective 
compliance due to a too low flow rate in young children, as previously reported by our group 18. 
Heated humidification was systematically proposed. The most appropriate and comfortable interface 
according to patient’s age, facial morphology and preference was chosen.  
 The interface was then tried first without the CPAP device. The parents (and the patient if 
possible) were trained to put on and off the interface. CPAP was then started at a minimal pressure 
of 4 cmH2O, which was progressively increased to the highest tolerated pressure level, while the 
patient was lying down calmly. The patient was then asked to keep the CPAP with the chosen pressure 
for at least 30 minutes. According to manufacturers’ indications, auto-titrating CPAP was only used 
in subjects weighting more than 30 kg 16,17. During that period, relaxation or distraction was obtained 
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with the patient’s favourite nursery rhymes, music, or calm videos, according to the age and 
preference of the patient.  
 Afterwards, the nurse reviewed the use and maintenance of the interface and CPAP device with 
the parents. An information and follow-up booklet on CPAP was explained and given to the parents. 
The parents were asked to contact the NIV unit by phone or email after one week and earlier if they 
encountered any problem at home. 
 A home care provider trained in paediatric NIV performed a first scheduled visit at home within 
the 3 days following the CPAP initiation and then on a weekly basis during the first month. During 
these visits, objective compliance, efficacy and comfort were assessed as well as the correct use and 
maintenance of the equipment. The data recorded on the in-built software of the CPAP device was 
systematically downloaded and transmitted to the hospital team. An overnight recording of pulse 
oximetry (SpO2) and transcutaneous carbon dioxide (PtcCO2) was performed (SenTec Digital 
Monitor, Therwil, Switzerland) at home when the CPAP use reached > 6 hours/night or at least once 
within the first two months. CPAP and/or interface adjustments were eventually performed at home 
according to the results. 
 A follow-up outpatient consultation with the paediatrician and the NIV nurse was scheduled 1 
month after CPAP initiation. Objective compliance and recorded data were reviewed via the 
respective in-built software (Encore Basic Version 2.2 and DirectView 2.2, Philips Herrsching, 
Germany, for Philips devices and ResScan Data Management software 5.0 and further versions, 
ResMed, NSW, Australia for ResMed devices). Potential problems or difficulties with CPAP were 
analyzed and the interface and/or CPAP settings were changed if necessary. Follow-up outpatient 
visits were then performed monthly during the first two months and then every three months. Subjects 
and their families were contacted by phone or via email (when preferred) every two weeks in the first 
two months. CPAP compliance and efficacy was checked via in-built software data at each visit. In-
hospital polygraphy (PG) or PSG with CPAP was only performed in case of persistent symptoms of 
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OSA despite an objective compliance > 6 hours/night or when the gas exchange and in-built software 
data were not conclusive or not interpretable. 
 Objective compliance was calculated as the median number of hours of CPAP use per night and 
the percentage of nights with a CPAP use > 4 hours/night. Non-compliance CPAP was arbitrarily 
defined as an objective CPAP use of less than 4 hours per night after the first two months. CPAP 
efficacy was evaluated using the OAHI on a PG/PSG or the AHI recorded by in-built software data 
of the CPAP device that was checked for accuracy, and the overnight gas exchange with CPAP. Data 
are presented as median and range or mean and standard deviation.  
 
Results 
 Thirty-one subjects were included in the outpatient program, which represented 35% of the 
subjects started on long term CPAP during the study period (Table 1). Fifty-seven subjects were not 
included because of an age ≤ 6 month (n=16), an unstable clinical state with an initiation in the 
intensive care unit (n=8), non-French-speaking family or a family living outside the Parisian area 
(n=33). The median age of the population at CPAP initiation was 8.9 years (range 0.8-17.5) with a 
predominance of male gender (n=19). The median BMI centile was 87.3 (range 5.7-99.6). The most 
common diagnosis was Down syndrome (n=7), followed by achondroplasia (n=3) and obesity (n=3). 
Median baseline OAHI was 12.5 events/h (range 4-100). 
 Twenty seven (87%) subjects achieved an excellent compliance after the first two months, 
with a median use of 08:21 h:min (range 05:45-12:20) per night (Table 2) at the follow-up visit. 
CPAP was used a median of 25 (range 18-30) nights per month and for more than 4 h/night during a 
median of 83 ± 17% of nights. The majority of subjects (81%) used a nasal mask. Fifteen subjects 
(55%) used a constant CPAP with a mean pressure of 8.5 ± 1.0 cmH2O. Auto-titrating CPAP was 
used in the 12 (45%) oldest subjects. The most common auto-titrating CPAP pressure ranges were 8-
12 cmH2O in 8 (67%) of the 12 patients.    
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 Four subjects never achieved a CPAP use of more than 4 hours per night. Three of these subjects 
were adolescents with Down syndrome (a boy of 16.2 years and two girls of 16.6 and 10.2 years 
respectively) and the last patient was an 8-year-old girl with an arteriovenous cervico-facial 
malformation. All these subjects combined variable degrees of developmental delay, behaviour 
problems and a deficient family structure that never adhered to the CPAP treatment. 
 Efficacy of CPAP was assessed after 2 months by nocturnal gas exchange in all the subjects, and 
by the AHI given by the in-built software of the CPAP device in 17 (63%) subjects and on a PSG/PG 
in 4 (15%) subjects (Table 3). None of the subjects spent ≥ 2% of night time with a SpO2 < 90% or a 
PtcCO2 > 50 mmHg. The OAHI on the PSG/PG, as well as the AHI given by the in-built software 
data on the CPAP device, improved dramatically (Figure 1). One child developed central sleep apneas 
with a central apnea index of 7 events/h that resolved with the decrease of CPAP pressure. With the 
exception of this patient, none other patients required several overnight assessments with CPAP in 
order to achieve the correction of OSA. 
 Three subjects were weaned from CPAP treatment after 21.5, 16.9 and 13.6 months of follow-up 
respectively. One patient with mucopolysaccaridosis improved after mandibular distraction 
osteogenesis while the other two subjects, one with 22q11 deletion and the other with a 
polymalformative syndrome, improved spontaneously with age. Concerning the non-compliant 
children, the boy with Down syndrome had a second adenoidectomy that resolved his OSA. The two 
girls with Down syndrome were switched to high flow air by nasal cannula but did neither comply 
with this type of respiratory support. The oldest girl had persistent OSA with an OAHI of 9 events/h 
and the mother decided to stop the follow-up at the last visit. The youngest girl, whose OAHI remains 
high at 45 events/h at the last PG control, will have an orthodontic treatment with surgical palatal 
enlargement. The girl with the arteriovenous cervico-facial malformation had a laser reduction of the 
mass with a control sleep study planned in the next months. 
 
Discussion 
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 Our study shows that an outpatient CPAP initiation program is feasible and efficacious in selected 
children with OSA with an excellent compliance in the majority of subjects and a correction of OSA. 
Indeed, 87% of the subjects achieved an excellent compliance with a median objective use of CPAP 
of about 8 hours per night and the correction of OSA. 
 One of the main concerns about CPAP is compliance to treatment. Most studies reported a 
suboptimal compliance with CPAP uses ranging from 4.7 to 5.3 h/night despite a behavioural 
program and a close follow-up 19,20. Possible explanations for the excellent compliance observed in 
the present study may include the use of a CPAP educational program with age-adapted tools. 
Different types of intervention such as supportive interventions during follow-up, educational 
interventions and behavioural therapy have proven their efficacy to improve CPAP usage in adult 
subjects 21. To our knowledge, only one study has evaluated the effect of educational interventions 
on CPAP compliance in children, showing that 3 out of 4 preschool children maintain the benefit of 
education intervention over time22. We have developed this type of intervention since several years, 
which may explain the excellent compliance (over 8 hours/night) reported in a previous study from 
our group 18. Importantly, especially for children, it is crucial to choose the age- and developmental-
adjusted interventions that best match individual patient needs in order to reach the most successful 
and cost-effective therapy (online Figures 1 and 2) 21. Second, few children in our study were initiated 
to CPAP due to obesity (n=3), which has been recognized as a risk factor for poor adherence 20,23. 
Finally, the close collaboration with home care providers trained in pediatric CPAP may have 
contributed to the excellent compliance. These home care providers perform regular home visits and 
transmit to the hospital team the objective CPAP compliance data which allows prompt adjustments 
during the first weeks of treatment. Indeed, the first weeks of CPAP treatment are crucial for CPAP 
success 24 . The close follow-up visits during the first weeks with overnight recording of nocturnal 
gas exchange during CPAP allows immediate and efficacious adjustment of the interface and the 
CPAP settings 25.  
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 However, 4 (13%) subjects never accepted CPAP despite repeated visits and treatment 
adjustments. Three of these subjects had Down syndrome and all these subjects had some degree of 
developmental delay, behavioural problems and most importantly, a deficient family structure. CPAP 
failure was particularly high in a recent study where 5 out of 10 children with Down syndrome and 
OSA did not accept CPAP 26. All these children were deficient in tests of adaptive behaviour, visual-
motor integration, and achievement. Importantly, investment and motivation of the family is 
absolutely mandatory for the success of long term CPAP. In our experience, a supportive family is 
probably one of the greatest predictor of CPAP success27.   
 The efficacy of the outpatient CPAP program with regard to the correction of OSA was excellent 
and comparable to previous work from our group. CPAP was associated with a normalization of 
nocturnal gas exchange 18,28 and a dramatic decrease of the OAHI and AHI 28. Moreover, at the present 
time, we observed no long-term failure among the compliant subjects and none of the subjects 
required a tracheotomy. 
 Our study has some limitation. First, the subjects included in the outpatient initiation program 
were not compared to a control group. We did not take this option because of the selection criteria of 
the outpatient population. Indeed, in clinical practice, because of medical and practical constraints, 
only around 35% of the total population started on long term CPAP was eligible for this program. 
Finally, in a previous study from our group, during which CPAP was initiated in the hospital for all 
the subjects, the mean objective CPAP compliance was found to be as high as 8:17 ± 2:30 h/min per 
night 18. Another limitation of our study is that the correction of OSA was not always controlled by a 
PSG/PG. However, we have shown that when CPAP is performed by a skilled and experienced team, 
residual respiratory events during CPAP are rare 28. Concerning the use of the in-built software data 
of the CPAP devices, studies in adult subjects have shown the reliability of the AHI given by the 
devices 29–31. Our group has very recently shown that automatic AHI given by the CPAP may 
overestimate the polygraphic AHI 32. We therefore checked the flow tracings on the CPAP software 
to ascertain the accuracy of reported AHI.   
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 In conclusion, the present study confirms that the initiation of CPAP in an outpatient setting 
is feasible and effective in selected pediatric subjects. A high rate of compliance can be achieved as 
well as a correction of OSAS. We strongly believe that our results highlight the importance of a 
dedicated pediatric CPAP/NIV unit working in close collaboration with trained pediatric homecare 
providers for the initiation and the follow-up of these subjects.  
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Figure Legends 
 
Figure 1. 
AHI before and after treatment 
Abbreviations: Apnea Hypopnea Index = AHI (events/h) 
 
Online Figure 1. 
Booklet for educational intervention. 
 
Online Figure 2. 
Teddy bear breathing with a CPAP device.  
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Table 1: Demographic data and characteristics of the subjects (n=31). 
 
Female to male ratio 12/19  
Age, years (median, range) 8.9 (0.8-17.5) 
BMI, centile (median, range) 87.3 (5.7-99.6) 
Predisposing conditions Down syndrome 
Achondroplasia  
Obesity 
22q11 deletion 
Prader Willi syndrome 
Pycnodysostosis 
Mucolipidosis type 1 
Mucopolysaccaridosis type 2 
Crouzon syndrome 
Chiari malformation type 2 
Pierre Robin sequence 
Polymalformative syndrome 
Cervicofacial venous malformation 
Idiopathic OSA 
Immunodeficiency with lymphoid tissue 
hyperplasia  
7 
3 
3 
2 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
1 
OAHI, events/h (median, range) 12.5 (4-100) 
 
Abbreviations: BMI: body mass index, OSA: obstructive sleep apnea, OAHI: obstructive apnea-
hypopnea index 
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Table 2: Continuous positive airway pressure (CPAP) compliance and equipment (n=27). 
 
Duration of follow-up, months (median, range) 12.3 (2.2 – 25.2) 
Objective CPAP compliance over the last month (n=27) 
· Average use per night, h:min (median, range)  
· Percentage of nights with CPAP use > 4 hours, %  
(mean ± standard deviation)  
Average nights use per month, nights (median, range) 
 
08:21 (05:45-12:20) 
83 ± 17 
 
25 (18-30) 
Constant CPAP pressure, cmH2O (mean ± SD) (n=15) 8.5 ± 1.0 
Interface (n=27) 
- Nasal mask  
- Facial mask 
- Nasal prongs 
 
22 
3 
2 
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Table 3. Continuous positive airway pressure efficacy data of the 27 compliant subjects.  
 
 
Poly(somno)graphy apnea-hypopnea index (events/h), n= 4 
 
2 (0-2) 
 
In-built software apnea-hypopnea index (events/h), n =17 
 
2 (0-4) 
 
Nocturnal gas exchange, n= 27 
Mean SpO2 (%) 
Minimal SpO2 (%) 
Time spent with SpO2 < 90% (%) 
Oxygen Desaturation Index (events/h) 
Mean PtcCO2 (mmHg) 
Maximal PtcCO2 (mmHg) 
            Time spent with PtcCO2 > 50 mmHg (%) 
 
 
97 (93-100) 
91 (84-96) 
0 (0-1) 
1 (0-9) 
41 (35-48) 
46 (42-52) 
0 
!
Abbreviations: SpO2: pulse oximetry, PtcCO2: transcutaneous carbon dioxide. 
Data are presented as median (range). 
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A B S T R A C T
Objective: Central sleep apnea (CSA) syndromes are rare in children and data in children over one year
of age are scarce. The aim of the study was to describe the sleep characteristics, underlying disorders,
management, and outcome of children with CSA.
Patients/Methods: A retrospective chart review of all children >1 year of age, diagnosed with CSA on a
laboratory sleep study during a 20-month period, was performed. CSA was defined by a central apnea
index (CAI) >5 events/h. The clinical management and the patient’s outcome were analyzed.
Results: Eighteen of 441 (4.1%) patients recorded during the study period had CSA. The median CAI, pulse
oximetry, and oxygen desaturation index were 13/h (range 6–146), 96% (93–98%), and 18/h (6–98), re-
spectively. Neurosurgical pathologies represented the most common underlying disorders with Arnold–
Chiari malformation in four and ganglioglioma in three patients. Other underlying disorders were Prader–
Willi syndrome (N = 3), achondroplasia (N = 2), and Down syndrome, with one patient having an
achondroplasia and a Down syndrome. The remaining six patients had other genetic diseases. The most
common investigation was brain magnetic resonance imaging (MRI). Individualized management with
neurosurgery and/or chemotherapy, continuous positive airway pressure (in two patients having asso-
ciated obstructive events), or noninvasive ventilation resulted in an improvement in CSA and the clinical
presentation in 11 patients.
Conclusion: CSA is rare in children >1 year of age. Underlying disorders are dominated by neurosurgical
disorders. Individualized management is able to improve CSA and the clinical condition in most patients.
© 2016 Elsevier B.V. All rights reserved.
1. Introduction
Central sleep apnea (CSA) is a rare but serious condition that may
be associated with arterial oxygen desaturation, increase in carbon
dioxide, arousals, and a hyperadrenergic state [1]. CSA is defined
as the absence of chest and abdominal movements associated with
a cessation of airflow for more than 20 s, or lasting more than two
baseline respiratory cycles if associated with an arousal, an awak-
ening or an oxygen desaturation of at least 3% [2]. The central apnea
index (CAI) is defined as the number of central apneas per hour of
sleep. Central apneas (CAs) are physiological in newborns and infants,
whose index of up to five events per hour is considered within the
normal range [3,4]. Although a CAI >1/h is by convention diagnos-
tic of CSA, a CAI up to 5/h has been reported in healthy children
[4–8]. Therefore, a CAI >5/h is considered by some authors to be
outside the normal range [9].
CSA is the hallmark of congenital central hypoventilation syn-
drome (CCHS), which is a rare genetic disease associated with a
PHOX2Bmutation [10]. CSA is rare outside of this situation and only
limited data have been reported in the literature about children over
one year of age. Most observations are case reports and few series
on children have been reported [9]. Brainstem lesions, such as
Arnold–Chiari malformation, or brainstem compression, as ob-
served in patients with mucopolysaccharidosis or achondroplasia,
may also be responsible for CSA [11–14]. CSA has also been ob-
served in association with Prader–Willi syndrome and
hypothyroidism [15–17].
The aim of the study was to describe the sleep characteristics,
underlying disorders, management, and outcome of children over
one year of age diagnosed with CSA at a single pediatric sleep center.
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2. Methods
2.1. Patients
All the patients between the ages of one and 18 years who un-
derwent an overnight level 3 polysomnography (PSG) or polygraphy
(PG) in our sleep laboratory between September 2013 and April 2015
were considered for inclusion. Patients were referred to the sleep
laboratory either for symptoms of sleep-disordered breathing or
because of an underlying disease that is associated with an in-
creased risk of sleep-disordered breathing. Only patients with a CAI
>5/h were identified for further analysis. Patients with CCHS were
excluded. The medical records of all the patients were systemati-
cally reviewed and data were collected on the patient’s medical
history and demographics. Interventions after the baseline sleep
study, subsequent sleep studies, and outcomes were analyzed for
every patient. The study was conducted in agreement with the
French regulations and received appropriate legal and ethical ap-
proval from the Ethical Committee of Necker University Hospital
(CPP Ile de France II).
2.2. Overnight sleep studies
All sleep studies were performed in the sleep laboratory of Necker
hospital. All patients were accompanied by one parent through-
out the night. Neither sedation nor sleep deprivation was used on
any patient.
The following standardized measurements were simultane-
ously recorded during every level 3 PSG or PG: nasal flow through
a nasal pressure transducer, pulse oximetry by a pulse oximeter
(SpO2), oximeter pulse wave form, thoracic and abdominal respi-
ratory inductance plethysmography, digital synchronized infrared
video monitoring (Cidelec, St Gemmes sur Loire, France or Alice 6,
Philips Respironics, St Priest, France), and transcutaneous carbon
dioxide pressure (PtcCO2, SenTec, Therwil, Switzerland). For PSG, the
following data were also recorded: electroencephalogram (C3A2, C4A1,
O1A2, and O2A1), right and left electro-oculogram, submental, an-
terior tibialis electromyogram, and electrocardiography.
Scoring of sleep stages and respiratory events were performed
according to the actualized 2012 scoring rules of the American
Academy of Sleep Medicine [2]. The following definitions for re-
spiratory events were used for scoring purposes [2]. CA was defined
as the absence of airflow with the cessation of respiratory effort,
lasting more than 20 s or of shorter duration and associated with
an arousal and/or a 3% oxygen desaturation. CA occurring after gross
body movements or after sighs was not included in the analysis.
Obstructive apnea (OA) was defined as the absence of nasal airflow
with continued chest wall and abdominal movements for at least
two breaths. Mixed apnea was defined as an apnea that usually
begins as central and ends as obstructive according to changes in
the chest, abdominal, and flow traces. Hypopnea was defined as a
decrease in nasal airflow of at least 30% with a corresponding de-
crease in pulse oximetry (SpO2) of at least 3% and/or an arousal. The
apnea–hypopnea index (AHI) was calculated as the sum of apneas
and hypopneas per hour of total sleep time. An obstructive AHI
(OAHI) <1.5/h and CAI <5/h were considered as normal. All the PSGs/
PGs were scored by two experienced pediatric sleep specialists.
Mean, minimal SpO2 values, and the percentage of total sleep
time spent with SpO2 <90%were calculated. The oxygen desaturation
index (ODI) was defined as the number of SpO2 drops of at least
3% per hour of total sleep time. Mean, maximal values of PtcCO2
and the percentage of total sleep time spent with a PtcCO2 >50mmHg
were calculated.
Repeat sleep studies were performed or planned for all 18 pa-
tients. As there are no recommendations or guidelines, we chose
to define an improvement by a >50% reduction in the CAI in the
repeat sleep studies as it was thought to represent a true change
rather than intra-individual variability.
3. Results
3.1. Patients
Four-hundred and forty-one children over the age of one year
underwent an overnight sleep study in our laboratory during the
study period. Eighteen patients (4.1%) had a CAI >5/h (Table 1).
Apneas during sleep and wakefulness were reported only by the
parents of patient #7 who suffered from a ganglioglioma; all the
other patients had no symptoms of sleep-disordered breathing and
were referred to the sleep laboratory for a systematic sleep study.
Neurosurgical pathologies represented the most common un-
derlying disorders with four patients (patients #1 to #4) having an
Arnold–Chiari malformation and three patients (patients #5 to #7)
having a ganglioglioma. Other underlying disorders were Prader–
Willi syndrome (N = 3, patients #8 to #10), achondroplasia (N = 2,
patients #11 and #12), and Down syndrome (patient #13), with
patient #12 having both an achondroplasia and a Down syn-
drome. The remaining five patients had various other genetic diseases
(patients #14 to #18).
3.2. Polygraphic data
A level 3 PSG was performed in two patients (patients #6 and
#10) whereas a PG was performed in all the other patients. The CAI
was highly variable with five patients having a CAI between 5/h and
6/h (patients #3, #4, #13, #16, and #17), the other patients having
a CAI between 11/h and 146/h, with the highest value being ob-
served in a patient with a ganglioglioma (patient #5). Four patients
had exclusively CSA (patient #2 and patients #16 to #18) whereas
two other patients (patients #13 and #15) also had some obstruc-
tive events. Mean SpO2was ≥94% in all the patients except in patient
#2 who had an Arnold–Chiari malformation. Minimal SpO2 was
below 90% except in one patient with Prader–Willi syndrome (patient
#2) but only two patients spent more than 1% of the recording time
with a SpO2 <90% (patients #1 and #13). The ODI was very high with
a median value of 18/h. Only two patients had a maximal PtcCO2
>50 mmHg (patients #7 and #13).
3.3. Interventions and outcome of the patients
Table 2 shows intervention and outcome of the patients.
A brain magnetic resonance imaging (MRI) was performed in
all the patients. This MRI revealed a cervico-medullary compres-
sion in six patients, in the four patients with an Arnold–Chiari
malformation, in one patient with a ganglioglioma (patient #7),
and another patient with achondroplasia (patient #12). A cervico-
medullary decompression was performed in five patients (patients
#1, #2, #3, #4, and #7) and could not be performed in patient
#12 (achondroplasia with Down syndrome). Patient #1 was suc-
cessfullymanaged by noninvasive ventilation (NIV) due to persistence
of the CSA after the cervico-medullary decompression. Patient #3
required a tracheostomy after the cervico-medullary decompres-
sion because of an increase in CSA. A modification of the
chemotherapy was associated with an improvement in CSA in
patient #6 who suffered from a ganglioglioma. The other patient
with a ganglioglioma (patient #7) was successfully managed with
servo-assisted ventilation after the persistence of CSA despite a
cervicomedullary decompression. A spontaneous resolution of the
CSA was observed in one patient with Prader–Willi syndrome
(patient #9) and one patient with achondroplasia (patient #11).
Acetazolamide was tried in the two patients with Prader–Willi
syndrome (patients #8 and #10). A 50% reduction in CAI was
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observed in patient #8, who later improved spontaneously. Non-
invasive continuous positive airway pressure (CPAP) was initiated
in two patients who had associated obstructive events (patients
#13 and #15). CPAPwas associatedwith an improvement inminimal
SpO2, ODI, and hypercapnia in patient #1 and with an improve-
ment in the ODI in patient #15. Three patients moved abroad and
were lost to follow-up (patient #5, #12, and #14). Clinical follow-
up continues in all the other 15 patients, with repeat sleep studies
being planned in the three patients who had no intervention after
initial diagnosis (patients #16 to #18). These patients had a normal
MRI.
In summary, an improvement in CSA was observed in 11 pa-
tients, one patient required a tracheostomy, follow-up is continued
for three patients, and three patients were lost for follow-up.
4. Discussion
To our knowledge, this study is the largest series of CSA in chil-
dren older than one year of age published to date. The main findings
are that the prevalence of CSA reaches almost 5% (4.1%), but this
number may be underestimated due to a lack of clinical symp-
toms in the vast majority of patients. Causes are dominated by
neurosurgical disorders such as Arnold–Chiari malformations, ce-
rebral tumors, and occipito-cervical compression. Finally, an
individualized, multidisciplinary management approach, based on
the clinical presentation, may result in an improvement of CSA in
majority of patients. This may include neurosurgery, chemothera-
py, and noninvasive respiratory support.
The prevalence of CSA in our population was similar to a recent
study by Kritzinger et al. [9]. They included children under the age
of one year, finding a prevalence of 5.4% as compared to a preva-
lence of 4.1% in the present study. This moderate difference may be
explained by a recruitment bias, the fact that CSA was diagnosed
by a PSG in the study by Kritzinger et al. and a PG in the present
study, and the inclusion of children younger than one year of age
by Kritzinger et al. Both reports could underestimate the real prev-
alence of CSA as patients are generally asymptomatic, as opposed
to patients with obstructive sleep apnea. In the present series, only
one patient with a ganglioglioma complained of apneas which were
witnessed by his parents during sleep. This underlines the impor-
tance of a systematic sleep study in all children having any disorder
or risk factor for CSA. As the prevalence, prognosis, and outcome
of CSA are largely unknown, it is unknown at which intervals these
children need to be assessed.
Brain MRI had a highest diagnostic yield of the investigations
performed with 40% (six out of 15 patients) of the patients having
a cervicomedullary compression requiring a neurosurgical inter-
vention. None of the patients had PHOXB2 genetic testing because
all the patients were older than one year of age and none pre-
sented with alveolar hypoventilation and diffuse autonomic nervous
system dysregulation [10]. Moreover, all the patients had an un-
derlying disorder that may be associated with or cause CSA.
Neurosurgical disorders were the leading cause of CSA in the present
series, representing 39% (seven of 18) of the patients. One patient
with achondroplasia and Down syndrome had a stenosis of the
foramen magnum on brain MRI (patient #12). These two diseases
are known to be associated with brainstem compression, which
underlines the importance of a systematic screening with MRI
and a sleep study in children with achondroplasia or Down syn-
drome [14,18,19]. Patients with Down syndrome may effectively
present OA but CSA may also be observed [19]. Cervicomedullary
decompression is generally effective in correcting the CSA in pa-
tients with Arnold–Chiari malformation, as observed in patient
#2 [20]. Patient #1 had an unexplained medullary malformation
with no improvement after a cervicomedullary decompression.Ta
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Table 2
Interventions and evolution of the patients.
Patient Underlying disease Intervention Delay between
PG (months)
CAI AHI Mean
SpO2 (%)
Minimal
SpO2 (%)
ODI
(events/h)
% time with
SpO2<90%
Mean PtcCO2
(mmHg)
Maximal
PtcCO2 (mmHg)
Follow-up
1 Medullary
malformation
CMD 2 81 82 94 83 80 4 NA NA
3 80 92 96 78 63 4 37 40 Brain MRI: persistence of
the ptosis of the cerebellar
tonsils
NIV 12 2 2 96 92 0 0 38 41 Follow-up of NIV
2 Arnold–Chiari
malformation
CMD 2 0 0 98 92 0 0 38 41 Not necessary
3 Arnold–Chiari
malformation
CMD Tracheostomy after CMD
4 Arnold–Chiari
malformation
CMD Uneventful CMD
5 Ganglioglioma None Lost for follow-up (abroad)
6 Ganglioglioma Chemotherapy continued 9 4 12 95 87 49 0 50 54 Brain MRI: stability of the
lesions, modification of
chemotherapy
7 Ganglioglioma CMD 13 32 111 95 85 98 0.3 41 47
Servo-assisted ventilation 14 0 0 95 92 1 0 48 50 Servo-assisted ventilation
continued
8 Prader–Willi syndrome Acetazolamide 125 mg/j 8 20 20 97 91 7 0 39 44 Acetazolamide withdrawal
9 Prader–Willi syndrome None 7 1 2 98 91 1 0 41 44 Normal brain MRI
10 Prader–Willi syndrome Acetazolamide since 15 days 4 3 8 96 87 7 0 38 39 Normal brain MRI
After acetazolamide withdrawal 10 4 4 94 86 3 0 NA NA
11 Achondroplasia 2 7 7 97 85 2 0 40 45 Normal brain MRI
None 12 1.9 4 97 86 3.5 0 42 46
12 Achondroplasia + Down
syndrome
None Stenosis of the foramen
magnum on brain MRI Lost
for follow-up (abroad)
13 Down syndrome CPAP 4 NA NA 99 92 2 0 NA NA
CPAP 8 NA NA 95 92 1 0 49 56 CPAP continued
14 Arthrogryposis + hypothyroidism None 12 4 24 96 78 36 1 NA NA Lost for follow-up (abroad)
15 Polymalformation CPAP 2 NA N/A 98 85 3 0 35 38
Autotitrated CPAP 4 25 32 NA NA 23 NA 37 38
Palatal cleft repair + CPAP 6 NA N/A 95 90 11 0 44 45
CPAP 11 0 31 96 82 13 0 36 39 CPAP continued
16 Spondyloepiphyseal
dysplasia congenita
None Normal brain MRI
17 Cornelia de
Lange + Pierre Robin
syndrome
None Normal brain MRI
18 Potocki–Lupski
syndrome
None Normal brain MRI PG
planned
Abbreviations: AHI, apnea–hypopnea index; CAI, central apnea index; CMD, cervico-medullary decompression; CPAP, continuous positive airway pressure; MRI, magnetic resonance imaging; NA, not available; NIV, noninvasive
ventilation; ODI, oxygen desaturation index; PG, polygraphy; PtcCO2, transcutaneous carbon dioxide pressure; SpO2, pulse oximetry.
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CSA of this patient was thereafter completely corrected by nonin-
vasive ventilation set in a controlled mode. In another neurosurgical
patient with a ganglioglioma, CSA was corrected with servo-
assisted ventilation [21]. CSA has been observed in children with
Prader–Willi syndrome [16,22]. The management of CSA associ-
ated with Prader–Willi syndrome is challenging in the absence of
any therapeutic evidence or recommendation. Acetazolamide was
not tolerated in one patient and the effect was moderate in another
patient. Spontaneous improvement was observed in the third patient
with Prader–Willi syndrome. However, in these three patients,
central apneas were generally of short duration and not associ-
ated with severe hypoxemia, desaturation, or hypoventilation.
Noninvasive CPAP was initiated with success in two patients who
had associated obstructive apneas, one patient with Down syn-
drome, and another patient with a polymalformative syndrome
and cleft palate. The treatment of these obstructive events was
associated with an improvement in nocturnal gas exchange in
both patients. The three last patients had rare genetic diseases,
namely spondyloepiphyseal dysplasia congenita, Pierre Robin syn-
drome with Cornelia de Lange syndrome, and Potocki–Lupski
syndrome, all of which have been reported to be associated with
CSA [23–25].
Our study has several limitations. This was a single-center study
with an unavoidable recruitment bias. Due to poor cooperation and
neurocognitive impairment in some patients, a full PSG could not
be performed. PG is not able to identify post-arousal central or sleep–
wake transition central events from true central events that lead
to arousals. Therefore, it is possible that the real prevalence and se-
verity of CSA were underestimated.
In conclusion, asymptomatic children with underlying disor-
ders or known risk factors for CSA should be referred for a sleep
study in a timely manner in order to detect CSA or other sleep dis-
orders. Similarly, any child with CSA should undergo a brain MRI.
An individualized management strategy can therefore improve CSA
and the clinical presentation in most patients.
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Sleep-disordered breathing is a common feature in childrenwith achondroplasia. The aim of our
study was to review the poly(somno)graphic (P(S)G) findings and consequent treatments in
children with achondroplasia followed in the national reference center for skeletal dysplasia. A
retrospective review of the clinical charts and P(S)G of 43 consecutive children (mean age
3.9 ± 3.5 years) with achondroplasia seen over a period of 2 years was performed. Twenty four
(59%) children had obstructive sleep apnea (OSA). Thirteen children had an obstructive apnea-
hypopnea index (OAHI) < 5/hr, four had an OAHI between 5 and 10/hr, and seven had an
OAHI ≥ 10/hr. Ten of the 15 children who had previous upper airway surgery still had an
abnormal P(S)G. All the patients with an AHI ≥ 10/hr were under 7 years of age and none had a
prior tonsillectomy. The children who underwent adeno-tonsillectomy, coupled in most cases
with turbinectomy,were significantly older (meanage7.5 ± 3.5 vs. 3.5 ± 1.7 years old,P = 0.015)
and had significantly better P(S)G results than those who underwent only adeno-turbinectomy.
No correlationwas observed between themean AHI value at the baseline P(S)G and the type of
academic course (standard, supported or specialized). In conclusion, OSA is common in children
with achondroplasia. The observation of a reduced prevalence of OSA after (adeno-)
tonsillectomy is in favor of this type of surgery when possible.
K E YWORD S
achondroplasia, neurosurgery, polysomnography, sleep apnea, tonsillectomy
1 | INTRODUCTION
Achondroplasia is the most frequent form of short-limb dwarfism. Its
incidence is between 1 in 10,000 and 1 in 30,000 affecting more than
250,000 individuals worldwide (Baujat, Legeai-Mallet, Finidori,
Cormier-Daire, & Le Merrer, 2008; Horton, Hall, & Hecht, 2007).
The genetic defect has been identified as an arginine for glycine
substitution of the aminoacid residue at position 380 in the gene
encoding for fibroblast growth factor receptor 3 (FGFR3) (Shiang et al.,
1994). Most of the clinical features of achondroplasia are either direct
or indirect consequences of increased FGFR3 signaling on endochon-
dral bone growth. Affected individuals exhibit short stature with
predominant rhizomelic shortening of the limbs, characteristic facies
with frontal bossing and midface hypoplasia, exaggerated lumbar
lordosis, limitation of elbow extension, genu varum, and trident hand
(Bellus et al., 1995). Natural history studies identified a higher
mortality among children comparedwith the general populationwith a
causative association with foramen magnum stenosis and sudden
death (Simmons, Hashmi, Scheuerle, Canfield, & Hecht, 2014; Wynn,
King, Gambello, Waller, & Hecht, 2007).
Sleep-disordered breathing is a common finding in patients with
achondroplasia. The combination ofmidface hypoplasia, micrognathia,
and depressed nasal bridge causing narrow nasal passages or choanal
stenosis, relative adenoids, and tonsils hypertrophy, relative macro-
glossia, a high palate and decreased temporo–mandibular joint
mobility and airway muscles hypotonia predisposes these patients
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to upper airway obstruction and obstructive sleep apnea (OSA)
(Holzman, Mancuso, & Polaner, 2008). Cervical cord compression at
the cervical medullary junction may cause central sleep apneas (CSA)
and may require surgical decompression in infancy or early childhood
(Baujat et al., 2008).
TheAmericanAcademyof Pediatrics (AAP) recommends perform-
ing neuroimaging and polysomnography (PSG) at the time of diagnosis
and in case of suggestive symptoms of sleep-disordered breathing
(Trotter & Hall, 2005). Still, few studies have analyzed serial
polygraphies (PG) and therapeutic interventions in children with
achondroplasia. Mogayzel et al. reviewed the data of 88 children
(Mogayzel, Carroll, Loughlin, Hurko, Francomano, & Marcus, 1998).
Despite prior upper airway surgery or neurosurgery, 42 children had
an abnormal overnight PSG, with 18 children having severe anomalies.
Similar findings were observed in another cohort of 46 children
(Afsharpaiman, Sillence, Sheikhvatan, Ault, & Waters, 2011).
The aim of our study was to analyze the P(S)G findings with the
prior and subsequent therapeutic interventions in a large cohort of
consecutive children with achondroplasia followed in a national
reference center.
2 | MATERIALS AND METHODS
2.1 | Patients
We conducted a retrospective review of the sleep studies and
management of all consecutive children with achondroplasia who
were followed at our national reference centre for skeletal dysplasia
between September 2013 and September 2015. All the children
carried the Gly380Arg (G380R) mutation on the FGFR3 gene. Sleep
studies are performed once a year, with the first study being
performed between the age of 6 and 12 months of age in infants
diagnosed or referred to the reference centre for skeletal dysplasia
before the age of 1 year. Clinical data including coexisting medical
conditions, surgical history, use of non invasive ventilation (NIV), and
academic level were obtained from the patients’ files. The study was
approved by the ethical committee and informed consent was
obtained from parents and/or children.
2.2 | Sleep study
Overnight PG (Cidelec, Saint Gemme sur Loire, France or Alice 6,
Respironics, Carquefou, France) with the recording of nasal flow,
respiratory movements (by respiratory inductance plethysmography),
tracheal sound, body position, heart rate, pulse oximetry (SpO2) and
transcutaneous carbon dioxide (SenTec Digital Monitor, SenTecInc,
Therwil, Switzerland) were performed in room air (Berry et al., 2012).
Overnight PSG monitoring included in addition to the PG study:
electrocardiogram, central and occipital electroencephalogram (O1A2,
O2A1,C4A1,C3A2), right and left electrooculogram (ROC/A1, LOC/A2),
and submental and leg electromyograms (EMG). The choice of a PS or a
PSGwas let to the attending sleep specialist: a PSGwas performedwhen
abnormalities of sleep architecture or non-respiratory sleep disorders
were suspected, a PGwas performed in the other cases. The sleep study
was recorded on videotape with an infrared video camera.
Obstructive apnea was defined as a drop in nasal flow amplitude
by 90% of baseline for at least two respiratory cycles, with continued
or increased inspiratory effort. Central apnea was defined as a drop in
nasal flow amplitude by 90%of baselinewithout inspiratory effort, of a
duration of at least two breaths and associated with an arousal, an
awakening, or a 3% oxygen desaturation (OD), or of a duration of at
least 20 sec. Mixed apnea was defined as a drop in nasal flow
amplitude by 90% of baseline for at least two respiratory cycles with
the absence of inspiratory effort during one portion of the event and
the presence of inspiratory effort during another portion, regardless of
which portion comes first. Hypopnea was defined as a drop in nasal
flow amplitude by 30%of baseline of a duration of at least two breaths,
associated with an arousal, an awakening, or a 3% OD (Berry et al.,
2012).
Apnea-hypopnea index (AHI) was calculated as the sum of the
apnea and hypopnea events per hour of total sleep. Sleep study was
considered normal in case of an apnea index < 1 event/hr and
AHI < 1.5 events/hr (Uliel, Tauman, Greenfeld, & Sivan, 2004). Mild
sleep apnea was defined as an AHI between 1.5 and 5 events/hr,
moderate sleep apnea as an AHI between 5 and 10 events/hr, and
severe sleep apnea as an AHI ≥ 10 events/hr. The oxygen desaturation
index (ODI) was considered abnormal when >5 events/hr.
2.3 | Therapeutic interventions
All the patientswere seen every 6months during the first 2 years of life
and then once a year by pediatrician, medical geneticist, pediatric ENT
surgeon, and neurosurgeon. Indications for ENT surgery were large
with upper airway surgery being performed in case of clinical upper
airway obstruction, such as hypertrophy of the adenoids, tonsils, and/
or turbinates, a fortiori but not obligatory, associated with obstructive
sleep apnea (OSA). When there was no surgically accessible airway
obstruction or when ENT surgery was not able to reduce the IAH < 10
events/hr, noninvasive continuous positive airway pressure (CPAP) or
bilevel ventilation (BiPAP) in case of associated nocturnal alveolar
hypoventilation was initiated (Simmons et al., 2014).
Cervical decompression was performed after a multidisciplinary
evaluation based on a neurological examination, a cerebral and
cervico-medullar MRI and a sleep study (Julliand et al., 2012; Wynn
et al., 2007).
2.4 | Statistical analysis
All continuous variables were expressed asmean ± standard deviation,
or as median and interquartiles. Comparisons between two quantita-
tive variables were done using the Student t-test in case of normally
distributed population or the Mann–Whitney Rank test, otherwise.
Comparisons between three quantitative variables were done using
the One Way Analysis of Variance (ANOVA) in case of normally
distributed population or the Kruskal–Wallis One Way ANOVA on
ranks test, otherwise. Comparisons between qualitative variableswere
done using theChi-square test. Correlation between two variableswas
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done using the Pearson correlation test in case of normally distributed
population or the Spearman correlation test otherwise. A P
value < 0.05 was considered as statistically significant.
3 | RESULTS
3.1 | Patients
Forty-seven consecutive children with achondroplasia were evaluated
at our center during the study period. Three patients were excluded
from the analysis because they were already treated with BiPAP at the
time of the baseline P(S)G and one patient was excluded because of a
concomitant Down syndrome.Forty-three patients were therefore
included in the analysis (Table 1). The mean age at the baseline P(S)G
was 3.9 ± 3.5 years (range 0.3–13.3 years). Most of the patients were
young, with 10 (23%) patients being younger than 1 year of age and 9
(21%) patients being between 1 and 2 years old. Seventeen (39%)
patients had a previous sleep study in other medical centers. Two
patients had a PSG and 41 patients had a PG. Before the baseline P(S)
G, 11 patients (26%) had a prior ENT surgery, 2 patients had prior
neurosurgery, and 4 patients had both surgeries (Table 1).
3.2 | Sleep-disordered breathing
Twenty four (56%) patients had an abnormal P(S)G presenting OSA..
Table 2 shows patients characteristics according to severity of
OSA. Thirteen (29%) patients had mild OSA, four (9%) had a moderate
OSA, and seven (16%) had a severe OSA (Table 2). Two patients (5%)
were treated prior to the baseline P(S)G studywithNIV for severeOSA
and had a PG in spontaneous breathing in order to know if NIV could
be withdrawn. Moderate to severe OSA was still present in these two
patients (with an IAH of 5/hr and 18/hr). Table 2 compares the surgical
history and nocturnal gas exchange of the patients without and with
OSA. Patients without and with OSA did not differ with regard to age
or a history of prior ENT surgery or neurosurgery. Minimal SpO2 was
lower and theODIwas significantly higher in patientswith severeOSA
as compared to patients without OSA. All the patients with mild or
severe OSA were younger than 8 years old (Figure 1). As expected, a
significant positive correlation (r = 0.676, P–< 0.001) was observed
between the AHI and the ODI (Figure 2).
3.3 | Prior ENT surgery
Fifteen (35%) patients had upper airway surgery prior to the baseline
P(S)G, associated or not with other therapeutic interventions (Table 1).
Time elapsed between the surgical intervention and the baseline P(S)G
ranged from 2months to 4 years (mean 23 ± 14months). Among these
15 patients, 10 (67%) patients had still an abnormal P(S)G (Table 2).
The six children who underwent prior adeno-tonsillectomy
(associated with turbinectomy in four children) were significantly
older (mean age 7.5 ± 3.5 vs. 3.5 ± 1.7 years old, P = 0.015) and had
significantly better P(S)G and nocturnal gas exchange parameters than
those who had an adeno-turbinectomy (Table 3). All the patients an
AHI ≥ 10/hr were under 7 years of age (Figure 3A and B). None of
these patients had a prior tonsillectomy.
3.4 | Neurosurgery
Cervical and cerebral MRI reports were available for 32 of the 43
patients (74%). Radiological abnormalities were reported in 24/32
patients but only six patients (14% of total population) had a prior
neurosurgery. Cervical decompression was required in five patients
because of severe stenosis of the foramen magnum associated with
radiological and/or clinical signs of medullar injury. Three of the six
patients with prior neurosurgery had moderate or severe OSA
(Table 2).
3.5 | Academic level or learning skills
Nineteen (44%) of the 43 patients were preschoolers and at the time of
the baseline P(S)G: 15 patients had a normal neuro-cognitive
development while generalized hypotonia and/or speech delay was
observed in four patients. Among the 24 school-aged patients, 15 (62%)
followed a standard academic course, 4 (17%) needed individualized
teaching support, and4 (17%) attended a specialized school for children
with developmental delay and/or learning disabilities. Academic level
was not available in one patient. No correlation was observed between
the mean AHI value at the baseline P(S)G and the type of academic
course (standard, supported or specialized).
3.6 | Management after the baseline P(S)G
Figure 4 shows the follow up of the patients after the baseline P(S)G.
3.6.1 | Upper airway surgery
All the seven patients with severe OSAS were evaluated by a pediatric
ENT specialist. Five of these patients underwent ENT surgery (adeno-
turbinectomy, n = 2, adeno-tonsillectomy, n = 1, adeno-tonsillectomy
with turbinectomy,n = 1, tonsillectomywith turbinectomy,n = 1) even if
three of these patients had already prior ENT surgery 2–4 years before
the baseline P(S)G. In one of these patients, adeno-turbinectomy was
TABLE 1 Patients’ characteristics and previous surgical interventions
Characteristics of patients (n = 43)
Age at the P(S)G (years) 3.9
± 3.5
Sex (M/F) 22/21
Number of patients who had previous surgical
interventions
16
ENT surgery 15
Adeno-turbinectomya 9
Adeno-tonsillectomy 2
Adeno-tonsillectomy+ turbinectomy 4
Neurosurgerya 6
P(S)G, poly(somno)graphy; M, male; F, female; ENT surgery, otorhinolar-
yngology surgery. Data are presented as mean ± standard deviation.
aFour patients had both adeno-turbinectomy and neurosurgery.
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coupled with immediate CPAP initiation because of extremely severe
OSA with an AHI 159 events/hr. CPAP was also started in a second
patient because of anAHI of 10/hr despite an adeno-tonsillectomywith
turbinectomy 9 months before his baseline P(S)G. P(S)G was repeated
5months later in a last patientwhohadno symptomsandneither clinical
airway obstruction at the time of his baseline P(S)G; this second P(S)G
showed an AHI of 2 events/hr. A complete normalization of nocturnal
transcutaneous gas exchanges and the AHI on the in-built software of
the CPAP device was observed in the two patients treated with
nocturnal CPAP.
In the group with mild to moderate OSAS; one patient had a
cervico-medullary decompression and an adeno-turbinectomy because
of rarebutprofoundoxygendesaturations andhypercapnia; onepatient
TABLE 2 Patients’ characteristics and distribution according to the severity of obstructive sleep apnea
OAHI < 1.5 events/hr
(n = 19)
OAHI 1.5–5 events/hr
(n = 13)
OAHI 5-10 events/
hr (n = 4)
OAHI ≥ 10 events/
hr (n = 7) P value
Age (years) 4.4 ± 3.7 (range
0.3–12.4)
3.4 ± 3.9 (range
0.3–13.3)
4.2 ± 3.6 (range
0.3–7.8)
3.3 ± 2.2 (range
0.5–6.2)
0.728
Sex (M/F) 9/10 6/7 4/0 3/4
Previous interventions
ENT surgerya 5 3 2 5 0.403
Adeno-turbinectomy 2 1 1 5
Adeno-tonsillectomy 1 1 0 0
Adeno tonsillectomy+
Turbinectomy
2 1 1 0
Neurosurgerya 3 0 1 2
No intervention 13 10 1 2
Nocturnal gas exchanges
Minimal SpO2 (%) 91 ± 4 87 ± 7 86 ± 6 75 ± 14 0.007°
3% Oxygen desaturation index
(events/hr)
2 ± 3 6 ± 6 4 ± 3 38 ± 34 <0.001°
Maximal PtcCO2 (mmHg) 43 ± 3 43 ± 2 44 ± 8 50 ± 9 0.341
OAHI, obstructive apnea-hypopnea index; M, male; F, female; ENT surgery, upper airway surgery; PtcCO2, transcutaneous carbon dioxide pressure; SpO2,
pulse oximetry. Data are presented as mean ± standard deviation.
aFour patients had both adeno-turbinectomy and neurosurgery. ° Statistically significant between OAHI < 1.5 and ≥10 events/hr.
FIGURE 1 Relationship between patients’ age and AHI (A) and
desaturation index (B) according to the previous treatments. AHI,
apnea-hypopnea index; ENT, upper airway surgery; NS,
neurosurgery; NIV, noninvasive ventilation
FIGURE 2 Relationship between AHI and desaturation index
according to the previous treatment patients have undergone. AHI,
apnea-hypopnea index; ENT, upper airway surgery; NS,
neurosurgery; NIV,noninvasive ventilation
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previously treated with CPAP had to restart his treatment because of
the resumptionofhisOSAS;onepatienthadanadenoidectomybecause
of recurrentmiddle ear infectionwith speechdelay; andonepatientwas
started on NIV because of a persistent lobar atelectasis.
In the group of patients without sleep apneas, one patient was
successfully treated by CPAP because of an alveolar hypoventilation
due to a restrictive syndrome.
3.6.2 | Neurosurgery
One patient had a cervical decompression with adeno-turbinectomy
because of the presence of a foramen magnum re-ossification and a
moderate OSAS. This patient had already required neurosurgery for a
cervical decompression 7 years before.
4 | DISCUSSION
Themain results of our study are thatOSAwas observed in 24 (56%) of
43 children with achondroplasia followed at a national reference
center for skeletal dysplasia. Importantly, all the patients with severe
OSA were younger than the age of 7 years and none of the patients
with a history of tonsillectomy had severe OSA.
The prevalence ofOSA in achondroplasia varies from 10% to 87%,
according to the definition of OSA (Julliand et al., 2012; Mador and
Tobin, 1990; Nelson et al., 1988; Stokes et al., 1983; Waters, Everett,
Sillence, Fagan, & Sullivan, 1993; Waters, Everett, Sillence, Fagan, &
Sullivan, 1995) (Table 4). In the present study, the prevalence of OSA
remained high despite prior, and sometimes repeated, upper airway
surgery in more than 1/3 of the patients. The number of children who
had prior ENT surgery before the baseline P(S)G evaluation was
comparable to those reported in other studies (Julliand et al., 2012;
Schlüter, De Sousa, Trowitzsch, & Andler, 2011; Sisk, Heatley,
Borowski, Leverson, & Pauli, 1999; Tasker et al., 1998). Persistent
OSA after ENT surgery has been reported by several authors. Six of 10
children (60%, and 14% of the global series) who had adeno-
tonsillectomy for OSA required CPAP treatment for persistent OSA
(Waters et al., 1995). More recently, two patients (mean age 2.6 years)
out of five had a persistent OSA despite clinical improvement after
upper airway surgery (Collins andChoi, 2007). An improvement inOSA
was observed in five patients with OSA treated by various surgical
procedures after a median delay of 6.5 months (range 3–13 months)
but three patients did not normalize their AHI and ODI and two
required NIV (Julliand et al., 2012).
Importantly, in the present study, incomplete correction of OSA
was observed in all the patients in whom tonsillectomy was not
possible or not performed. Similar findings were observed in another
cohort of 95 children with achondroplasia (Sisk et al., 1999). Indeed,
the recurrence ofOSA in their populationwas significantly lower (20%)
in the 24 children who had a tonsillectomy than in the 10 children who
had an adenoidectomy (90%). Of note, OSA was defined on clinical
evidence of OSA without systematic P(S)G. These observations are in
agreement with studies in healthy children with OSA, which showed
that a tonsillectomy with adenoidectomy translated into a greater
TABLE 3 Patients’ characteristics according to ENT surgery
Adenoidectomy + Turbinectomy (n = 9) Adenoidectomy + Tonsillectomy (± Turbinectomy) (n = 6) P value
Age (years) 3.5 ± 1.7 7.5 ± 3.7 0.015
AHI (events/hr) 10 (2.5–34.5) 1.5 (1–2) 0.045
3% ODI (events/hr) 13 (3.3–32) 0.5 (0–2) 0.021
PtcCO2 max (mmHg) 48 ± 7.6 44 ± 1.6 0.025
SpO2min (%) 85 (66–91) 93 (91–93) 0.039
AHI, apnea-hypopnea index; 3% ODI, 3% oxygen desaturation index; PtcCO2 max, maximal transcutaneous carbon dioxide pressure; SpO2min, minimal
pulse oximetry. Data are presented as mean ± standard deviation or median [interquartiles].
FIGURE 3 Relationship between patients’age and AHI (A) or
desaturation index (B) according to the type of ENTsurgery; AHI,
apnea-hypopnea index
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improvement of OSA than either procedure alone (Guilleminault, Li,
Khramtsov, Pelayo, &Martinez, 2004; Guilleminault, Li, Quo, & Inouye,
2004). However, in the present study, the type of ENT surgery was
determined by the ENT surgeon on the clinical examination of the
child. In infants, it are essentially the adenoids that may be enlarged,
whereas hypertrophy of the tonsils is observed at an older age. This
explains why the mean age of the children who underwent
tonsillectomy was significantly older than those who had adenoidec-
tomywithout tonsillectomy (Table 3). Turbinectomy can be performed
at any age but again only when the size of the turbinates is sufficient.
To conclude, this observation justifies 1) a regular and systematic sleep
evaluation in all children until the age of possible potential
tonsillectomy (i.e., 6–8years) and 2) an “aggressive” attitude with
regard to upper airway surgery. The high incidence of persistent OSA
justifies a systematic P(S)G control 2–4 months after the upper airway
surgery.
As reported by our group in a previous study on 30 children
with achondroplasia, none of the patients had isolated CSA (Julliand
et al., 2012). CSA may increase the risk of sudden unexpected death
in infants (Pauli et al., 1984), and as children with achondroplasia
are still at a much higher risk of death compared with the general
population (Simmons et al., 2014), CSA detection should be one of
the criteria to be taken into account in favor of neurosurgical
intervention. Neurosurgery was performed in six of our patients on
the basis of abnormal cervical and cerebral MRI, sometimes
associated with clinical symptoms, but not on the presence of
CSA on a P(S)G. Unfortunately, P(S)G was not performed before
neurosurgery in these six patients. Several studies have tried to
identify non-radiological predictors of brain stem compression in
infants with achondroplasia. (Waters et al., 1995) did not find any
correlation between somesthetic potentials, CSA and brainstem
compression in a group of 30 children with achondroplasia. Similar
findings were observed by White et al. (White, Parnell, Kifle,
Blackledge, & Bompadre, 2015) in a group of 17 achondroplastic
children (mean age 2.4 years). These authors found that T2 cord
signal abnormalities or clinical findings of clonus were the most
predictive factors of the need of subsequent cord decompression,
however these observations were weakened by the fact that five of
the six patients with a CSAI > 5 events/hr were younger than
6 months old, as it is known that a CSAI up to10–20 events/hr may
be observed in healthy infants during the first year of life (Ng and
Chan, 2013). However, even if CSA is rare and insufficient as the
only screening tool for foramen magnum stenosis, systematic
overnight sleep studies with neuroimaging are recommended
during infancy as stated by a recent international consensus
agreement on evaluation and treatment of foramen magnum
stenosis in achondroplasia during infancy (Trotter and Hall, 2005;
White et al., 2016).
Although achondroplasia is associated with normal intelligence
capacity, mild developmental delay or learning difficulties may be
observed as a consequence of undertreated chronic upper airway
obstruction, middle ear dysfunction, craniocervical junction stenosis,
thoracolumbar kyphosis, bowing of the lower legs and psychological
problems (Trotter and Hall, 2005). Neurocognitive dysfunction and
abnormal behavior are the most common and severe consequences of
OSA in childrenwithout underlying diseases (Marcus et al., 2012). Few
studies have assessed the impact of sleep-disordered breathing in
children with achondroplasia. A relationship has been observed
between severe respiratory dysfunction with abnormal PSG and a
lower intellectual potential in 13 achondroplastic infants (Hecht,
Thompson, Weir, Patchell, & Horton, 1991) but very little is known
about academic level of achondroplastic children in relation to the
presence of sleep apneas. In our study, 62% of the school-aged
children followed a standard academic course and only 17% attended
a specialized school. We did not observe a correlation between the
academic level and P(S)G results but many other factors may be
involved in the development retardation and learning difficulties of
achondroplastic children such as hypoacousia due to chronic serous
otitis media (Ireland et al., 2011).
Our study has several limitations, such as its retrospective single
centre design and the frequent use of PG instead of PSG. Our study
population was not homogenous with regard to previous history and
treatments and age distribution. P(S)G was not systematically
performed before every surgical procedure in all the patients.
However, compared to our previous experience, this study highlights
how a more radical surgical approach to airway obstruction could
FIGURE 4 Treatments and outcomes of patients after the sleep study. OSAS, obstructive sleep apnea syndrome; n, number of patients in
each category; ENT surgery, upper airway surgery; NIV, non invasive ventilation
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lower incidence of OSA in children with achondroplasia managed
according to a protocolized respiratory management at a national
reference center (Julliand et al., 2012).
In conclusion, our data confirm that OSA is common in children
with achondroplasia. Children with achondroplasia should have
systematic ENT and P(S)G evaluation until at least the age of 8 years.
The observation of a reduced prevalence of OSA after (adeno-)
tonsillectomy is in favor of this type of surgery when possible.
However, correction of OSA should be checked by a P(S)G after every
therapeutic intervention.
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ChildrenwithDown syndrome are at increased risk of obstructive sleep apnea (OSA). The aimof
the study was to describe the management of OSA in a large cohort of children with Down
syndrome. A retrospective analysis of sleep studies and consequent management was
performed for all consecutive Down syndrome patients evaluated between September 2013
and April 2016. The data of 57 patients were analyzed: 51/53 had an interpretable overnight
polygraphy and4 the recording of nocturnal gas exchange.Meanageat baseline sleep studywas
6.2 ± 5.9 years. Eighteen patients (32%) had prior upper airway surgery.Mean apnea-hypopnea
index (AHI) was 14 ± 16 events/hr with 41 of the 51 (80%) patients having OSAwith an AHI >1
event/hr and 20 patients (39%) having an AHI ≥10 events/hr. Consequently, eight patients
(14%) had upper airway surgery. OSA improved in all patients except two who needed
noninvasive respiratory support. Nineteen (33%) patients required noninvasive respiratory
support. Mean age at noninvasive respiratory support initiation was 7 ± 7 years. On 11 patients
with objective adherence data available, mean compliance at 2 ± 1 years of treatment was
excellent with an average use per night of 8 hr46 ± 3 hr59 and 9 patients using the noninvasive
respiratory support >4 hr/night. Noninvasive respiratory support was associated with an
improvement of nocturnal gas exchange. The prevalence of OSA is high in Down syndrome.
Upper airway surgery is not always able to correct OSA. Noninvasive respiratory support
represents then an effective treatment for OSA and good compliance may be achieved in a
majority of patients.
K E YWORD S
continuous positive airway pressure, Down syndrome, noninvasive ventilation, sleep apnea,
treatment adherence, upper airway surgery
1 | INTRODUCTION
Down syndrome (DS), defined by an extra copy of chromosome 21, is
the commonest chromosomal disorder (Parker et al., 2010), with an
estimated prevalence in the United States from 9.0 to 11.8 per 10,000
live births (Shin et al., 2009). Patients withDS are predisposed to upper
airway obstruction and obstructive sleep apnea (OSA) due to altered
craniofacial anatomy with midfacial and mandibular hypoplasia,
glossoptosis with relative macroglossia, frequent adenotonsillar
hypertrophy, muscle hypotonia with an increased prevalence
of pharyngo-laryngomalacia and subglottic and/or tracheal stenosis
(Lal, White, Joseph, van Bakergem, & LaRosa, 2015). These anatomical
predisposing factors for OSA are aggravated by obesity, hypothyroid-
ism, and gastroesophageal reflux disease (Lal et al., 2015). Sleep-
disordered breathing is common in patients with DS with a prevalence
of OSA between 30% and 66% (Alexander et al., 2016; Bassell, Phan,
Leu, Kronk, & Visootsak, 2015; Lal et al., 2015). Moreover, patients
with DS tend to have severe OSA (Goffinski et al., 2015) which
adversely affects language, neurocognitive development, behavior,
functional outcome, and quality of life (Breslin et al., 2014; Brooks
et al., 2015; Churchill, Kieckhefer, Bjornson, & Herting, 2015; Edgin
et al., 2015).
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Adeno-tonsillectomy represents the first line surgical treatment
for severe OSA (Lal et al., 2015). However, adeno-tonsillectomy is
significantly less effective in children with DS as compared to non-DS
children (Shete, Stocks, Sebelik, & Schoumacher, 2010). In the case of
persistent OSA, noninvasive continuous positive airway pressure
(CPAP) or noninvasive ventilation (NIV) in the case of associated
alveolar hypoventilation, is recommended (Amaddeo, Moreau et al.,
2016; Kaditis et al., 2016). However, the implementation of CPAP/NIV
may be more difficult and therapeutic compliance may be reduced in
patients with DS as compared to non-DS patients (Brooks et al., 2015).
The aim of the study was first, to describe the sleep respiratory
parameters of a large cohort of DS patients and second, the
management of OSA with a particular emphasis on upper airway
surgery and CPAP/NIV.
2 | MATERIALS AND METHODS
2.1 | Patients
Clinical and sleep study data of all consecutive DS patients followed at
the sleep unit of Necker Children hospital (Paris, France), between
September 2013 and April 2016 were retrospectively analyzed.
Follow-up data were collected for patients who underwent upper
airway surgery and/or who were treated with CPAP/NIV.
2.2 | Sleep data
All sleep studies were performed in the sleep laboratory of Necker
hospital. All patients were accompanied by one parent throughout the
night. Neither sedation nor sleep deprivation were used on any
patient.
The following standardized measurements were simultaneously
recorded during every polygraphy: nasal flow through a nasal pressure
transducer, pulse oximetry by a pulse oximeter (SpO2), thoracic and
abdominal respiratory inductance plethysmography, synchronized
infrared video monitoring (Cidelec, St. Gemme sur Loire, France or
Alice 6, Philips Respironics, St. Priest, France), and transcutaneous
carbon dioxide pressure (PtcCO2, SenTec, Thurnwill, Switzerland).
Scoring of respiratory events was performed according to the
2012 scoring rules of the American Academy of SleepMedicine (Berry
et al., 2012). The following definitions for respiratory eventswere used
for scoring purposes (Berry et al., 2012). Obstructive apnea (OA) was
defined as the absence of nasal airflow with continued chest wall and
abdominalmovements for at least two breaths. Central apnea (CA)was
defined as the absence of airflow with the cessation of respiratory
effort, lasting more than 20 s or of shorter duration and associated
with an arousal and/or a 3% oxygen desaturation. CA occurring after
gross bodymovements or after sighs were not included in the analysis.
Mixed apnea was defined as an apnea that usually begins as central
and ends as obstructive according to changes in the chest, abdominal,
and flow traces. Hypopnea was defined as a decrease in nasal airflow
of at least 30% with a corresponding decrease in SpO2 of at least 3%
and/or an arousal. The apnea-hypopnea index (AHI) was calculated as
the sum of apneas and hypopneas per hour of time on bed. The
obstructive AHI was defined as the number of obstructive apneas-
hypopneas per hour of time in bed with an obstructive AHI (OAHI) < 2
events/hr being considered as normal (Marcus et al., 1992;
Montgomery-Downs, O’Brien, Gulliver, & Gozal, 2006; Uliel, Tauman,
Greenfeld, & Sivan, 2004). Central apnea index (CAI) was defined as
the number of central apneas per hour of time in bed, with a CAI < 5
events/hr being considered as normal (Kritzinger, Al-Saleh, & Narang,
2011).
Mean and minimum SpO2 values were calculated. The oxygen
desaturation index (ODI) was defined as the number of SpO2 drops of
at least 3% per hour of total time in bed. Mean and maximal values of
PtcCO2 were gathered and the percentage of total time in bed spent
with a PtcCO2> 50mmHg were calculated. All the SpO2/PtcCO2 data
that were not interpretable (probe detachment, outlier data, artifacts)
were discarded from the analysis.
2.3 | Upper airway surgery
All patients were evaluated by a pediatric ear, nose, and throat (ENT)
surgeon. Upper airway surgery with adenoidectomy ± tonsillec-
tomy ± turbinectomy were variably performed according to the
clinical ENT examination in case of an AHI > 5 events/hr (Kaditis
et al., 2016).
2.4 | CPAP/NIV
Continuous positive airway pressure was initiated in case of an
AHI > 10 events/hr, despite upper airway surgery or when upper
airway surgery was not indicated, by a pediatrician and a nurse with
expertise in CPAP/NIV and therapeutic education (Amaddeo, Frapin,
& Fauroux, 2016; Amaddeo, Moreau et al., 2016). CPAP/NIV was
started in an out-patient setting in selected patients, or during a short
hospitalization of two to three nights in patients with severe
behavioral problems or neurocognitive impairment. CPAP titration
was performed during a daytime nap study in the outpatient setting
and during the night in the inpatient setting (Kushida et al., 2008).
CPAP was changed for NIV in case of persistent desaturations and/or
hypercapnia despite the highest tolerated CPAP pressure (Kushida
et al., 2008). Continuous positive airway pressure/NIV initiation was
performed within a specific therapeutic education program adjusted
on mental age, cognition, and cooperation. The therapeutic education
tools integrated booklets, a teddy bear breathing with NIV, and playful
evaluation tools (see http://vnietsommeil.aphp.fr and Online Supple-
ment). Patients were discharged after a therapeutic education session.
Home visits with overnight gas exchange recording were performed
every 2weeks during the first 2months and then every 1–3months by
technicians trained in pediatric CPAP/NIV. Patient adherence data
were downloaded from the in-built software of the device during the
routine hospital and home care provider visits (Ramirez et al., 2013).
Themean daily adherence, themean number of nights with CPAP/NIV
use, and the number of nights the patient used CPAP/NIV for more
than 4 hrwere analyzed. The duration of homeCPAP/NIV use alsowas
reported.
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2.5 | Statistical analysis
Data are expressed as mean ± standard deviation, median (range). The
comparison of the characteristics of the patients was performed using
the Student’s t-test in case of normal distribution or Mann–Whitney
rank sum test otherwise. Comparisons between qualitative variables
were done using the χ2 test. The comparison of the nocturnal gas
exchanges before and after the initiation of the CPAP/NIV was done
using the paired t-test in case of normal distribution or the Wilcoxon
signed rank test otherwise. A p-value ≤ 0.05 was considered as
statistically significant.
3 | RESULTS
3.1 | Patients and sleep data
Fifty-seven patients were included in the study (Table 1). Mean age at
baseline sleep study was 6.2 ± 5.9 years. Associated disorders were
common with 58% of the patients having an associated cardiopathy,
30% being treated for hypothyroidism and/or asthma, and 23% being
treated for gastro-oesophageal reflux. Eighteen (32%) patients had
prior upper airway surgery at a mean age of 5.1 ± 3.4 years before the
baseline sleep study, with amajority of patients having adenoidectomy
and/or tonsillectomy.
The results of the baseline sleep study are shown in Table 2. Fifty-
three patients had a polygraphy with recording of nocturnal gas
exchange and four had only a recording of nocturnal gas exchange.
Two polygraphies were not interpretable. Mean AHI was 14 ± 16
events/hr, with 20 of the 51 patients (39%) having severeOSA defined
by an AHI ≥ 10 events/hr (Table 2 and Figure 1). OSA was observed at
any age (Figure 1). Of the 26 patients younger than the age of 4 years,
22 (85%) had an AHI > 1 event/hr, 16 (62%) had an AHI > 5 events/hr,
and 11 (42%) had an AHI ≥ 10 events/hr.
Of the 18 patients who had upper airway surgery before the
baseline sleep study, 6 had an AHI between 1 and 5 events/hr, 2 an
AHI between 5 and 10 events/hr, and 4 an AHI ≥ 10 events/hr
(Supplementary Online Table S1). The mean age of the patients who
had prior upper airway surgery was higher than the age of patients
who did not have prior upper airway surgery (Supplementary Online
Table S1). There was a trend for mean AHI to be higher in patients
without prior surgery (16 ± 18 events/hr) as compared to those with
TABLE 1 Characteristics of the patients
Total population,
n = 57
Age at first study (years), mean ± SD, median
[min;max]
6.2 ± 5.9, 4.0
[0.2;24.7]
Male/female (number) 31/26
Body mass index, mean ± SD (Kg/m2) 19.0 ± 4.9
Body mass index z-score, mean ± SD 1.7 ± 4.0
Associated disorders
Cardiopathy (n, %) 33 (58)
Ventricular septal defect (n) 8
Atrial septal defect (n) 9
Ventricular atrial communication (n) 8
Other (n) 14
Arterial pulmonary hypertension (n, %) 11 (19)
Hypothyroidism (n, %) 17 (30)
Asthma (n, %) 17 (30)
Gastro-oesophageal reflux (n, %) 13 (23)
Prior upper airway surgery (n, %) 18 (32)
Adenoidectomy (n) 15
Tonsillectomy (n) 17
Turbinoplasty (n) 2
Other (n) 2
TABLE 2 Baseline sleep data of the 57 patients
Respiratory events (n = 51)
Mean AHI (events/hours), mean ± SD, median
[min;max]
14 ± 16,
7 [0;62]
AHI ≤ 1 events/hr, n (%) 10 (19)
AHI > 1 and ≤5 events/hr, n (%) 12 (24)
AHI > 5 and <10 events/hr, n (%) 9 (18)
AHI ≥ 10 events/hr, n (%) 20 (39)
Mean central AI (events/hours), mean ± SD,
median [min;max]
1 ± 2,
0 [0;10]
Central AI > 5 events/hr, n (%) 4 (8)
Mean obstructive AI (events/hours), mean ± SD,
median [min;max]
8 ± 11, 3
[0;45]
Obstructive AI > 5 events/hr, n (%) 16 (31)
Obstructive AI > 10 events/hr, n (%) 10 (19)
Nocturnal gas exchange (n = 57)a
Mean SpO2 (%), mean ± SD, median [min;max] 95 ± 3,
96 [82;99]
Minimal SpO2 (%), mean ± SD, median
[min;max]
83 ± 14, 86
[61;98]
% of time with SpO2 < 90% (%) 13 ± 29,
0 [0; 100]
Patients with >10% of time with a SpO2 < 90%, n
(%)
9 (18)
Mean 3% ODI (events/hours), mean ± SD,
median [min;max]
17 ± 21,
10 [2;86]
ODI > 10 events/hr, n (%) 24 (47)
Mean PtcCO2 (mmHg), mean ± SD, median [min;
max]
43 ± 5,
43 [34;53]
Maximal PtcCO2 (mmHg), mean ± SD, median
[min;max]
48 ± 6,
47 [36;68]
% of time with PtcCO2> 50mmHg (%), mean
± SD, median [min;max]
4 ± 17, 0
[0;95]
Patients with >10% of time with a
PtcCO2> 50mmHg, n (%)
3 (6)
AHI, apnea-hypopnea index; AI, apnea index; ODI, oxygen desaturation
index; SpO2, pulse oximetry; PtcCO2, transcutaneous carbon dioxide.
aFour patients had only nocturnal gas exchange without a polygraphy, the
nocturnal gas exchange data of these patients are included in the gas
exchange data.
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prior surgery (9 ± 13 events/hr) but this was not statically significant
(p = 0.054) (Supplementary Online Table S1). Similar results were
observed for the mean obstructive AI. Only the ODI and the minimal
SpO2 differed between the two groups. Indeed, the ODI was higher
and minimal SpO2 was lower in patients without prior upper airway
surgery as compared to those with prior surgery (20 ± 22/hr vs.
11 ± 18/hr, p = 0.033 for the ODI and 82 ± 8% vs. 89 ± 6%, p = 0.003
for minimal SpO2).
Four patients had severe symptoms of sleep disordered breathing
with witnessed apneas and arousals, snoring, and sweating which
justified prompt overnight gas exchange assessment. The abnormali-
ties of gas exchange in room air required immediate CPAP, which was
initiated in the intensive care unit for two patients (Figure 2). These
patients did not have a polygraphy but their baseline nocturnal gas
exchange data are included in Table 2.
3.2 | Therapeutic management of OSA
Eight patients with severe OSA (AHI ≥ 10 events/hr) had upper airway
surgery after the baseline sleep study with seven children having
adenoidectomy and tonsillectomy and one adenoidectomy only
(Table 3 and Figure 2). Patients treated with ENT surgery had a
higher AHI than those not treated with ENT surgery (mean AHI
26 ± 11 vs. 13 ± 19 events/hr, p = 0.045). In the five patientswho had a
control sleep study after surgery, mean AHI decreased from 26 ± 11
events/hr before surgery to 13 ± 19 events/hr after surgery. A control
sleep study is planned in the three remaining patients. Two patients
subsequently required CPAP (Figure 2) because of persistent OSA
(AHI of 47 and 11 events/hr) despite ENT surgery (Figure 2).
Nineteen (33%) patients required CPAP (n = 15) or NIV (n = 4)
after the baseline sleep study (Table 4). The four patients treated with
NIV had persistent alveolar hypoventilation despite CPAP. Patients
who required CPAP/NIV did not differ from those who did not require
CPAP/NIV with regard to age (5.9 ± 4.9 years vs. 6.9 ± 7.7, p = 0.839)
and tomean BMI z-score (p =NS) (Supplementary Online Table S2) but
they had a higher mean AHI (26 ± 18/hr) than those not requiring this
treatment (9 ± 13/hr, p < 0.001) (Supplementary Online Table S3).
Similarly, mean OAI and ODI were also higher in the patients
requiring CPAP/NIV than those who did not (Supplementary Online
Table S3).
FIGURE 1 Apnea-hypopnea index (AHI) according to the age of the patient and his medical history. NRS, noninvasive respiratory support
(including continuous positive airway pressure or noninvasive ventilation); ENT, ear, nose, and throat
FIGURE 2 Flow chart of the patients. ICU, intensive care unit; CPAP, continuous positive airway pressure; NIV, noninvasive ventilation;
ENT, ear, nose, and throat
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Upper airway surgery and CPAP/NIV were associated with an
improvement of nocturnal gas exchange (Table 3). All the parameters
improved but this was significant only for minimal SpO2, the
percentage of time with SpO2 < 90%, and the ODI.
The data concerning CPAP/NIV are shown in Table 4. The mean
age at CPAP/NIV initiation was 7 ± 7 years with a wide range (0.4–23
years). Mean duration of treatment at the time of the study was 2 ± 1
years. CPAP/NIV adherence was available only in 11 patients, mainly
because of a too young age in 4 patients which did not allow an
accurate interpretation of actual ventilator use (Caldarelli et al., 2013).
Compliance was goodwith an average use per night of 8 hr46 ± 3 hr59
and 9/11 patients using CPAP/NIV > 4 hr/night. Three patients could
be successfully weaned from CPAP/NIV. Finally, no complications
were observed with surgery or CPAP/NIV.
4 | DISCUSSION
This study confirms the high prevalence and severity of OSAS in
children with DS and the limited efficacy of upper airway surgery to
prevent or cure OSA. CPAP/NIV was necessary in 33% of the patients
and highly efficient on nocturnal gas exchange. Importantly, a good
compliance could be obtained in the majority of patients.
The high prevalence and increased severity of OSA in
patients with DS has been observed in all age groups. Sleep
apnea was increased three- to fourfold in children and adults in a
large epidemiological study performed in Australia which
compared the prevalence of acquired cardiovascular diseases in
4,081 patients with DS and 16,324 controls over a period of
17 years (Sobey et al., 2015). Another large epidemiological study
analyzed the global morbidity associated with DS in a cohort of
6,430 patients with DS and 19,176 controls in the United
Kingdom over a period of 9 years (Alexander et al., 2016). The
global incidence rate ratio for OSA in the patients with DS versus
controls was 5.3. The risk of OSA has been shown to be even
more important in young children. Indeed, in a group of 59 infants
<6 months of age, referred to a DS clinic at a tertiary hospital
because of symptoms of sleep-disordered breathing, 95% had an
AHI ≥ 2/hr and 71% met the criteria for severe OSA with an
AHI ≥ 10/hr (Goffinski et al., 2015). The diagnosis and effective
treatment of OSA in infants and children with DS is of paramount
importance as poor sleep quality and OSAS have been shown to
be associated with poor cognitive function, and in particular
verbal intelligence quotient and cognitive flexibility (Breslin et al.,
2014; Brooks et al., 2015), language development (Edgin
et al., 2015), and functional outcomes in daily life (Churchill
et al., 2015). The present study confirms the high prevalence and
severity of OSA in children with DS with 29 patients (57%) having
an abnormal AHI and 20 (39%) severe OSA with an AHI ≥ 10/hr.
Adeno-tonsillectomy has a limited efficacy on OSA in DS. In a
small study that evaluated 11 children with DS, mean AHI decreased
from 15.3 ± 12.6 events/hr before adeno-tonsillectomy to 9.1 ± 10.5
after surgery with 6 of the 11 patients requiring CPAP or NIV for
persistent OSA (Shete et al., 2010). Our study confirms the limited
TABLE 3 Efficacy of upper airway surgery and CPAP/NIV on nocturnal gas exchange
Upper airway surgery CPAP/NIV
Before surgery (n = 8) After surgery (n = 5)a p-value
Before CPAP/
NIV (n = 19)
With CPAP/
NIV (n = 16) p-value
Mean delay (years) Not applicable 0.5 ± 0.1, Not applicable 0.8 ± 0.7,
0.5 [0.4;0.7] 0.6 [0;1.9]
Mean SpO2 (%) 94 ± 3, 96 ± 1, 0.269 94 ± 4, 96 ± 2, 0.142
94 [89;97] 97 [94;97] 94 [86;99] 96 [92;99]
Minimal SpO2 (%) 77 ± 9, 84 ± 7, 0.063 82 ± 7, 88 ± 6, 0.02
81 [61;85] 88 [73;88] 82 [71;93] 90 [73;95]
% of time with SpO2 < 90% (%) 8 ± 17, 0 ± 0, 0.205 21 ± 34, 1 ± 3, 0.01
1 [0;49] 0 [0;0] 1 [0;100] 0 [0;11]
ODI (events/hr) 26 ± 14, 18 ± 22, 0.267 30 ± 26, 5 ± 5, 0.003
25 [11;48] [8;57] 23 [2;76] 3 [92;99]
Mean PtcCO2 (mmHg) 44 ± 5, 45 ± 3, 0.624 43 ± 5, 42 ± 5, 0.131
46 [37;49] 45 [42;48] 43 [36;53] 42 [31;48]
Maximal PtcCO2 (mmHg) 52 ± 5, 49 ± 4, 0.501 50 ± 7, 47 ± 3, 0.137
52 [46;58] 49 [47;54] 48 [40;68] 48 [42;52]
% of time with PtcCO2 > 50mmHg (%) 6 ± 13, 6 ± 13, 0.500 0 ± 1, 0 ± 0, 1
0 [0;30] 0 [0;25] 0 [0;2] 0 [0;0]
CPAP, continuous positive airway pressure; NIV, noninvasive ventilation; SpO2, pulse oximetry; ODI, oxygen desturation index, PtcCO2, transcutaneous
carbon dioxide pressure.
Data are presented as mean ± SD and median [range].
an = 5 because three patients are scheduled for a sleep study.
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benefit of upper airway surgery in children with DS. Indeed, even if
adeno-tonsillectomywas associatedwith a significant improvement of
OSA, almost half of the children had persistent OSA, which was not
correlated to age, gender, or BMI z-score (Maris, Verhulst, Wojcie-
chowski, Van de Heyning, & Boudewyns, 2017). These results may be
explained by the multifactorial nature of the upper airway obstruction
associating anatomical and functional factors such as midfacial and
mandibular hypoplasia, glossoptosis with relative macroglossia, and
muscle hypotonia (Lal et al., 2015). A systematic sleep study is thus
recommended before and after each upper airway surgery in patients
with DS.
Continuous positive airway pressure or NIV in case of alveolar
hypoventilation, is indicated if OSA persists after upper airway
surgery (Amaddeo, Moreau et al., 2016; Kaditis et al., 2016). One-
third (33%) of the patients in the present study required CPAP/NIV,
which underlines the severity of OSA in this population. The AHI
threshold for CPAP/NIV initiation has not been validated in children
but levels AHI > 5 or 10 events/hr are usual (Amaddeo, Moreau
et al., 2016; Kaditis et al., 2016). However, in clinical practice, the
initiation of CPAP/NIV is based on an association of clinical
symptoms and sleep parameters, taking in account not only the
AHI but also the SpO2 and PtcCO2 levels, as well as sleep quality
(Amaddeo, Frapin et al., 2016). CPAP and NIV are very effective to
treat OSA ± alveolar hypoventilation, as shown by the significant
improvement of nocturnal gas exchange in the present study
(Table 3). Of note, four patients had such severely abnormal gas
exchange that a polygraphy was not necessary for the initiation of
CPAP or NIV which was started immediately (and in the intensive
care unit for two patients).
Themajor problemof CPAP/NIV in childrenwithDS is compliance
with treatment. Poor compliance or refusal of CPAP/NIV is
significantly more common in these patients as compared to patients
without DS, mainly because of behavioral disorders and neuro-
cognitive impairment. In a recent study, the patients who did not
comply with CPAPwere deficient in tests of adaptive behavior, visual-
motor integration, and achievement (Brooks et al., 2015). However,
good compliance may be achieved, as observed in the present study,
with a pediatric CPAP/NIV team, having an expertise in therapeutic
education and CPAP/NIV (Amaddeo et al., 2015; Caldarelli et al.,
2013). Indeed, the objective compliance in our patients was excellent
with an average use of CPAP/NIV per night of 8 hr46 ± 3 hr59 and 9/
11 patients using CPAP/NIV>4 hr/night (Table 4). Five patients did not
tolerate CPAP/NIV treatment because of major behavioral disorders
and family dysfunction.
We are aware of the limitations of our study. First, it was a single-
center, retrospective study explaining that adherence data were
incomplete. Second, the patients had a polygraphy and not a
polysomnography which does not give information on sleep architec-
ture and sleep quality and may underestimate the numbers of
hypopneas (Tan, Gozal, Ramirez, Bandla, & Kheirandish-Gozal, 2014).
Finally, poly(somno)graphy was not systematically performed before
all upper airway surgery.
In conclusion, the present study confirms the high prevalence and
increased severity of OSA in children with DS. Upper airway surgery
represents a first line treatment but has a limited efficacy. CPAP orNIV
represent a very effective therapeutic option in case of persistent OSA
after upper airway surgery. The major problem of CPAP/NIV is
compliance but good results may be achieved by an experienced
pediatric CPAP/NIV team.
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a b s t r a c t
Background and objectives: Infants with congenital myasthenic syndrome (CMS) are at risk of
brief resolved unexplained event (BRUE) and sleep-disordered breathing. The aim of the
study was to explore sleep in infants with CMS with a particular focus on heart rate (HR)
variability.
Methods: Overnight polygraphy was performed and HR variations associated with respi-
ratory events were analysed. Bradycardia and tachycardia were defined as a variation of HR
of ±10 bpm from baseline and analysed as events/hour.
Results: The data of 5 infants with CMS were analysed. Two patients had known mutations
(COLQ and RAPSN). One patient had a tracheostomy. The apnoea-hypopnoea index (AHI)
was abnormal in all the patients (range 2.8e47.7 events/h), with the highest AHI being
observed in the 3 youngest infants. Nocturnal transcutaneous gas exchange was normal in
all patients except the tracheostomised patient. Mean HR was 114 ± 23 bpm with a mean
HR index of 4.5 ± 4.3 events/h. The amplitudes of HR variations (bradycardia or tachy-
cardia) were around 15e20 bpm, regardless of the type of respiratory event, and compa-
rable between patients. No correlations were found between HR indexes or variations and
the type and mean duration of respiratory events. Ventilatory support was initiated in 3
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SFEMG, stimulation single fibre electromyography; NIV, non-invasive ventilation; BRUE, brief resolved unexplained event; PSG, poly-
somnography; SDB, sleep-disordered breathing; HR, heart rate; PG, polygraphy; CSA, central sleep apnoea; OSA, obstructive sleep
apnoea; MSA, mixed sleep apnoea; AHI, apnoea-hypopnoea index; PtcCO2, transcutaneous carbon dioxide; DI, desaturation index;
DDesaturation, maximal variation in SpO2 desaturation; DHR, variations in HR.
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infants immediately after the sleep study because of a high AHI and/or nocturnal
hypoventilation.
Conclusions: All 5 infants had an abnormal AHI with younger infants having the highest
AHI. Three infants required ventilatory support after the polygraphy, underlining its clin-
ical usefulness. No significant abnormalities of HR were observed during the sleep studies.
© 2017 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights
reserved.
1. Introduction
Congenital myasthenic syndromes (CMS) are a heterogeneous
group of disorders caused by an abnormal signal transmission
at the motor endplate, a special synaptic contact between the
motor axon and the skeletal muscle fibre. The molecular de-
fects involved in CMSmay be caused bymutations in different
genes encoding presynaptic, synaptic and postsynaptic
neuromuscular junction proteins,1 all leading to muscle
weakness. Targeted genetic analysis is done if a phenotypic
clue points to one or limited number of genes.2 However,
40e50% of genes involved in CMS are still not identified.3
Despite important advances in the understanding of molec-
ular pathogenetic mechanisms involved in CMS, diagnostic
challenges remain, particularly in childhood, and diagnosis
may be delayed because of symptom overlaps and misdiag-
nosis.1,3,4 The diagnosis of CMS is therefore based on the as-
sociation of clinical signs, electroneuromyography (ENMG)
and muscle biopsy.2 Indeed, fatigable weakness especially of
ocular and cranial muscles, a positive family history and
ENMG studies, with repetitive nerve stimulation (RNS) and
stimulation single fibre electromyography (StimSFEMG),5 can
assist the diagnosis. In case of negative diagnostic tests but
suggestive symptoms, a therapeutic trial with short-acting
cholinesterase inhibitors is recommended.6
Infants with CMS may present with respiratory distress,
recurrent episodic apnoeas when awake, bulbar weakness,
vocal cord palsy, stridor and laryngospasm requiring non-
invasive ventilation (NIV) and/or a tracheostomy.1,2,7e9
Myasthenic crisis causing respiratory failure has been
shown to be associated with about 10%mortality.10Moreover,
3 studies reported the presence of severe and recurrent brief
resolved unexplained events (BRUE) as first symptoms in in-
fants, which investigations led to the diagnosis of CMS.6,8,9
Even if the role of polysomnography (PSG) was found to be
neither sufficiently distinctive nor predictive of BRUE,11 recent
guidelines recommended a systematic PSG in infants who
have experienced a BRUE or when there is clinical evidence of
sleep-disordered breathing (SDB).12 A PSG is thus theoretically
recommended in all infants with a suspicion of or confirmed
CMS, as these infants are at high risk to develop BRUE and/or
SDB due to the combination of hypotonia, apnoea and/or
laryngospasms.13
Surprisingly, very few studies analysed breathing pattern
and heart rate (HR) variations during sleep in infants with
CMS.13 As infants with CMS may present with SDB and as
respiratory events are associated with variations in HR, we
wanted to see if respiratory events were associated with
abnormal HR variations, which could precipitate or explain
BRUE in these infants. The aim of our study was therefore to
analyse respiratory events and HR variability during sleep in
infants with CMS.
2. Patients and methods
2.1. Patients
We conducted a retrospective review of the clinical charts and
polygraphies (PG)/PSG of infants with CMS younger than 2
years old, who were referred to the Sleep and Noninvasive
ventilation Unit of Necker Hospital in Paris or to the Bron-
chopneumology Unit of Children Hospital Bambino Gesu` in
Rome between April 2011 and September 2015. PG/PSG was
performed because of the suspicion of a neuromuscular dis-
order or the confirmation of CMS, SDB and/or the presence of
BRUE. Diagnosis of CMS was based on characteristic clinical
symptoms, with suggestive ENMG and/or muscular biopsy
and/or DNA analysis. Clinical data such as family history,
clinical symptoms and their evolution, genetic and metabolic
studies, ENMG studies, including RNS and StimSFEMG of
orbicularis oculi, muscle biopsy, cardiac monitoring, electro-
encephalography, upper airway examination, pH monitoring,
oesophagus-stomach-duodenum contrast, videofluoroscopy,
cerebral magnetic resonance imaging (MRI), chest computed
tomography scans, coexisting medical conditions, surgical
history such as tracheostomy and gastrostomy, use of NIV and
evaluation of symptoms of SDB were gathered. The study was
approved by the ethical committee (CPP Ile de France II, n"
2014-03-09 SC) and informed consent was obtained from
parents.
2.2. Sleep study
Overnight PG/PSG was performed during spontaneous
breathing in room air with the recording of nasal flow, res-
piratory inductive plethysmography, tracheal sound, body
position, HR, and pulse oximetry (SpO2) (Cidelec poly-
somnograph, CID102L8D, Angers, France; Alice 6LDX Sleep-
ware by Philips-Respironics, Carquefou, France;
Compumedics Sleep Monitoring System C510, Charlotte, NC,
USA).14 The sleep study was recorded on videotape with an
infrared video camera. Obstructive sleep apnoea (OSA) was
defined as a drop in nasal flow amplitude by 90% of baseline
for at least two respiratory cycles, with continued or
increased inspiratory effort. Central sleep apnoea (CSA) was
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defined as a drop in nasal flow amplitude by 90% of baseline
in absence of inspiratory effort, during at least two breaths
associated with an arousal, an awakening, or a 3% SpO2
desaturation, or of a duration of at least 20 s. In infants under
1 year of age, CSA may be associated with a decrease in HR to
less than 50 bpm for at least 5 s or less than 60 bpm for 15 s.14
A mixed sleep apnoea (MSA) was defined as a drop in nasal
flow amplitude by 90% of baseline for at least two respiratory
cycles with the absence of inspiratory effort during one
portion of the event and the presence of inspiratory effort in
another portion, regardless of which portion comes first.
Hypopnoea was defined as a drop in nasal air pressure
transducer amplitude by 30% of baseline for duration of two
missed breaths, associated with an arousal, an awakening, or
a 3% SpO2 desaturation.
14 The duration of each respiratory
event was reported.
The apnoea-hypopnoea index (AHI) was calculated as the
sum of the apnoea and hypopnoea events per hour of total
sleep. Sleep study was considered normal in case of an apnoea
index <1 event/h and AHI <1.5 events/h.15 Mild sleep apnoea
syndrome was defined as an AHI between 1.5 and 5 events/h,
moderate sleep apnoea syndrome for an AHI between 5 and 10
events/h, and severe sleep apnoea syndrome for an AHI #10
events/h. Alveolar hypoventilation was defined as a minimal
SpO2 < 90% for 10% of sleep time and/or a transcutaneous
carbon dioxide pressure (PtcCO2) >50 mmHg for 10% of sleep
time.16 The 3% desaturation index (DI) was calculated as the
number of 3% SpO2 desaturation per hour of total sleep, and
was considered abnormal when >5 events/h. Maximal varia-
tion in SpO2 desaturation (DDesaturation) was calculated as
SpO2 drop from baseline to the nadir occurring after each
scored respiratory event. Variations in HR (DHR) over ±10 bpm,
occurring after each scored respiratory event, were reported. A
reduction of HR of 10 bpm or more was considered as a
bradycardia, while an increase of 10 bpm or more was
considered as a tachycardia. The HR, bradycardia and tachy-
cardia indexes were calculated as the number of HR variations,
bradycardia or tachycardia per hour of total sleep, respectively.
Transcutaneous carbon dioxide (PtcCO2) was recorded by a
SenTec Digital Monitoring System monitor (SenTec AG,
Therwil BL Switzerland). The mean and maximum PtcCO2
were calculated.
2.3. Statistical analysis
All continuous variables were expressed as mean ± standard
deviation, or as median and interquartiles. Correlation be-
tween variables was done using the Pearson correlation test in
case of normally distributed population or the Spearman
correlation test otherwise. A p value < 0.05 was considered as
statistically significant.
3. Results
3.1. Patients
The data of 5 infants (4 girls) with CMS were analysed
(Table 1). Patients #1 and #5 had a positive family history for
BRUE. Patients #4 and #5 were preterm infants, born at 35
weeks of gestational age. All the patients but patient #4 had
neonatal respiratory distress, requiring intubation with me-
chanical ventilation at birth in patients #2, #3, and #5. All the
patients had hypotonia, swallowing disorders, poor weight
gain and/or recurrent episodes of BRUE. Search for metabolic
disorders was negative, electroencephalography and brain
MRI were normal in all patients, while electrocardiography
showed vagal hyperactivity in patient #5. Initial heart ultra-
sound reported an interventricular communication and a
patent foramen ovale in patient #1, an atrial septal defect in
patient #3, and an aorta coarctation in patient #5 which was
surgically corrected at the age of 12 months. Heart defects
resolved in the other patients before the sleep study. Airway
endoscopy showed a laryngomalacia in patients #2 and #5.
Tracheostomy was performed in patient #3 at the age of 4
months because of severe hypotonia and upper airway
obstruction not relieved by NIV. StimSFEMG of orbicularis
oculi was performed and abnormal in 4 patients, evidencing
abnormal jitter measurement and block conduction.
Genetic exam revealed mutations in COLQ and RAPSN in
patients #1 and #2, respectively, who were consequently
treated respectively with salbutamol and ambenomium
chloride. No known mutations were found in patient #3
(SMN1, TRPV4, COLQ, CHRNG, RAPSN), patient #4 (COLQ, RAPSN,
CHAT, DOK7, DM1, GFPT1, SCN4A), nor in patient #5 (CHRNE,
RAPSN, DOK7, COLQ, CHAT, CHRNB1, CHRND, SCN4A). Patients
#3 and #4 were treated with pyridostigmine and salbutamol,
while patient #5 was treated with ambenomium chloride with
improvement of peripheral muscle weakness but not of vocal
cord palsy with the persistence of laryngospasms.
3.2. Sleep study
The mean age at sleep study was 11.0 ± 9.8 months (range
3e24 months) (Table 2). Mean recording time was
313 ± 107 min (range 146e436 min), and only patient #1 had a
nap study. Patient #3 was breathing spontaneously on his
tracheostomy. Only patients #1 and #2 were treated at the
time of the sleep study.
Mean AHI was 15.4 ± 18.3 events/h (range 2.8e47.7), with
the youngest infants having a higher AHI (Fig. 1 and Table 2).
The mean hypopnoea index (10.1 ± 15.2 events/h) was higher
than themean total apnoea index (5.1± 3.1 events/h). SDBwas
characterised by predominant hypopnoeas in #1 and #3, OSA
in patients #2, MSA in patient #4 and CSA in patient #5 (see
Fig. 2).
Sleep SpO2 and PtcCO2 were normal in all the patients
except in patient #3, who had a SpO2<90% for 7% of night time
and a mean PtcCO2 slightly above 50 mmHg (Table 2).
Mean 3% DI was 13.3 ± 14.7 events/h with a wide range
(2.8e39.0 events/h). However, the mean DDesaturation
occurring after the respiratory events was comparable among
patients (5.3 ± 1.4%, range 3.7e7.0%) (Table 3).
No BRUE occurred during the sleep studies and no HR
values < 60 bpm or >180 bpm were observed. Mean HR was
114± 23 bpm,with slightly low values in patients #1, #4 and #5.
Mean HR index was 4.5 ± 4.3 events/h, with the tracheotom-
ised patient (patient #3) having no HR variations. Mean
bradycardia index was 3.0 ± 2.6 events/h and mean tachy-
cardia index was 1.5 ± 2.0 events/h.
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Fig. 1 e Distribution of the respiratory events in the 5 patients. OAI: obstructive apnoea index; CAI: central apnoea index;
MAI: mixed apnoea index; HI: hypopnoea index.
Fig. 2 e Bradycardia and tachycardia indexes according to the patients and the type of respiratory events. A: obstructive
sleep apnoeas (OSA): patient #3 had no OSA; B: central sleep apnoeas (CSA); C: hypopnoeas: patient #4 had no hypopnoea; D:
mixed sleep apnoeas (MSA): patients #2 and #3 had no MSA.
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Interestingly, the amplitudes of DHR during tachycardia or
bradycardia were quite similar between patients, around
15e20 bpm, regardless of the type and the duration of respi-
ratory event (Fig. 3 and Table 3). Patient #5 presented a single
DHR of %53 bpm (bradycardia) associated with a CSA of 11 s of
duration. This was the highest DHR observed among the pa-
tients. The mean duration of respiratory events was similar
whether the events were associated either with bradycardia
(9.2 ± 1.1 s) or tachycardia (9.2 ± 1.8 s) (Table 3).
When considering the relationship between AHI, 3% DI,
andHR indexes, the only significant positive correlations were
found between the AHI and the 3% DI and the tachycardia
index (r ¼ 0.934, p ¼ .02 and r ¼ 0.915, p ¼ 0.03 for the AHI and
the 3% DI, respectively) (Fig. 4).
3.3. Clinical outcomes of the patients
Three patients (#1, #3, #5) were treated by nocturnal ventila-
tion after the sleep study because of a high AHI and/or
nocturnal hypoventilation. Nocturnal NIV was started in pa-
tients #1 and #5, while patient #3 was treated by invasive
ventilation on her tracheotomy. In patient #4, ventilatory
support was started 23 months after our study due to a
worsening of nocturnal gas exchange during follow-up. Pa-
tient #2 did not require nocturnal ventilation because of
normal nocturnal gas exchange at repeated 6-months in-
tervals controls.
4. Discussion
Our study is the first to analyse sleep and HR variations in
infants with CMS. Our results show that 1) all the infants had
an abnormal AHI with higher values at younger age and 2) no
BRUE or significant abnormalities in HR were observed during
the sleep studies.
Patients with CMS are at increased risk for SDB due to
hypotonia of the upper airway and respiratory muscles which
may cause nocturnal hypoventilation, episodic apnoea, lar-
yngospasm, and/or BRUE. None of the patients had a specific
respiratory muscle testing,17,18 but as CMS is characterised by
a global muscle weakness, it is highly probable that respira-
tory muscles are also involved in these patients. This may
explain the heterogeneity of the respiratory events scored on
the sleep studies. Indeed, hypotonia of the upper airway
muscles may cause “real” obstructive events, as observed in
the 2 youngest patients (#1 and #2). But these events may also
be falsely scored as “obstructive” in case of paradoxical
breathing with opposition phase on the thoracic and abdom-
inal belts, due to diaphragmatic dysfunction or weakness of
the intercostal muscles.19,20 Patients with respiratory muscle
weakness may also present progressive simultaneous
decrease in airflow and thoracic and abdominal movements
accompanied or not by a change in gas exchange, suggestive
of a global inspiratory muscle weakness or a decrease in
central drive.19e21 These events are scored as a “hypopnea”
when followed by a 3% desaturation or an arousal,14 but are in
fact periods of decreased ventilation due to respiratorymuscle
weakness. Hypoxaemia and hypercapnia occurs only when
the level of hypoventilation falls below a certain threshold,
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which was observed only in the tracheotomised patient. The
observation that the 4 other patients had an abnormal AHI
despite normal gas exchange underlines the importance of a
systematic PSG/PG in infants with CMS.
Of note, a high AHI was observed in the 2 youngest pa-
tients, despite treatment with salbutamol and ambenonium.
These drugs are effective to treat hypotonia but not to impede
sudden vocal cord palsy or laryngospasms, which are thought
to be a direct expression of neuromuscular junction
dysfunction. The two oldest patients had a lower AHI, sug-
gesting an improvement of SDB with age in CMS patients.
We performed an in depth analysis of HR andHR variations
during sleep in the 5 infants in order to test the hypothesis
that respiratory events may be associated with abnormal HR
variability, which may predispose these infants to BRUE.
Indeed, recent guidelines recommend to perform a PSG in
infants who have experienced BRUE and/or who present
SDB.11,12 Indeed, the analysis of respiratory events and HR
seems interesting as an altered cardiovascular autonomic
function and reduced arousability has been reported in in-
fants with BRUE and apnoeas and/or OSA.22e24 To our
knowledge, no such studies have been reported in infants
with CMS. Bradycardia is the most common cardiac rhythm
abnormality associated with sleep apnoea, with a positive
correlation with longer episodes and more severe OSA.25e27
The role of oxygen desaturation as trigger of severe brady-
cardia during OSA is controversial, as the prolonged negative
intrathoracic pressures during OSAmay bemore important as
a trigger of increased vagal tone than oxygen desaturation.25,28
Bradycardia occurring during an apnoea represents a vagal
response to hypoxaemia aiming at limiting the oxygen con-
sumption of the heart.29,30 However some studies also re-
ported the occurrence of tachycardia associated with
respiratory events during sleep in infants or preschool chil-
dren with OSA.31e34 Tachycardia may be due to arousals, as
arousals are characterised by an activation of the sympathetic
nervous system resulting in brief tachycardia.32,35 Moreover,
cardiovascular alterations may be different according to the
sleep stages and vary from infancy to adulthood.23,29,34 How-
ever, as PSG was not available in all our patients, we could not
assess HR variations according to sleep stages or arousals.
Although we observed significant positive correlations be-
tween the AHI and the 3% DI and the tachycardia index, no
abnormal HR values or HR variations were observed during
the sleep studies in the 5 infants. HR variations associated
with respiratory events were observed in all the patients
Fig. 3 e Mean variations of heart rate according to the patients and the type of respiratory events. A: obstructive sleep
apnoeas (OSA): patient #3 had no OSA; B: central sleep apnoeas (CSA); C: hypopnoeas: patient #4 had no hypopnoea; D:
mixed sleep apnoeas (MSA): patients #2 and #3 had no MSA.
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except the tracheostomised patient. The absence of HR vari-
ations in this patient may be explained by the presence of the
tracheostomy, as reported in adult patients.31,36
The results of the PG/PSG had a clear direct impact on the
patients' management, underlying the interest to prompt a
sleep study in patients with suspicion of CMS. Indeed, NIV or
invasive mechanical ventilation was required immediately
after the sleep study in 3 patients. NIV was started in another
patient 23 months later, because of the appearance of
nocturnal hypoventilation, emphasizing the importance of
long term follow-up sleep studies.
CMS is a rare disease and the small number of patients is a
clear limitation of the study. The clinical phenotypes were
very different, as usually observed in CMS, with only 2 pa-
tients having a known mutation. No generalisation can be
made of an increased severity of SDB in younger infants
because of the limited number of patients. However, during
the study period, no patient with CMS died at our 2 centres,
which is not in favour of the hypothesis that older patients
survive because they are less affected. PSG was not available
in all the patients precluding the analysis of events according
to sleep stages. Furthermore, as the fatigability of the respi-
ratory muscles and the clinical symptoms vary typically over
time in CMS, a single sleep studymay not be representative of
the infant's habitual sleep, highlighting the necessity to repeat
sleep studies. A follow-upwith repeated PSGwas not available
at the time of the study but is actually ongoing.
5. Conclusion
In conclusion, sleep studies were abnormal in all the 5 infants
included in the present study and led to the initiation of
nocturnal ventilator support in 3 cases. We did not observe
significant HR abnormalities during the sleep studies, despite
a history of BRUE in 3 infants. Systematic longitudinal PSG
with coupled HR monitoring and autonomic markers should
be part of the diagnostic tests and follow-up of infants with
CMS, independently of a history of BRUE, to evaluate auto-
nomic control, disease evolution and treatment efficiency.
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Abstract
Objectives: A significant number of children are able to discontinue long term
continuous positive airway pressure (CPAP) or noninvasive ventilation (NIV) but the
underlying disorders, weaning criteria, and outcome of these children have not been
studied.
Study design: Retrospective cohort follow up.
Subject selection: Consecutive children who were weaned from long term CPAP/NIV
between October 2013 and January 2016.
Methodology: Underlying disorders, weaning criteria, and clinical outcome were
analyzed.
Results: Fifty eight (27%) of the 213 patients on long termCPAP/NIV could beweaned
from CPAP/NIV with 50 patients being weaned from CPAP and 8 from NIV. Most
patients were young children with upper airway anomalies, Prader Willi syndrome or
bronchopulmonary dysplasia. CPAP/NIV was discontinued following spontaneous
improvement of sleep-disordered breathing in 33 (57%) patients, upper airway surgery
(n = 14, 24%), maxillofacial surgery (n = 6, 11%), neurosurgery (n = 1, 2%), upper airway
and neurosurgery (n = 2, 3%), or switch to oxygen therapy (n = 2, 3%). CPAP/NIV was
discontinueddue tonormal nocturnal gas exchangeduring spontaneousbreathing in all
patients, with an obstructive apnea-hypopnea index ≤6 events/h on a combined
poly(somno)graphy in 27 patients. A relapse of obstructive sleep apnea was observed
after a median delay of 2 years in six patients who resumed CPAP and in one patient
who underwent midface distraction.
Conclusions: Weaning from CPAP/NIV is possible in children treated with long term
CPAP/NIV but is highly dependent on the underlying disorder. Spontaneous
improvement is possible but most children need specific surgery. Long term follow-
up is necessary in children with underlying disorders.
K E YWORD S
children, continuous positive airway pressure, nocturnal gas exchange, noninvasive
ventilation, polysomnography, sleep apnea
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1 | INTRODUCTION
Long term noninvasive continuous positive airway pressure (CPAP)
and noninvasive ventilation (NIV) involve the delivery of ventilatory
assistance through a noninvasive interface, as opposed to invasive
ventilation via a tracheostomy. The number of children treated at
home with this type of respiratory support is expanding exponen-
tially.1–3 The majority of children, and especially those treated with
CPAP, have underlying conditions associated with upper airway
anomalies that may improve spontaneously with age or after surgical
interventions. As such, most children requiring CPAP for Pierre Robin
syndrome, achondroplasia, craniofacial stenosis, or laryngo- or
tracheomalacia may be weaned from CPAP.4–9 Infants with broncho-
pulmonary dysplasia treatedwith CPAPmay also improvewith age and
may be weaned from CPAP after a variable time delay.7 On the other
hand, weaning from NIV is most often impossible in children with
neuromuscular disorders.10
Although criteria used to initiate long term CPAP/NIV have been
recently analyzed,11 information on the criteria that are used in clinical
practice to discontinue CPAP/NIV is lacking, as well as the clinical
outcome of the patients after CPAP/NIV weaning. The aim of the
present study was to analyze the clinical characteristics of the children
in whom long term CPAP/NIV was discontinued, the criteria that
allowed CPAP/NIV weaning, and the clinical outcome of the patients.
2 | MATERIALS AND METHODS
All consecutive children treated with long term CPAP/NIV at the NIV
and sleep unit in Necker Children’s Hospital, defined as the use of
CPAP/NIV for more than 2 months after hospital discharge, and who
could be weaned from CPAP/NIV between October 2013 and
January 2016 for at least 3 months, were included in the study.
Indeed, routine follow-up of children requiring long term CPAP/NIV
includes the regular evaluation of CPAP/NIV tolerance and efficacy
but also the need to continue CPAP/NIV. In general, the need to
continue or not CPAP/NIV is assessed once a year, depending on the
patient’s underlying disease, his/her age, and the evolution of his/her
respiratory status. As such, for each patient, clinical data and overnight
gas exchange and/or sleep study data that allowed discontinuation of
CPAP/NIV were collected. Long term clinical follow-up was also
recorded.
Polysomnography (PSG) or respiratory polygraphy (PG) were
performed using CID 102™ (Cidelec, Angers, France) or Alice™
(Respironics, Carquefou, France). The recorded data included airflow,
body position, body movements, thoracic, and abdominal movements
assessed by inductance belts, and pulse oximetry (SpO2). Respiratory
events were scored according to the American Academy of Sleep
Medicine (AASM) manual.12 The obstructive apnea-hypopnea index
(OAHI) was defined as the number of obstructive apneas and
hypopneas per hour of time in bed (or total sleep time in case of
PSG) with an OAHI <2 events/h being considered as normal.13–15
Central apnea index (CAI) <5 events/h was considered as normal.16,17
Oxygen desaturation was defined as a fall in SpO2 of at least 3% and
the oxygen desaturation index (ODI) was defined as the number of
oxygen desaturation per hour of time in bed (or total sleep time in case
of PSG). Nocturnal hypoxemia was defined as the presence of a SpO2
≤90% for at least 2% of night time18 and the ODI was considered as
abnormal when >1.4 events/h.13
Overnight transcutaneous carbon dioxide (PtcCO2) recordings
were performedwith the SenTecDigital Monitor (SenTec Inc., Therwil,
Switzerland). Mean, maximal PtcCO2, and the percentage of night time
spent with a PtcCO2 greater than 50mmHg were recorded.
19
Nocturnal hypercapnia was defined by a PtcCO2 ≥50mmHg for at
least 2% of night time.18
According to our protocol, discontinuation of NIV or CPAP was
authorized when all four major criteria were fulfilled with at least two
minor criteria (Table 1). The major criteria were 1) disappearance of
nocturnal and daytime symptoms of sleep-disordered breathing after
several nights sleeping without CPAP/NIV, such as snoring, sweating,
arousals, labored breathing, change in behavior or attention, 2)
percentage of recording time spent with a SpO2≤90% <2%, 3)
percentage of recording time spent with a PtcCO2≥50mmHg <2%,
and 4) OAHI <10 events/h for patients who underwent a PSG/PG. The
minor criteria were 1) minimal SpO2 >90%, 2) maximal PtcCO2
<50mmHg, and 3) ODI ≤1.4 events/h. All the data are presented as
median and range. The protocol was approved by the local ethical
committee (CPP Ile de France II, n° 2014-03-09 SC).
3 | RESULTS
A total of 213 patients were treated with long term CPAP/NIV during
the 27 months of the study period. Fifty eight (27%) patients could be
weaned from CPAP/NIV according to the inclusion criteria. Three
patients started on CPAP during the study period were excluded from
the study because they never accepted the treatment. All the patients,
except two patients with OSA, had an underlying disorder (Table 2).
TABLE 1 Criteria that may allow weaning from continuous positive
airway pressure (CPAP) or noninvasive ventilation (NIV)
Major criteria
1) disappearance of nocturnal and daytime symptoms of sleep-
disordered breathing after several nights sleeping without
CPAP/NIV, such as snoring, sweating, arousals, labored
breathing, change in behavior or attention,
2) percentage of recording time spent with a SpO2 ≤90% <2%,
3) percentage of recording time spent with a PtcCO2 ≥50mmHg
<2%,
4) obstructive apnea-hypopnea index <10 events/h on a
poly(somno)graphy
Minor criteria
1) minimal SpO2 >90%
2) maximal PtcCO2 <50mmHg
3) oxygen desaturation index ≤1.4 events/h.
SpO2, pulse oximetry; PtcCO2, transcutaneous carbon dioxide.
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Median age at CPAP/NIV initiation was 1.4 years (range 0.01-16.2
years) with a median duration of CPAP or NIV of 0.98 (range 0.2-7.5)
and 3.96 years (range 0.3-8.9), respectively. Five patients (8%)
(laryngeal paralysis (n = 2), Crouzon syndrome (n = 1), Treacher Collins
syndrome (n = 1), and Hanhart syndrome (n = 1)) had a history of
tracheotomy. CPAP allowed weaning from tracheotomy in all these
patients. The majority (n = 50, 86%) of the weaned patients were
treated with CPAP, with only 14% being treated with NIV. The
underlying diagnoses of the children treated with NIV were Prader
Willi syndrome (n = 3), Goldenhar syndrome (n = 1), mucopolysacchar-
idosis type II (n = 1), idiopathic OSA (n = 1), lung sequelae of a viral
infection (n = 1) and acute respiratory distress syndrome (n = 1).
Thirty three (57%) patients improved spontaneously over time,
without need for any specific intervention. The main underlying
conditions of these patients were bronchopulmonary dysplasia, Pierre
Robin syndrome, laryngomalacia, laryngeal paralysis, and Prader Willi
syndrome. Two patients (3%) with polymalformative syndrome were
switched from CPAP to oxygen therapy because of the improvement
of the airway obstruction but persistence of isolated hypoxemia. The
sleep-disordered breathing of the other patients improved after ENT
surgery (n = 14, 24%, adenotonsillectomy, turbinectomy, and/or
resection of the ary-epiglottic folds), maxillofacial surgery (n = 6,
11%), neurosurgery (n = 1, 2%), or a combination of ENT and
neurosurgery (n = 2, 3%). No patient included in the study discontinued
CPAP or NIV because of intolerance or side effects.
The results of the overnight gas exchange ± PSG/PG during
spontaneous breathing that allowed discontinuation of CPAP/NIV are
given in Table 3. These sleep studies were performed after a median
TABLE 2 Characteristics and outcome of the weaned patients
Male/Female 38/20
Age at CPAP/NIV initiation (years), median (range) 1.4 (0.01-16.2)
Ventilatory mode, n (%)
CPAP 50 (86%)
NIV 8 (14%)
Duration of CPAP/NIV (year), median (range) 1.12 (0.16-8.85)
CPAP 0.98 (0.16-7.49)
NIV 3.96 (0.27-8.85)
Primary diagnosis, n (%) Laryngeal obstructiona 9 (16%)
Pierre Robin syndrome 6 (10%)
Prader Willi syndrome 6 (10%)
Treacher Collins syndrome 6 (10%)
Bronchopulmonary dysplasia 4 (7%)
Achondroplasia 3 (5%)
Idiopathic OSA 2 (3%)
Craniofaciostenosis (Crouzon, Apert) 2 (3%)
Pycnodysostosis 2 (3%)
Mucopolysaccharidosis 2 (3%)
Polymalformative syndrome 2 (3%)
Mandibular hypoplasia 2 (3%)
Lung sequelae of viral infection/ARDS 2 (3%)
Otherb 10 (21%)
Reason of CPAP/NIV weaning, n (%) Spontaneous improvement: 33 (57%)
Switch to oxygen therapy: 2 (3%)
After surgery:
ENT surgery 14 (24%)
Maxillofacial surgery 6 (11%)
Neurosurgery 1 (2%)
ENT and neurosurgery 2 (3%)
CPAP, continuous positive airway pressure; NIV, noninvasive ventilation; OSA, obstructive sleep apnea; ARDS, acute respiratory distress syndrome; ENT,
ear, nose, and throat.
aLaryngomalacia (n = 5), laryngeal paralysis (n = 4).
bDown syndrome (n = 1), Hanhart syndrome (n = 1), Noonan syndrome (n = 1), brainstem dysfunction (n = 1), thoracic scoliosis (n = 1), tracheomalacia (n = 1),
congenital myasthenia with hypothyroidism (n = 1), bifid uvula (n = 1), facial macrosomia (n = 1), retromicrognathia (n = 1).
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delay of 1.2 (0.1-7.8) months after discontinuation of CPAP/NIV and
showed no significant periods of time with a SpO2≤90% and/or a
PtcCO2 ≥50mmHg. Among the 27 patients who underwent PG/PSG,
themaximal OAHIwas 6 events/h. The results of the two patients with
polymalformative syndromewhowere switched fromCPAP to oxygen
therapy are not included in Table 3. These two patients had normal
PtcCO2 values with severe hypoxemia with a mean SpO2 between 90
and 93%, a minimal SpO2 between 76 and 85%, an ODI between 15
and 22 events/h, and a time spent with a SpO2 ≤90 between 4 and
25%.
Figure 1 shows the median age at CPAP/NIV initiation and
median duration of treatment for the most common disorders. CPAP
was initiated during the first months of life in infants with Pierre
Robin syndrome, Treacher Collins syndrome, bronchopulmonary
dysplasia, and laryngeal anomalies. Duration of CPAP was short in
these infants and did not exceed 1 year. CPAP or NIV was started at
an older age in children with achondroplasia or Prader Willi
syndrome with the longest duration of CPAP being observed in
patients with achondroplasia.
All the patients had a long term clinical follow-up. Thirty-five
patients with craniofacial or upper airway malformations had a second
sleep study after a median delay of 8months after the first sleep study.
Seven patients had a long term relapse of their OSA with an OAHI
ranging between 11 and 53 events/h after a discontinuation of CPAP
since 1-3 years (Table 4). OSA was treated with a resumption of CPAP
in six patients and a neurosurgical intervention (Lefort III midface
distraction) in the patient with pycnodysostosis. In two out of the six
patients, CPAP was started prior to maxillofacial surgery. Finally, no
patient died or required a tracheotomy.
4 | DISCUSSION
This study is one of the first to analyze the characteristics of
consecutive children who were weaned from CPAP or NIV over a
period of 27 months in a large NIV center at a pediatric university
hospital. Approximately one quarter of the patients could be weaned
from CPAP or NIV, with 57% of the patients improving spontaneously
with age, whereas the others improved after specific surgery. Nearly all
the patients had an underlying disorder, with the majority having
malformations of the upper airways. Although the results of the sleep
studies that allowed the discontinuation of CPAP or NIV were within
the normal limits, long term follow-up ismandatory as a relapse of OSA
was observed in seven patients.
Discontinuation of CPAP or NIV is common in the pediatric
population. Indeed, as many as 21% of a cohort of 144 children
followed at a single center in Vancouver could be weaned from CPAP
or NIV after 5 years, and 42% after 10 years.2 But this percentage is
highly dependent on the underlying disorders. Indeed, the children
who could be weaned from CPAP/NIV presented mainly neuromus-
cular disorders, spinal injury, abnormal ventilator control, craniofacial
abnormalities, and airway malacia. In another center in the
Netherlands, where the majority of children had neuromuscular
disorders, only 7 of the 197 children followed over a period of nearly
30 years could discontinue CPAP or NIV.1 The number of childrenwho
can be weaned from CPAP or NIV is particularly high in disorders or
conditions which improve spontaneously with age such as broncho-
pulmonary dysplasia, Pierre Robin syndrome and airwaymalacia. In our
experience, infants with bronchopulmonary dysplasia or laryngeal
obstruction requiring CPAP could all be weaned from their ventilator
support after a period of 6 months to 3 years.7 Some infants with
Down syndrome or Prader Willi syndrome may also improve
spontaneously over time but relapses of OSA are common at an older
age mainly because of overweight and obesity.20
TABLE 3 Results of sleep studies that prompted weaning from
continuous positive airway pressure or noninvasive ventilation
Duration of spontaneous breathing before
the sleep study (months) 1.2 (0.1-7.8)
Nocturnal gas exchange (n = 56)a
Mean SpO2 (%) 97 (93-100)
Minimal SpO2 (%) 91 (84-97)
Time spent with SpO2 <90% (%) 0 (0-1)
Oxygen Desaturation Index (event/h) 2 (0-18)
Mean PtcCO2 (mmHg) 40 (31-47)
Maximal PtcCO2 (mmHg) 44 (38-49)
Time spent with PtcCO2 >50mmHg (%) 0 (0-0)
Polysomnography/Polygraphy (n = 27)
Obstructive apnea-hypopnea index
(events/h)
1 (0-6)
Obstructive apnea index (events/h) 0 (0-1)
SpO2, pulse oximetry; PtcCO2, transcutaneous carbon dioxide.
Data are given as median (range).
aThe nocturnal gas exchange of the two patients who were switched from
continuous positive airway pressure to oxygen therapy are not included in
the table but detailed in the text.
FIGURE 1 Median age at continuous positive airway pressure
(CPAP) or noninvasive ventilation (NIV) initiation (white bars) and
median duration (gray bars) of CPAP or NIV for the most common
disorders (in years). Pierre Robin, Pierre Robin syndrome; TC,
Treacher Collins syndrome; BPD, bronchopulmonary dysplasia;
larynx, laryngeal obstruction, that is, laryngomalacia or laryngeal
paralysis; ACH, achondroplasia; PW, Prader Willi syndrome
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Almost half of the patients improved after specific interventions.
This is explained by the fact that patients had some type of upper
airway obstruction that could be relieved by surgical interventions
aiming at enlarging or stabilizing the upper airway such as adeno-
tonsillectomy, turbinectomy, resection of the ary-epiglottic folds,
mandibular distraction osteogenesis or midface distraction. As these
interventions are not possible at any age, CPAP may be necessary as a
“bridge” to wait for the optimal timing of surgical intervention. This is
particularly true for children with craniofaciostenosis in whom
corrective craniofacial surgery is not possible at a too young age.21
We have also observed recently that tonsillectomy is a very effective
treatment of OSA in young children with achondroplasia, but this
intervention is neither possible at a too young age.9 Mandibular
distraction osteogenesis should also be timed optimally. The two
adolescents, one with Treacher Collins syndrome and one with
mandibular hypoplasia due to juvenile idiopathic arthritis, had a
mandibular distraction osteogenesis at a pre-pubertal age, 13 and
12 years old respectively, with complete resolution of their OSA. After
the completion of pubertal growth, they developed severe symptom-
atic OSA requiring resumption of CPAP (Table 3). They could be
definitely weaned from CPAP only after a second mandibular
distraction osteogenesis once the pubertal growth spurt was
completed. This underlines the necessity of a regular long term
follow-up of these children by pediatric ENT and maxillofacial
specialists having an expertise in genetic disorders. Indeed, OSA
relapsed in these patients without any additional risk factor such as
weight gain or hypertrophy of the lingual tonsils.
There are no recommendations or guidelines for weaning children
from ventilator support.10 In our clinical practice, weaning is
considered in the following situations. In patients with OSA, a sleep
study during spontaneous breathing is normally performed once a
year. Due to the long lasting effects of CPAP andNIV, a delay of at least
2 weeks is recommended for a sleep study during spontaneous
breathing. Indeed, several mechanisms such as a reduction in mucosal
edema,22 a beneficial effect on sleep fragmentation which is known to
enhance airway collapsibility,23 an improvement of the central
ventilator response to hypercapnia,24 and an increase in upper airway
muscle tone,25 may account for this prolonged benefit. In patients
having abnormalities of the upper airway, corrective surgery may cure
theirOSA. Aminimal delay corresponding to the timing associatedwith
the maximal benefit is recommended to perform a sleep study during
spontaneous breathing. This delay may last from approximately 2-6
months, according to the type of surgery. Finally, a progressive
reduction of CPAP or NIV tolerance or compliance, in the absence of
technical problems such as masks intolerance, may be due to a
spontaneous improvement of sleep disordered breathing. For weaning
patients fromCPAP/NIV,we took arbitrarily the inverse criteriawe use
for the initiation for CPAP/NIV, that is, no symptoms of sleep-
disordered breathing, normal nocturnal gas exchange and an
OAHI <10 events/h.11 In clinical practice, however, the situation is
not always so clear cut and individual specificities such as the age of
the patient and the underlying diagnosis, the tolerance and the
subjective benefit of CPAP/NIV, potential side effects of treatment
such as skin injury or facial deformity, are important to be taken in
account.
We acknowledge that our study has several limitations. Our data
reflect clinical practice at a single specialized center in pediatric NIV
andmay not be applicable to other centers. Moreover, our recruitment
may also differ from other centers with a majority of patients having
complex genetic disorders. However, the pathologies presented by our
TABLE 4 Characteristics of the patients with a relapse of obstructive sleep apnea after a first successful weaning of continuous positive airway
pressure
Patient gender Diagnosis
Age at
CPAP
weaning
(years) Reason of CPAP weaning
Time delay
between CPAP
weaning and
follow-up
polygraphy
(years)
Obstructive
apnea-
hypopnea
index
(events/h) Intervention
1 male Polymalformative syndrome
with thoracic scoliosis
2 Spontaneous improvement 1 18 Resumption of CPAP
2 female Down syndrome 3 Spontaneous improvement 3 18 Resumption of CPAP
3 male Treacher Collins syndrome 8 Spontaneous improvement 2 11 Resumption of CPAP
4 male Achondroplasia 8 Adenotonsillectomy 1 11 Resumption of CPAP
5 male Pycnodysostosis 8 Spontaneous improvement 1 20 Lefort III midface
distraction
6 male Treacher Collins syndrome 13 Mandibular distraction 2 24 Resumption of CPAP
followed by a second
mandibular distraction
7 male Mandibular hypoplasia due to
juvenile idiopathic arthritis
14 Mandibular distraction 3 53 Resumption of CPAP
followed by a second
mandibular distraction
CPAP, continuous positive airway pressure.
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patients are comparable to that of other pediatric centers in Europe.3,6
Secondly, we definedweaning from long-termCPAP/NIV as the use of
CPAP/NIV for more than 2 months after hospital discharge with a
successful weaning for at least 3 months. This excluded thus all the
patients who failed to tolerate CPAP/NIV for more than 2 months or
who could not discontinue their treatment for at least 3 months. The
time elapsed between the discontinuation of CPAP or NIV and the
sleep studywas variablewith amedian delay of 1.2months and a range
of 0.1-7.8 months. Finally, we arbitrarily selected a core of weaning
criteria for CPAP/NIV. These criteria have not been validated or
compared to criteria used in other centers. Also, a PSG/PG was not
performed in all the patients. Future multicenter studies would be
helpful at validating the most pertinent clinical and sleep criteria to
allow weaning from CPAP/NIV.
In conclusion, weaning from CPAP/NIV is possible in children
treated with long term CPAP/NIV but is highly dependent on the
underlying disorder. Spontaneous improvement is possible but most
children need specific surgery. Long term follow-up is necessary in
children with associated disorders.
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Summary 
Purpose 
The aim of the study was to analyze the diagnostic and therapeutic value of a polygraphy (PG) 
in infants hospitalized for unexplained respiratory failure or life-threatening events in the PICU. 
Material and Methods 
The PG of 13 infants (4 girls), mean age 6.8 ± 7.7 months, were analyzed.  
Results 
Eight infants were admitted for unexplained respiratory failure and 5 for life-threatening events. 
PG showed features suggestive of respiratory muscle weakness in 5 infants whose final 
diagnoses were nemaline rod myopathy (n=2), congenital myasthenia (n=2), and diaphragmatic 
dysfunction (n=1). Four of these patients were successfully treated with noninvasive ventilation 
(NIV). PG was suggestive of brainstem dysfunction in 4 infants; 2 were treated successfully with 
NIV and another with caffeine. PG showed obstructive sleep apnea in 3 infants; 2 were treated 
successfully with NIV and one patient was lost during follow up. A typical pattern of congenital 
central hypoventilation syndrome was observed in the last patient who was treated successfully 
with invasive ventilation. One patient with diaphragmatic dysfunction and one with brain stem 
dysfunction died. 
Conclusions 
PG may assist the diagnosis and guide the management of unexplained respiratory failure or 
life-threatening events in infants hospitalized in the PICU.  
 
Keywords: polygraphy, respiratory failure, pediatric intensive care unit, infant, neuromuscular 
disorder, brainstem dysfunction.  
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Introduction 
 
Respiratory failure is the most common reason of admission to the pediatric intensive 
care unit (PICU). Indeed, in a recent prospective multicentre survey including more than 10,000 
children, the respiratory system was the most common primary system of dysfunction 
representing 33.5% of admissions [1]. In the majority of patients, the cause of the respiratory 
failure is obvious such as acute asthma, bronchiolitis or another type of respiratory infection in a 
previously healthy or an immunocompromised child. More rarely, the respiratory failure is due to 
the exacerbation of an underlying disease such as a neuromuscular or lung disease. Acute 
“unexplained” respiratory failure occurring without a precipitating factor or any clinical context 
(such as fever) that may orientate a diagnosis, in an infant without a known or defined underlying 
condition, is rare and requires a prompt diagnosis in order to institute the most appropriate 
treatment.  
Respiratory polygraphy (PG) analyzes the breathing pattern and gas exchange during 
sleep, enabling the diagnosis of central and/or obstructive apneas or hypopneas [2]. But, by 
recording simultaneously airflow and thoracic and abdominal movements, it may also show 
tracings evocative of a respiratory muscle dysfunction or a hypoventilation, characterized by a 
decrease in the amplitude of breathing, which may not fulfil the strict criteria of apnea or 
hypopnea [3, [4]. PG has the advantage that it is totally noninvasive and may be performed at 
the bedside, inside the PICU. PG, by giving information on the breathing pattern and consequent 
abnormal gas exchange, may also guide treatment, and in particular noninvasive ventilation 
(NIV) in case of alveolar hypoventilation and noninvasive continuous positive airway pressure 
(CPAP) in case of obstructive events [5]. 
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The aim of the study was to describe the PG findings and the therapeutic implications of 
this investigation in infants admitted to the PICU with unexplained respiratory failure or life 
threatening events. 
 
Material and methods 
 
Patients 
 
The PG of all consecutive infants admitted to the medical PICU between September 
2013 and September 2015 were analyzed. The PICU comprises 13 beds and admits a mean of 
500 children between the age of one month and 18 years for acute medical conditions per year. 
The medical records of the patients were systematically reviewed and medical history 
and demographics data were collected for each patient. Interventions after the PG and the 
patient’s outcome were analyzed. The study was conducted in agreement with the French 
regulations and received appropriate legal and ethical approval from the Ethical Committee of 
Necker university hospital (CPP Ile de France II). 
 
Polygraphy 
 
PG with the recording of nasal pressure by means of a nasal canula, thoraco-abdominal 
movements by means of inductive plethysmography, respiratory sound, body position, pulse 
oximetry (SpO2), and heart rate was performed during spontaneous breathing in room air 
(Cidelec, Saint Gemme sur Loire, France or Alice 6, Respironics, Carquefou, France). All events 
were scored according to the American Academy of Sleep Medicine (AASM) manual and 
following update  [2, [6]. Obstructive apnea was defined as the absence of nasal airflow, with 
continued chest wall and abdominal movements for at least two breaths. Central apnea was 
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defined as the absence of airflow with the cessation of respiratory effort, lasting more than 20 
seconds or of shorter duration and associated with a bradycardia in infants less than one year of 
age and/or a3% desaturation; central apnea occurring after gross body movements or after 
sighs was not considered as a pathological finding. Mixed apnea was defined as an apnea that 
usually began as central and ended as obstructive according to changes in the chest, 
abdominal, and flow traces. Hypopnea was defined as a decrease in nasal airflow of at least 
30% with a corresponding decrease in SpO2of at least 3% and/or an arousal. The apnea-
hypopnea index (AHI) was calculated as the sum of apnea and hypopnea events per hour of 
total sleep time [2].  
Besides these apneic and hypopneic events, other events were looked for: 
· progressive simultaneous decrease in airflow and thoracic and abdominal movements 
accompanied or not by a change in gas exchange, suggestive of a decrease in central drive 
or global inspiratory muscle weakness [3, [4] 
· paradoxical breathing with opposition phase on the thoracic and abdominal belts, suggestive 
of diaphragmatic dysfunction or weakness of the intercostal muscles [4]. 
Mean, minimal pulse oximetry (SpO2) values and the percentage of total sleep time spent 
with SpO2 < 90% were calculated. The oxygen desaturation index (ODI) was defined as the 
number of SpO2 drops of at least 3% per hour of total sleep time. Transcutaneous carbon 
dioxide pressure (PtcCO2) was recorded using the SenTec Digital Monitor (software version 
SMB SW-V06.10; MPB SW-V04.03). Mean and maximal values of PtcCO2 were calculated. All 
the SpO2/PtcCO2 data that were not interpretable (probe detachment, outlier data, artifacts) were 
discarded from the analysis. 
 
Statistical analysis 
 
Data are expressed as mean ± standard deviation or median [25%-75% interquartiles]. 
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Results 
 
During the 2 year period, 19 PGs were performed in children hospitalized in the PICU. 
Six PG were performed in children with a known underlying disease (bronchopulmonary 
dysplasia (n=2), Pierre Robin syndrome (n=1), Rubinstein-Taybi syndrome (n=1), tongue 
hemangioma (n=1), and brainstem dysfunction (n=1). Thirteen PG were performed in infants (4 
girls), median age 7 months (range 1 to 24 months) without a known underlying condition. The 
reason for PICU admission was acute respiratory failure in 8 infants and life-threatening events 
requiring resuscitation maneuvers with hypoxemia ± hypercapnia, and bradycardia in the 5 other 
patients (Table 1). None of the patients had fever and no precipitating factor was identified for all 
patients. Chest X-rays, electrocardiography, echocardiography were normal in all patients. All 
the infants presented a least one for the following clinical features: peripheral or axial muscle 
weakness (n=8, patients #1 to #9 with the exception of patient #5), swallowing difficulties with 
false passages (n=4, patients #6 to #9), episodes of bradycardia (n=5, patients #6 to #9 and 
patient #12), and/or acute obstructive events (n=3, patients #10 to #12). Patient #5 presented 
features of generalized scleroderma and patient #13 was tracheotomised in his country because 
of recurrent severe episodes of respiratory failure and referred to our center with the suspicion of 
metabolic disease.  
The results of the PG are presented in Table 2. A daytime nap PG was performed in the 
10 infants aged less than 6 months whereas an overnight PG was performed in the 3 older 
patients (Table 2). All the studies were performed in room air with a mediananalysable time of 
146 min (range 64 to 510 min).  
Patients #1 and #2 had a high AHI, composed mainly of hypopneas, with severe 
hypoxemia and hypercapnia. The PG tracings showed tachypnea with repeated episodes 
associating a simultaneous decrease in airflow and thoracic and abdominal movements followed 
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by a desaturation and an arousal, suggestive of global inspiratory muscle weakness (Figures 1a 
and 1b). Nemaline rod myopathy was confirmed in the 2 patients. Respiratory status improved 
spontaneously in patient #1 who did not require ventilator support. NIV during night and nap 
sleep corrected the alveolar ventilation in patient #2. Patient #3 had few respiratory events but 
repeated episodes of a simultaneous decrease in airflow and opposition phase on the thoracic 
and abdominal belts followed by a desaturation, occurring at the end of the night, suggestive of a 
decrease of diaphragmatic endurance (Figure 2a). Patient #4 had an AHI of 52/h and an ODI of 
34/h. The PG tracing showed recurrent episodes of a simultaneous decrease in airflow and 
thoraco-abdominal belts (Figure 2b). The PG recordings were suggestive of a respiratory muscle 
weakness or dysfunction. Further investigations showed that these 2 patients had congenital 
myasthenia. Both were successfully treated with NIV. Patient #5 had a tracing evocative of 
diaphragmatic dysfunction. Indeed, when she was awake, airflow was present, with an 
opposition phase on the thoraco-abdominal belts, which was explained by the fact that she 
breathed exclusively with her accessory inspiratory muscles. When she felt asleep, because of 
the reduction of the activity of the inspiratory intercostal muscles during rapid eye movement 
(REM) sleep, airflow decreased to almost zero, with a simultaneous disappearance of the 
opposition phase. This lead to a profound desaturation and an arousal, and the cycle restarted 
again (Figure 3).  
Patients #6, #8, and #9 had extremely high AHI (between 63 and 104 events/h), with 
mainly obstructive events for patient #6 and central events for patients #8 and #9 (Figure 4). 
They spent between 6 and 12% of the recording time with a SpO2< 90%, without overt 
hypercapnia. In these 3 patients, as well in patient #7, breathing pattern was very irregular. The 
PG findings, in association with swallowing dysfunction, bradycardia, axial hypotonia, and a 
normal cerebral magnetic resonance imaging led to the diagnosis of brainstem dysfunction in 
these 4 infants. Patients #6 and #9 were treated with NIV but patient #6 died when NIV was 
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withdrawn during a travelling abroad. Evolution was spontaneously favourable in patient #7 and 
patient #8 improved with caffeine.  
PG showed severe obstructive respiratory events in patients #10 to #12 (Figure 1 online). 
Patients #10 and #11 were found to have severe laryngomalacia on an endoscopic evaluation 
and were treated successfully with noninvasive CPAP. The endoscopic evaluation showed 
severe pharyngeal hypotonia in patient #12 who returned to his country without treatment and 
was lost during follow up. 
Patient #13 was an otherwise healthy infant who had undergone a tracheotomy in 
Ukraine because of recurrent episodes of severe respiratory failure. His PG showed a severe 
simultaneous decrease in airflow and thoraco-abdominal movements as soon as he felt asleep, 
with profound hypoxemia and hypercapnia, without causing an arousal reflex (Figure 2 online). 
This tracing was suggestive of central congenital hypoventilation syndrome which was confirmed 
by a genetic analysis revealing a de novo heterozygous mutation in the PHOX2B gene 
responsible for a 5 alanine expansion within the 20 alanines on the C-terminal of the PHOX2B 
protein. This patient is doing well with invasive ventilation on his tracheotomy during sleep.  
 
Discussion 
 
To our knowledge, this is the first study showing the diagnostic value of a PG in the PICU 
in infants admitted for unexplained respiratory failure or life-threatening events. Indeed, sleep 
studies are generally used to diagnose OSA and prescribed and interpreted within that context. 
But the analysis of the airflow and thoraco-abdominal breathing pattern can show more very 
useful information, outside the context of OSA, and in particular in case of respiratory muscle 
weakness and/or dysfunction, or abnormalities of the respiratory drive. In the present study, the 
PG tracings showed features suggestive of respiratory muscle dysfunction, abnormal central 
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drive or obstructive respiratory events, guiding appropriate diagnostic investigations and an 
effective treatment.  
Studies on polysomnography (PSG) or PG in the PICU are scarce  [7]. None of these 
studies dealt with the diagnostic value of PG. Indeed, the aim of these studies was to analyze 
sleep quality in children hospitalized for burns or to evaluate the effects of neuromuscular 
blockade on sleep quality [7].  
PG is rarely used as a diagnostic tool in neuromuscular diseases. However, it may be 
informative by showing features evocative of respiratory muscle weakness [8]. Global inspiratory 
muscle weakness is characterized by a decrease in tidal volume, with a simultaneous decrease 
in airflow and thoraco-abdominal expansion in the PG tracing. These events may be 
misinterpreted as “central apneas” when the clinical context is not taken into account as 
neuromuscular patients are unable to generate large inspiratory pressures  [3]. On the other 
hand, other events, such as severe diaphragmatic weakness as observed in patient #5, may be 
misinterpreted as “obstructive” when the diaphragmatic weakness causes paradoxical 
movement of the chest and the abdomen even without narrowing of the upper airway  [4]. 
Finally, the high desaturation index in these patients may be explained by the reduction in lung 
volume and thus the “oxygen reserve”  [3]. In order to maintain minute ventilation, breathing rate 
increases with the appearance of a rapid shallow breathing. This index has been shown to be 
significantly increased in children with neuromuscular disease requiring NIV  [9]. Respiratory 
muscle fatigue may be evoked when these above mentioned features appear after a certain 
delay, as in patient #3 in whom features of alveolar hypoventilation appeared at the end of the 
night and who was shown to have congenital myasthenia. The PG tracing was particularly 
helpful in patient #5. The disappearance of opposition phase on the thoraco-abdominal belts 
every time she felt asleep, was explained by the physiological decrease of the activity of the 
accessory inspiratory muscles during REM sleep [3, [4]. Indeed, during this phase, breathing 
efficiency relies solely on the diaphragm. As she had severe diaphragmatic dysfunction, sleep 
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resulted in a profound decrease in tidal volume and pulse oximetry, which ended with an 
arousal. 
Brainstem dysfunction in the newborn is an association of symptoms rather than an 
established disease, originally described in the Pierre Robin sequence [10, [11]. Patients present 
with neonatal suck and swallowing difficulties, pharyngo-oesophageal uncoordination, upper 
airway obstruction due to upper airway hypotonia, vagal overreactivity, and a normal cerebral 
magnetic resonance imaging. Abnormalities in central drive are common but have been rarely 
documented on a sleep study. In these patients, PG showed an irregular breathing pattern, 
which may concern breathing frequency and/or breathing amplitude with a variable association 
of central and obstructive events. An extremely high central apnea index was observed in 
patients #8 and #9 (Figure 4) whereas the respiratory were obstructive in patient #6, which may 
be explained by hypotonia of the upper respiratory airway. 
Most infants with obstruction of the upper airways have suggestive clinical symptoms 
such as stridor, inspiratory retractions, hyperextension of the neck, which predominate during 
sleep and agitation. However, in the 3 patients in our study, the clinical symptoms were 
permanent, causing respiratory failure or severe life-threatening events with bradycardia. The 
observation of severe typical obstructive respiratory events on the PG was in agreement with the 
endoscopy of the upper airways which showed severe laryngomalacia in 2 patients.  
Congenital central hypoventilation syndrome is a rare neurocristopathy with disordered 
central drive [12]. The clinical presentation is typically during the newborn period with alveolar 
hypoventilation during sleep, or in more severely affected patients, during sleep and 
wakefulness. The severity of the clinical presentation is correlated to the number of alanine 
repeats on the PHOX2B gene. PG tracing, showing an immediate profound decrease in flow and 
thoraco-abdominal belts as soon as he felt asleep, causing severe hypoxia and hypercapnia 
without any arousal reflex, was highly suggestive of the diagnosis of congenital central 
hypoventilation syndrome which was confirmed by the genetic analysis. 
A
C
C
E
P
T
E
D
 M
A
N
U
S
C
R
IP
T
ACCEPTED MANUSCRIPT
!!"
"
"
Our study has several limitations. Most of the patients had a daytime nap PG and not an 
overnight recording. It has been showed that nap sleep study parameters are not very sensitive 
in predicting abnormal overnight sleep findings, but when nap study parameters are abnormal, 
the chance of an abnormal overnight sleep study is very high  [13, [14]. As we did not perform a 
PSG, we were not able to check sleep architecture and quality. Another limitation of PG as 
compared to PSG is the underestimation of hypopneas due to the impossibility to detect 
autonomic arousals. However, we do not think that a PSG would have changed the results of 
our study since the majority of the patients had an extremely abnormal AHI with profound 
desaturations during respiratory events. Paradoxical breathing is not always an expression of 
respiratory muscle weakness. Indeed, this breathing pattern is physiological in newborns and 
infants and decreases with age to disappear around the age of 3 years  [15, [16].  PG can detect 
reductions of airflow and thoracic-abdominal respiratory movements during sleep, these findings 
are graphically displayed and detectable but they are not quantitatively measurable. Finally, the 
number of patients is small but sufficiently informative to underline the usefulness of PG in 
infants with unexplained respiratory failure or life-threatening events. 
In conclusion, this study shows for the first time the diagnostic usefulness of a PG in 
infants hospitalized in the PICU for unexplained respiratory failure or life-threatening events. The 
PG tracings, when interpreted taking in account some pivotal clinical features, can orientate the 
diagnosis and guide the therapeutic management of these infants. This noninvasive 
investigation should be integrated in the diagnostic arsenal of these patients. 
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Legends of the figures 
 
Legend of figure 1 
 
a)  Polygraphy tracing of patient #1 showing an irregular breathing rate of 29/minute with 
tachycardia   (heart rate around 155 beats/minute) and repeated episodes associating a 
simultaneous decrease in airflow and thoracic and abdominal expansion without opposition 
phase followed by a desaturation suggestive of global inspiratory muscle weakness. 
b)  Polygraphy tracing of patient #2 showing and irregular breathing pattern with a progressive 
decrease in airflow and thoracic and abdominal expansion without opposition phase, 
accompanied by a profound desaturation and an arousal with a repeat of the previous 
breathing pattern, suggestive of global inspiratory muscle weakness. 
 
Legend of figure 2 
 
a) Polygraphy tracing of patient #3 showing repeated episodes of a simultaneous decrease in 
airflow and opposition phase on the thoracic and abdominal belts followed by a desaturation, 
occurring at the end of the night, suggestive of a decrease of diaphragmatic endurance 
b) Polygraphy tracing of patient #4 showing a very irregular breathing pattern with recurrent 
episodes of a simultaneous decrease in airflow and thoraco-abdominal belts with profound 
desaturations 
 
Legend of figure 3 
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Polygraphy tracing of patient #5 showing that after an arousal when she is is not still asleep, 
airflow is present, with an opposition phase on the thoraco-abdominal belts, which is explained 
by the fact that the patient breathes exclusively with her accessory inspiratory muscles. When 
the patient falls asleep, because of the reduction of the activity of the inspiratory intercostal 
muscles during rapid eye movement sleep, airflow decreased to almost zero, with a 
simultaneous disappearance of the opposition phase. This leads to a profound desaturation and 
an arousal, and the cycle restarts again. 
 
Legend of figure 4 
 
Polygraphytracing of patient #9 showing repeated central apneas causing severe desaturations. 
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Table 1: Anthropometrics, clinical presentation, final diagnosis and outcome of the 
patients 
Patient 
gender 
Age 
(months) 
Weight 
(kg) 
Height 
(cm) 
PICU 
admission 
Associated 
clinicalfeatures 
Final diagnosis Outcome 
Duration of 
follow up 
(months) 
1 
male 
3 5 56 
Respiratory 
distress 
Peripheral muscle 
weakness, swallowing 
dysfunction 
Nemaline rod 
myopathy 
Therapeutic 
abstention 
4 - alive 
2 
female 
4 5 40 
Respiratory 
distress 
Peripheral muscle 
weakness 
Nemaline rod 
myopathy 
NIV 12 -alive 
3 
male 
24 19 84 
Life 
threatening 
events 
Generalized muscle 
weakness and 
fatigability, swallowing 
dysfunction 
Congenital 
myasthenia 
NIV 11 - alive 
4 
female 
3 6 62 
Respiratory 
distress 
Axial hypotonia, 
swallowing dysfunction 
Congenital 
myastenia 
NIV 31 - alive 
5 
female 
14 8 75 
Respiratory 
distress 
Generalized 
inflammatory disorder 
Diaphragmatic 
dysfunction 
NIV 15 -death 
6 
female 
2 4 60 
Life 
threatening 
events 
Swallowing 
dysfunction, 
bradycardia, axial 
hypotonia, acute 
obstructive events 
Brainstem 
dysfunction 
NIV 2 - death 
7 
male 
4 6 55 
Life 
threatening 
events 
Swallowing 
dysfunction, 
bradycardia, 
axialhypotonia 
Brainstem 
dysfunction 
Therapeutic 
abstention 
2 - alive 
8 
male 
1 3 50 
Life 
threatening 
events 
Swallowing 
dysfunction, 
bradycardia, axial 
hypotonia 
Brainstem 
dysfunction 
cafeine 5 - alive 
9 
male 
2 5 57 
Respiratory 
distress 
Swallowing 
dysfunction, 
bradycardia, axial 
hypotonia 
Brainstem 
dysfunction 
NIV 4 - alive 
10 
male 
6 5 60 
Respiratory 
distress 
Acute obstructive 
events 
SCID T-B-NK+ 
and  
laryngomalacia 
CPAP 8 - alive 
11 
male 
3 4 45 
Respiratory 
distress 
Acute obstructive 
events 
Laryngomalacia CPAP 52 -alive 
12 
male 
2 6 59 
Life 
threatening 
events 
Acute obstructive 
events with bradycardia 
Pharyngomalacia 
Lost for 
follow up 
Lost for 
follow up 
13 
male 
21 15 80 
Respiratory 
distress 
Recurrent episodes of  
respiratory failure 
CCHS 
Invasive 
ventilation 
on 
tracheotomy 
14 - alive 
"
Abbreviations: PICU: pediatric intensive care, SCID: severe combined immune 
deficiency, OSA: obstructive sleep apnea, CCHS: congenital central hypoventilation 
syndrome, CPAP: continuous positive airway pressure, NIV: noninvasive ventilation. 
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Table 2: Polygraphic results 
 
Recordi
ng time 
(minute
s) 
Respiratory events Gas exchange 
Main 
polygraphic 
findings 
CAI 
(events
/h 
OAI 
(events/
h) 
AHI 
(event
s) 
Mea
n 
SpO
2 
(%) 
Minim
al 
SpO2 
(%) 
ODI 
(events/
h) 
% time 
with 
SpO2<9
0% 
Mean 
PtcC
O2 
(mmH
g) 
Maxim
al 
PtcCO
2 
(mmH
g) 
% time 
with 
PtcCO
2> 
50mm
Hg 
1 
male 
149 5 0 11 93 75 28 21 51 56 100 
Homogene
ous 
decrease in 
ventilation 
2 
fema
le 
117 0 6 50 91 79 56 27 46 53 1 
Homogene
ous 
decrease in 
ventilation 
3 
male 
420 4 0 7 97 76 21 1 na na na 
Homogene
ous 
decrease in 
ventilation 
at the end 
of the night 
with phase 
opposition 
on thoracic 
and 
abdominal 
belts 
4 
fema
le 
146 3 5 52 97 78 34 3 41 45 0 
Homogene
ous 
decrease in 
ventilation 
5 
fema
le 
510 0 0 0 95 85 85 2 67 83 100 
Tracing 
evocative of 
diaphragma
tic 
weakness 
6 
fema
le 
159 8 36 63 94 76 62 6 40 42 0 
Obstructive 
events with 
decrease in 
respiratory 
drive 
7 
male 
85 0 0 6 97 90 13 0 39 43 0 
Irregular 
breathing 
8 
male 
188 34 7 64 95 65 67 10 42 46 0 
Central 
events 
9 
male 
224 71 17 104 94 73 117 12 48 55 33 
Central 
events 
10 
male 
64 0 8 22 96 89 14 0 49 64 39 
Obstructive 
events with 
hypoventilat
ion 
11 
male 
84 0 31 95 89 51 95 31 54 64 100 
Obstructive 
events with 
hypoventilat
ion 
12 
male 
113 5 12 20 98 94 3 0 39 41 0 
Obstructive 
events with 
bradycardia 
13 
male 
120 0 0 0 92 82 30 40 68 70 100 
Decrease in 
central 
drive during 
sleep, 
normalizati
on during 
awakening 
"
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Abbreviations: CAI: central apnea index, OAI: obstructive apnea index, AHI: apnea-
hypopnea index, SpO2: pulse oximetry, PtcCO2: transcutaneous carbon dioxide, na: not 
available. 
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Long-term non-invasive ventilation in children
Alessandro Amaddeo, Annick Frapin, Brigitte Fauroux
Use of long-term non-invasive ventilation is increasing exponentially worldwide in children of all ages. The treatment 
entails delivery of ventilatory assistance through a non-invasive interface. Indications for use of non-invasive 
ventilation include conditions that aﬀ ect normal respiratory balance (eg, those associated with dysfunction of the 
central drive or respiratory muscles) and disorders characterised by an increase in respiratory load (eg, obstructive 
airway or lung diseases). The type of non-invasive ventilation used depends on the pathophysiological features of the 
respiratory failure. For example, non-invasive ventilation will need to either replace central drive if the disorder is 
characterised by an abnormal central drive or substitute for the respiratory muscles if the condition is associated with 
respiratory muscle weakness. Non-invasive ventilation might also need to unload the respiratory muscles in case of 
an increase in respiratory load, as seen in upper airway obstruction and some lung diseases. Technical aspects are 
also important when choosing non-invasive ventilation—eg, appropriate interface and device. The great heterogeneity 
of disorders, age ranges of aﬀ ected children, prognoses, and outcomes of patients needing long-term non-invasive 
ventilation underline the need for management by skilled multidisciplinary centres with technical competence in 
paediatric non-invasive ventilation and expertise in sleep studies and therapeutic education.
 Introduction
Long-term non-invasive ventilation entails delivery of 
ventilatory assistance through a non-invasive interface, 
as opposed to invasive ventilation via tracheostomy. The 
number of children treated at home with this type of 
respiratory support is increasing exponentially around 
the world.1–3 Some evidence suggests mortality is 
decreased with non-invasive ventilation, but the main 
benefi t of the treatment is indisputably better family 
experience and health-related quality of life.2,4–7 However, 
the increase in use of non-invasive ventilation contrasts 
with the shortage of validated criteria for initiation and 
the scant proven physiological benefi ts.8
There are two main types of non-invasive ventilation. 
First, continuous positive airway pressure (CPAP) 
delivers a constant positive pressure to the airways and 
aims to maintain airway patency throughout the entire 
breathing cycle. Second, biphasic positive airway 
pressure (BiPAP) aims to assist the breathing of the 
patient by delivering a supplemental higher positive 
pressure during every inspiration.
In this Review, we summarise paediatric disorders that 
might benefi t from long-term non-invasive ventilation 
and discuss indications and expected and proven 
benefi ts. Further, we describe available equipment and 
detail the follow-up and monitoring of patients. Finally, 
we conclude with questions about ethics of non-invasive 
ventilation and areas for future research.
Paediatric disorders that might benefi t from 
non-invasive ventilator support
Non-invasive ventilation is indicated for disorders that 
cause disequilibrium in the respiratory balance. 
Components of respiratory balance are the load imposed 
on the respiratory system, the capacity of the respiratory 
muscles, and the central drive (fi gure). In healthy people, 
the respiratory load—ie, the eﬀ ort the individual has to 
exert to generate a breath—is low, the capacity of the 
respiratory muscles is normal, and the central drive 
appropriately commands the respiratory muscles 
(fi gure A). In disorders characterised by an increase in 
respiratory load, or by a weakness of the respiratory 
muscles, the central drive increases its demands on the 
respiratory muscles (fi gure C). When this imbalance 
exceeds a certain threshold, hypoventilation (defi ned by 
hypercapnia and hypoxaemia) occurs. Severe upper 
airway obstruction, airway malacia, and advanced lung 
diseases (eg, cystic fi brosis, bronchopulmonary dysplasia, 
or bronchiolitis obliterans) might account for an excessive 
respiratory load (panel 1).9–15 Neuromuscular diseases that 
involve the motor neuron, the peripheral nerve, the 
neuromuscular junction, or the respiratory muscles can 
cause respiratory muscle weakness. Chest wall disorders 
(eg, kyphoscoliosis) could be associated with an increase 
in respiratory load and dysfunction of the respiratory 
Key messages
• Use of non-invasive ventilation is increasing exponentially 
worldwide in children of all ages
• Increased use of non-invasive ventilation contrasts with 
scant validated criteria for initiation of the treatment and 
few proven benefi ts
• Continuous positive airway pressure (CPAP) is not 
appropriate for treatment of sleep-disordered breathing in 
children with neuromuscular disease, and biphasic support 
(BiPAP) should be used when non-invasive ventilation is 
implemented in these patients
• Technical aspects of non-invasive ventilation—eg, 
interface and device—are crucial when choosing 
non-invasive ventilation
• Training of caregivers and patients and organisation of 
adapted home care are essential
• Heterogeneity of disorders, ages of aff ected children, 
prognosis, and outcomes of patients all underline the 
need for management by skilled paediatric 
multidisciplinary centres 
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muscles, with the respiratory muscles having a 
mechanical disadvantage because of distorsion of the 
chest wall. Disorders of the central drive are rare and 
could be congenital (eg, congenital central hypo ventilation 
syndrome [Ondine’s curse]) or acquired due to 
compression of or injury to the brainstem. Other 
disorders involving an impairment of two or more 
components of respiratory balance (eg, achondroplasia 
and mucopolysaccharidoses) can cause upper airway 
obstruction and brainstem compression.
The type of non-invasive ventilation needed by patients 
depends on the pathophysiological features of their 
respiratory failure. CPAP is the simplest type of 
non-invasive respiratory support and is indicated in cases 
of isolated obstruction of the upper or lower airways. 
Indeed, in the case of airway obstruction causing an 
increase in respiratory load, the two other components of 
respiratory balance (ie, the respiratory muscles and 
central drive) are unaﬀ ected, and restoration of suﬃ  cient 
airway patency throughout the entire breathing cycle 
normalises breathing (fi gure D).9,12 BiPAP is indicated 
when these two other components of respiratory balance 
are also impaired.
In lung diseases associated with an increase in respiratory 
load, the aim of non-invasive ventilation is to unload the 
respiratory muscles.10,11,14,16 Since aﬀ ected individuals have a 
normal central drive and preserved respiratory muscle 
capacity, ventilatory assistance that maintains the patient’s 
own breathing pattern by allowing them to trigger assisted 
breaths will be the most appropriate and comfortable.10,11 
Conversely, in individuals with weak respiratory muscles, 
the role of BiPAP will be to assist or replace, according to 
the severity of the weakness, the respiratory muscles by 
delivering positive pressure during inspiration. For these 
patients, triggering of the ventilator might be diﬃ  cult or 
impossible. A controlled mode with a back-up rate (ie, a 
minimum number of breaths delivered per min by the 
ventilator) close to the normal respiratory rate during sleep 
for age is recommended. Thus, CPAP is clearly not the 
treatment for sleep-disordered breathing in patients with 
neuromuscular disease. Finally, in individuals with an 
Figure: Respiratory balance
(A) Normal respiratory balance is when the load imposed on the respiratory system, the capacity of the respiratory 
muscles, and the central drive are in equilibrium. (B) A decrease in central drive (dotted line) causes a decrease in the 
activity of the respiratory muscles and, subsequently, a reduction in alveolar ventilation. (C) A weakness of the 
respiratory muscles or an increase in respiratory load causes an increase in central drive (bold arrow). Alveolar 
ventilation occurs when the imbalance exceeds a specifi c threshold. (D) Non-invasive ventilation can correct 
disequilibrium in the respiratory balance by replacing central drive, unloading (in case of an increase in respiratory 
load, as shown), or assisting the respiratory muscles (in case of respiratory muscle weakness).
Respiratory load
↑Respiratory load
Respiratory load
Respiratory load
Respiratory muscles
Respiratory muscles
Respiratory muscles
↓Respiratory muscle
performance
Central drive ↓Central drive
↑Central drive
Central drive
A
C
B
D
Non-invasive
ventilation
Panel 1: Examples of disorders that can cause 
disequilibrium in the respiratory balance
Increase in respiratory load
Anatomical abnormalities of the upper airway
• Treacher Collins syndrome
• Craniofaciostenosis
• Pierre Robin syndrome
• Pycnodysostosis
• Achondroplasia
• Tracheomalacia or laryngomalacia
• Congenital or acquired laryngotracheal stenosis
• Vocal cord paralysis
• Other upper airway malformation
• Storage diseases
• Neck masses or tumours
• Down’s syndrome
• Beckwith-Wiedemann syndrome
Lower airway obstruction
• Cystic fi brosis
• Bronchopulmonary dysplasia
• Bronchiolitis obliterans
Decrease in performance of respiratory muscles
• Spinal muscular atrophy
• Spinal cord injury
• Phrenic nerve injury
• Myasthenia
• Myopathies and dystrophies
Dysfunction of central drive
• Congenital central hypoventilation syndrome
• Brain injury by tumours or infection (encephalitis)
• Brainstem dysfunction (eg, Chiari malformation) 
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abnormal central drive, the BiPAP ventilator should be able 
to take over command of the respiratory muscles by means 
of a controlled mode.
Equipment and settings for non-invasive 
ventilation
Equipment for non-invasive ventilation comprises 
the interface, the circuit, and the device. Important 
improvements have been made in interfaces available for 
children (table). Interfaces can cover the nose (nasal 
mask), the nose and the mouth (nasobuccal mask), the 
face (total face mask), and, exceptionally, the mouth only 
(mouthpiece).17,18 Nasal pillows (or prongs or cannulas) are 
minimum contact interfaces that are available for children 
aged 5–7 years or older and are very well tolerated.17
Interfaces can be either vented or non-vented. Vented 
interfaces incorporate intentional leaks and are to be 
used with a single circuit (ie, with only an inspiratory 
line, the expiration occurring through the intentional 
leak on the interface) and a minimum positive expiratory 
pressure. Non-vented masks can be used with a double 
circuit (ie, with a separate inspiratory and expiratory line) 
or a circuit with an expiratory valve (ie, with only an 
inspiratory line, the expiration occurring through a valve 
that opens exclusively during expiration), with or without 
positive expiratory pressure. A minimum level of 
expiratory pressure is mandatory for vented masks, to 
allow the clearing of carbon dioxide during expiration.19,20
The choice of interface is decided by the patient’s age, 
weight, facial and skull anatomy for the fi tting of the 
headgear, nasal permeability and the eventual presence of 
mouth breathing, ventilatory mode (requiring a vented or 
non-vented interface), comfort and tolerance with the 
interface, and the patient’s ability and need to remove the 
interface unaided. Nasal masks and full face masks are 
also available for neonates and infants, which have 
contributed to the rapid expansion in use of non-invasive 
ventilation in young children.21 Children with maxillofacial 
deformities—eg, those with Treacher Collins syndrome—
will generally need a nasobuccal mask.22
Diﬀ erent modes of non-invasive ventilation are 
available. Constant CPAP is the simplest mode and has 
proven eﬃ  cacy in children with severe upper airway 
obstruction.9,12,15,23–25 Autotitrated CPAP is a mode during 
which positive airway pressure is adjusted automatically 
between a minimum and maximum airway pressure set 
by the prescriber, according to analysis of the fl ow curve 
and airway resistance by device software. More advanced 
modes—associated with a moderate decrease in airway 
pressure at the onset of expiration, or a variable increase 
in airway pressure during inspiration—are also 
available.26 Since all CPAP devices have been designed 
for adult patients, manufacturers recommend a 
minimum weight, usually between 10 kg and 30 kg, for 
use of the autotitrated and advanced CPAP modes. A few 
studies have compared constant CPAP with autotitrated 
and advanced CPAP modes, but superiority of these 
more complex modes has not been shown with respect to 
comfort or eﬃ  cacy, compared with constant CPAP.27,28
The aim of CPAP titration is to suppress any residual 
respiratory event and is usually done during poly-
somnography.29 Titration might also be done by means 
of recording oesogastric pressures, which refl ect the 
inspiratory and expiratory work of breathing. In infants 
with severe upper airway obstruction, setting the 
CPAP pressure to the highest tolerated pressure is 
recommended, because a setting based on non-invasive 
clinical variables (eg, improvement in oxygenation and 
CO2 levels, reduction in respiratory rate and heart rate, 
and increase in tidal volume) has been shown to 
underestimate the optimum CPAP pressure by a mean 
of 2 cm H2O in these patients.
15
During BiPAP, a higher level of positive pressure 
is delivered during inspiration by means of a volume-
targeted or pressure-targeted mode. With volume-targeted 
ventilation, the ventilator delivers a fi xed volume through-
out a given time span. The advantage of this mode is strict 
delivery of a preset volume; the main dis advantage is that 
this mode is not able to adjust to the variable requirements 
of the patient during sleep—eg, physiological changes in 
central drive, lung compliance, and airway resistance. 
Moreover, compensation for unintentional air leaks is not 
possible, which puts the patient at risk of receiving an 
insuﬃ  cient eﬀ ective inspired volume.30 With pressure-
targeted ventilation, the airfl ow is adjusted to generate a 
constant positive pressure during a given time span. The 
Advantages Disadvantages Side-eff ects
Nasal mask Small internal volume; large choice of 
diff erent industrial models
Not usable in case of mouth leaks Pressure sores, eye irritation if 
leaks, facial deformity
Nasobuccal mask Prevents mouth leaks Large volume; risk of inhalation of gastric content in case of 
gastro-oesophageal refl ux; impairs communication and 
vocalisation; increased aerophagia
Pressure sores, eye irritation if 
leaks, facial deformity
Total face mask Prevents mouth leaks Larger volume than nasobuccal mask; risk of inhalation of 
gastric content in case of gastro-oesophageal refl ux; impairs 
communication and vocalisation; increased aerophagia
Pressure sores, facial deformity
Nasal pillows Small and light; no pressure sores Not usable in case of mouth leaks Nasal irritation
Mouthpiece Small and light; no pressure sores; can 
be used intermittantly
Not useable during sleep None
Table: Advantages, disadvantages, and side-eff ects of interfaces for children
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delivered volume depends on the interaction between the 
preset pressure, the patient’s inspiratory eﬀ ort, and the 
respiratory mechanics.31 The main advantage of pressure-
targeted ventilation compared with volume-targeted 
ventilation is its ability to compensate for unintentional 
leaks. Patient–ventilator synchronisation is improved 
because fl ow can vary on a breath-to-breath basis. However, 
this mode requires that the device is able to detect the 
onset and end of inspiration of the patient, which can be 
diﬃ  cult in young children because of small airfl ows and 
volumes.12 Innovative modes, also called hybrid modes, 
use intelligent algorithms to adjust one or more settings 
automatically to achieve predefi ned targets.32 These hybrid 
modes, known as volume-targeting pressure ventilation 
(VTPV) or average volume-assured pressure support 
(AVAPS), combine the characteristics of both volume-
targeted and pressure-targeted ventilation to overcome 
previous limitations. These modes provide a predetermined 
target volume while maintaining the physiological benefi ts 
of the pressure-targeted mode. The ventilator measures or 
estimates the volume of each expired breath and adjusts 
inspiratory pressure auto matically within a predetermined 
range to ensure a stable target volume. Hybrid modes are 
used increasingly in paediatric patients despite scarcity of 
validated studies in children.33
BiPAP settings should be adjusted to the patient’s 
underlying disorder. In children with neuromuscular 
disease, the aim is to deliver a physiological tidal volume. 
This goal can be achieved with low inspiratory pressures 
in young infants with compliant lungs and chest wall, 
but higher inspiratory pressures will be necessary in 
older children, those with scoliosis, or patients who are 
obese. Expiratory pressures should be set at the lowest 
values, because patients with neuromuscular disease 
usually have no airway obstruction. A back-up rate close 
to the physiological breathing rate during sleep is 
recommended; inspiratory triggering of the ventilator 
can be diﬃ  cult for a child with weakened respiratory 
muscles and, therefore, a back-up rate is needed to avoid 
apnoea. In children with cystic fi brosis, the optimum 
settings for non-invasive ventilation have been assessed 
in physiological studies measuring the work of 
breathing.10,11,16 In these patients, the optimum mean 
inspiratory pressure was 16 cm H2O with no expiratory 
pressure, the inspiratory trigger should be sensitive, and 
a back-up rate is recommended to avoid apnoea.11,16 
In other lung diseases (eg, bronchiolitis obliterans), 
a high level of expiratory pressure might be necessary 
to counterbalance the intrinsic positive end-expiratory 
pressure.14 In any case, settings for CPAP or BiPAP 
should be set and adapted individually.
Negative pressure ventilation comprises the application 
of negative pressure around the chest during inspiration, 
to expand the thorax and generate a tidal volume. This 
method has been used for several decades, mainly in 
adult patients with neuromuscular disease, and its use in 
children is limited.5 However, use of negative pressure 
ventilation has expanded during the past few years 
because devices have improved greatly in performance 
and have become smaller. This type of ventilation could 
be worthwhile at night or for patients who cannot tolerate 
a non-invasive interface. However, the biggest problem 
with use of negative pressure ventilation is that of 
obstructive sleep-disordered breathing due to suppres-
sion of the normal preinspiratory activation of upper 
airway muscles. The eﬀ ectiveness of this approach 
should, therefore, be checked carefully because of the 
risk of persistent respiratory events and desaturations.34
Indications for and benefi ts of non-invasive 
ventilation
No criteria have been validated for when to start long-
term non-invasive ventilation in children. In clinical 
practice, non-invasive ventilation can be initiated in 
several situations: in an acute setting; after failure to 
wean a patient oﬀ  non-invasive ventilation in the 
paediatric intensive care unit; in cases of abnormal 
nocturnal gas exchange alone; or in patients with a high 
apnoea-hypopnoea index on polysomnography.8 The 
main challenges or diﬃ  culties for initiation of 
non-invasive ventilation in children are: deciding on the 
timing and type of investigation that should be done 
(eg, polysomnography, polygraphy, or an overnight gas 
exchange recording); and defi ning the values or 
thresholds of variables that are retained (eg, the oxygen 
or CO2 level, or the apnoea-hypopnoea index) with the 
assumption that their correction will be associated with 
a benefi t of non-invasive ventilation.8 These diﬃ  culties 
are attributable to the paucity of markers for end-organ 
morbidity associated with sleep-disordered breathing 
and chronic respiratory failure in children. Neuro-
cognitive dysfunction and behavioural disturbances are 
the most common and severe outcomes of obstructive 
sleep apnoea in children, but these deleterious eﬀ ects 
are highly variable from one child to another.35 Of note, 
morbidity associated with sleep-disordered breathing 
has been studied little in children needing non-invasive 
ventilation for disorders other than obstructive 
sleep apnoea.
A sleep study forms part of the routine assessment for 
a child with obstructive sleep apnoea. Polysomnography 
represents the gold standard, but polygraphy or 
continuous monitoring of nocturnal gas exchange 
by measurement of pulse oximetry (SpO2) and trans-
cutaneous partial pressure of CO2 (PtcCO2) can be used 
as an alternative procedure if full polysomnography is 
not available.36 Usual indications for CPAP are residual 
obstructive sleep apnoea after adenotonsillectomy 
(defi ned as an apnoea-hypopnoea index greater than 
fi ve events per h) and obstructive sleep apnoea related to 
obesity or craniofacial abnormalities.36 Every therapeutic 
intervention in a child with obstructive sleep apnoea 
should be evaluated after 6 weeks to 12 months. 
In practice, CPAP is prescribed in children with complex 
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obstructive sleep apnoea due to anatomical or structural 
abnormalities of the upper airways—eg, cranio-
facial malformations, Down’s syndrome, Prader-Willi 
syndrome, or morbid obesity.6,37,38 BiPAP is indicated if 
nocturnal hypoventilation persists despite optimum 
CPAP.36 CPAP is associated with an improvement in 
sleep variables—eg, the apnoea-hypopnoea index, gas 
exchange, attention defi cits, behaviour, sleepiness, and 
quality of life.6
Less consensus exists about the type of investigation 
and criteria for initiation of BiPAP in children with 
neuromuscular diseases. First, BiPAP might be justifi ed 
without a sleep study when the child presents with 
episodes of acute respiratory failure triggered by a 
respiratory infection or an anaesthetic procedure, since 
these events are markers of insuﬃ  cient respiratory 
reserve.39 Concerning the timing of a sleep study, 
validated recommendations are sparse, possibly because 
of the heterogeneity of neuromuscular disorders in 
children and the variability of respiratory involvement 
within a specifi c disease—eg, spinal muscular atrophy or 
collagen 6 (COL6) myopathies.40,41 Symptoms suggestive 
of sleep-disordered breathing did not diﬀ er in children 
with a neuromuscular disorder with or without overt 
nocturnal hypoventilation.42 These symptoms, therefore, 
cannot be used as predictors or markers of nocturnal 
hypoventilation; moreover, they can be diﬃ  cult to assess 
in young children and typically arise too late in the course 
of the disease to be of diagnostic value. With respect to 
the predictive value of lung function and other respiratory 
variables, researchers on a large prospective study of 
children with neuromuscular disorders did not identify a 
sensitive and specifi c daytime lung function or 
respiratory muscle test that was associated with or 
predictive of nocturnal hypoxaemia or hypercapnia.43 
The type of neuromuscular disorder should be taken 
into account, because nocturnal hypoventilation occurs 
more often in disorders characterised by prominent 
diaphragmatic weakness. Children with a COL6 
myopathy should be screened systematically for 
sleep-disordered breathing.44 Prioritised screening is also 
recommended for infants or young children with 
congenital myopathies or rapidly progressive neuro-
muscular diseases.45 In children with neuromuscular 
disease, documentation of nocturnal hypoventilation by 
means of polysomnography is recommended but not 
essential before starting BiPAP, because isolated 
abnormal nocturnal gas exchange can be suﬃ  cient to 
show hypoventilation and justify BiPAP initiation.46 
Indeed, nine of ten patients with neuro muscular disease 
or thoracic deformity and isolated nocturnal hypercapnia 
without daytime hypercapnia progressed to overt daytime 
respiratory failure within a period of 2 years.46 Moreover, 
in the presence of an abnormal overnight gas exchange 
recording or full polysomnography, criteria that are used 
to defi ne nocturnal hypoventilation are highly variable, 
which has practical outcomes because an indication for 
long-term non-invasive ventilation relies on detection of 
hypoventilation.47 The scoring of polysomnography in 
patients with neuromuscular disease needs specifi c 
expertise. Indeed, instead of apnoeic and hypopnoeic 
events, patients can present with a progressive 
simultaneous decrease in airfl ow and thoracic and 
abdominal movements accompanied or not by a change 
in gas exchange, suggestive of global inspiratory muscle 
weakness.48 Paradoxical breathing with opposition phase 
on the thoracic and abdominal belts can be a result of 
diaphragmatic dysfunction or weakness of the intercostal 
muscles and should not be interpreted falsely as 
obstructive events.48–50
Periods of reduced ventilation or paradoxical breathing 
(more so than obstructive or central apnoea-hypopnoea, 
particularly during rapid-eye movement sleep), which 
are associated with SpO2 less than 90% or PtcCO2 greater 
than 50 mm Hg, are indicative of insuﬃ  cient respiratory 
muscle performance and justify long-term BiPAP in 
children with neuromuscular disease. In clinical practice, 
however, many children with a progressive neuro-
muscular disease (eg, spinal muscular atrophy or 
Duchenne muscular dystrophy) are started on non-
invasive ventilation empirically. Indeed, limited access to 
sleep studies should not delay these patients accessing 
an eﬀ ective treatment, the most important requisite 
being that children should be followed up by a paediatric 
team with expertise in non-invasive ventilation.
Widespread use of BiPAP in children with neuro-
muscular disease contrasts with the few studies in which 
the benefi ts of BiPAP have been assessed in children. 
Findings of studies in small numbers of patients show 
that BiPAP is associated with normalisation of nocturnal 
and daytime gas exchange, an improvement in sleep 
quality, and a reduction in symptoms associated with 
sleep-disordered breathing.51–53 Non-invasive ventilation 
associated with mechanical insuﬄ  ation-exsuﬄ  ation, 
prevents thoracic deformities and consequent thoracic 
and lung hypoplasia in young children with neuro-
muscular disease.54 Intermittent positive-pressure 
breathing, which entails delivery of high inspiratory 
pressures generally on a daily basis during daytime, can 
increase ventilation in patients with neuromuscular 
disease.55 Both non-invasive ventilation and intermittent 
positive-pressure breathing are also eﬀ ective at prevention 
of atelectasis and the risk of pneumonia in children with 
neuromuscular disease.56
Children with cystic fi brosis do not have a validated 
indication for a sleep study or BiPAP. In a prospective 
multicentre study of 80 paediatric and adult patients with 
stable cystic fi brosis, who had a forced expiratory volume 
in 1 s (FEV1) less than 60% predicted, 13 (18%) patients 
spent more than 10% of night-time with SpO2 less than 
90% and 33 (47%) had PtcCO2 greater than 45 mm Hg.
57 
Nocturnal gas exchange correlated with daytime arterial 
blood gases, and nocturnal SpO2 correlated with FEV1. 
However, no correlation was recorded between the 
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subjective assessment of sleep quality (by means of 
questionnaires) and the objective evaluation of nocturnal 
gas exchange. No consensus exists about clinical 
situations or criteria that justify initiation of BiPAP in 
children with cystic fi brosis. Similar to adult patients 
with chronic obstructive pulmonary disease, BiPAP is 
recommended as a fi rst-line treatment for an acute 
hypercapnic respiratory exacerbation, without any 
evidence from prospective randomised studies.58–60 BiPAP 
is also prescribed largely for patients on lung transplant 
lists and those with insuﬃ  cient improvement after 
oxygen therapy.61 This usage contrasts with the conclusion 
of a Cochrane review, in which improvement of nocturnal 
gas exchange and diminished oxygen desaturation and 
respiratory muscle fatigue during chest physiotherapy 
were the only proven benefi ts of BiPAP in cystic fi brosis.62 
An unresolved question is the use of non-invasive 
ventilation for CO2 clearance in children with pulmonary 
hypertension due to primary lung or complex congenital 
heart disease; children with congenital heart disease are 
a burgeoning population with high-risk home needs.
In clinical practice, non-invasive ventilation is 
associated with improved feeding, weight gain, and 
growth, which supports fi ndings of physiological studies 
showing that non-invasive ventilation decreases the work 
of breathing and resultant caloric burn.9,63 In some 
studies, non-invasive ventilation was also associated with 
improved sleep quantity and quality, which has a positive 
eﬀ ect on neurocognitive and behavioural outcomes.6,64
Screening with at least an overnight gas exchange 
recording to detect nocturnal hypoxaemia or hypercapnia, 
and if possible with a complete sleep study, should be a 
priority in all children with upper airway obstruction and 
any type of neuromuscular or lung disease that might be 
associated with nocturnal hypoventilation. Symptoms of 
sleep-disordered breathing are insuﬃ  ciently sensitive 
and specifi c and tend to arise late in the course of the 
diﬀ erent diseases. Since poor sleep quality is associated 
with neurocognitive dysfunction, abnormal behaviour, 
and decreased quality of life, a trial of 1–3 months of 
non-invasive ventilation with a thorough assessment 
before and after the period of non-invasive ventilation, 
seems a reasonable option.
Practical follow-up of children
Non-invasive ventilation is a technically challenging 
treatment, but the ultimate aim is to perform it at home. 
It is usually initiated in hospital during a short admission, 
to acclimatise the patient to their treatment. Because 
non-invasive ventilation will be administered during 
sleep, overnight monitoring of sleep with the optimum 
settings—at least with an assessment of overnight 
gas exchange and ideally with polygraphy or poly-
somnography—is recommended before discharge. 
However, non-invasive ventilation might also be 
implemented in the home care setting, according to local 
resources, family capacity, patient’s stability, and other 
socioeconomic factors. Because of a shortage of hospital 
beds at our institution (Hôpital Necker Enfants-Malades, 
Paris, France), we have started outpatient initiation of 
non-invasive ventilation for selected patients, with 
eﬃ  cacy and compliance comparable with in-hospital 
initiation (unpublished data). A sleep study with 
non-invasive ventilation is recommended but can be 
postponed until the patient is well adapted to their 
treatment and is able to sleep at least 6 h with the device. 
Training of caregivers and the patient is essential. 
Caregivers must not only be familiar with putting on and 
taking oﬀ  the interface and device but also must have 
training for the diﬀ erent problems that might arise at 
home.65 Careful checking of the caregiver’s competence 
is mandatory. Availability of a trained home care provider, 
who is able to visit the patient at home on a regular 
as-needed basis, is an important requisite of success for 
outpatient initiation. However, the large variability in 
availability and quality of home care nursing to buttress 
parental care remains a limitation of home non-invasive 
ventilation in children.
Compliance with non-invasive ventilation is a major 
issue, because treatment eﬃ  ciency is related to length of 
nocturnal use.6 In most studies, fairly low compliance 
has been reported, with mean night-time use between 
3 h and 5 h.6,27,28 However, objective compliance close to 
the recommended sleep duration in children can be 
achieved by expert centres having a specifi c non-invasive 
ventilation therapeutic education programme.66 Close 
collaboration is necessary between the hospital team and 
the home care provider. Home care provider systems 
vary from one country to another, but the team visiting 
the patient at home must have expertise in paediatric 
non-invasive ventilation. Caregivers should be able to 
contact the home care provider for any technical 
assistance and the hospital team for any medical issue at 
any time.65
No validated guidelines are available for monitoring or 
long-term follow-up of children undergoing non-invasive 
ventilation. Timing of follow-up visits depends on the age 
and medical condition of the child. At our institution, 
we undertake a sleep study in hospital 1 month after 
initiation of non-invasive ventilation, then have at least 
one outpatient follow-up visit and one in-hospital full sleep 
study with non-invasive ventilation every 2–6 months. 
However, practice at other institutions and in other 
countries varies, with no evidence for superiority of one 
approach over another. However, overnight measurement 
of SpO2 with PtcCO2 recording during non-invasive 
ventilation usually takes place at every follow-up visit 
because many asymptomatic patients remain hypercapnic 
during sleep with non-invasive ventilation, despite a 
normal overnight SpO2 and normal daytime blood gases.
67 
This residual nocturnal hypercapnia can be corrected 
easily by simple measures—eg, changing the interface or 
the ventilator settings.67 Check-ups can also be done at 
home with adequate training of staﬀ .68 Simultaneous 
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analysis of the in-built software of the ventilator and 
the overnight gas exchange gives useful information 
on important issues such as objective compliance, 
unintentional leaks, respiratory rate, airway pressure, and 
respiratory events. However, because most devices are 
designed for adults, this information is not always reliable 
for children.69 Systematic polygraphic studies are 
recommended during non-invasive ventilation because 
residual respiratory events—eg, patient–ventilator 
asynchronies, unintentional leaks, persistent obstructive 
events with or without reduction in central drive, and 
persistent central or mixed events—are common in 
asymptomatic children with stable disease and might be 
accompanied by desaturations or arousals.70,71 Residual 
respiratory events are less common in asymptomatic 
children with stable disease after treatment with CPAP.38
Compared with most adult patients, a substantial 
number of children could be weaned oﬀ  their ventilator 
support over time.2 Indeed, some conditions (eg, 
Pierre Robin syndrome or bronchopulmonary dysplasia) 
improve spontaneously with increasing age.21,63 Other 
disorders, such as tracheal or laryngeal stenosis, 
Treacher Collins syndrome, or craniofaciostenosis, might 
improve after upper airway surgery, maxillofacial surgery, 
or neurosurgery. No recommendations or guidelines are 
available for weaning children oﬀ  ventilator support. 
Depending on the type of corrective surgery, a minimum 
delay of about 2–6 months is typical for weaning oﬀ 
non-invasive ventilation, corres ponding to the timing 
associated with the maximum benefi t of the surgical 
intervention. In the case of spontaneous improvement, a 
sleep study without CPAP or non-invasive ventilation is 
indicated at least 2–4 weeks after weaning oﬀ  ventilator 
support because of the long-lasting eﬀ ects of CPAP and 
non-invasive ventilation. In any case, long-term follow-up 
is recommended because of the possibility of recurrence 
of sleep-disordered breathing.72
Side-eff ects, limitations, and ethical aspects 
Non-invasive ventilation can be associated with side-
eﬀ ects (table). The most common are those caused by the 
interface and include skin injury from pressure sores, 
eye irritation because of unintentional air leaks, and 
facial deformity in young patients.73 Skin injury is less 
common than several years ago because of improvements 
in interfaces for children and the use of minimum 
contact interfaces such as nasal pillows. Mouth leaks can 
be minimised by use of a chin strap or a pacifi er in 
infants, or a change to a nasobuccal mask. Facial 
fl attening and maxillary retrusion can be prevented by 
use of nasal pillows or by alternating diﬀ erent 
interfaces—eg, a nasal mask and a nasobuccal mask. 
Other side-eﬀ ects might be attributable to the positive 
pressure. Aerophagia or gastric distension, and increased 
gastro-oesophageal refl ux, can be seen with high CPAP 
pressures or, in case of patient–ventilator asynchrony, 
with BiPAP. These abdominal side-eﬀ ects can be 
managed by decreasing the airway pressures or 
correcting patient–ventilator asynchrony. Autonomic 
arousals might be seen during persistent obstructive 
events with CPAP and during unintentional leaks with 
BiPAP.8,71
Non-invasive ventilation still has some limitations in 
the youngest children. A minimum weight of 5 kg is 
generally recommended as a cutoﬀ  for this treatment in 
the community. However, recommendations vary by 
country and, most importantly, these cutoﬀ s have not 
been validated clinically.
Sleep aﬀ ects the three components of the respiratory 
balance: respiratory load, the respiratory muscles, and 
central drive (fi gure). Physiological changes in respiratory 
and upper airway function, respiratory muscle power, 
and ventilatory response lead to reduced ventilation 
during sleep. Most patients need non-invasive ventilation 
only during sleep,1,2 but some patients will also need this 
treatment during the daytime, particularly individuals 
with advanced neuromuscular disease.74,75 In children 
with neuromuscular disease, mouthpiece ventilation 
during the daytime can prolong the duration of 
non-invasive ventilation and delay the timing of a 
tracheostomy.74–76 In a study of 30 adult patients with 
neuromuscular disease, patient-reported benefi ts of 
mouthpiece ventilation included a reduction in dyspnoea 
and fatigue and an improvement in speech and eating.75 
However, mouthpiece ventilation can be impossible or 
diﬃ  cult in very young children. Even if non-invasive 
ventilation is very eﬀ ective, it can be diﬃ  cult to apply 
around the clock on a long-term basis. Some expert 
teams have had successful experiences with non-invasive 
ventilation in children with neuromuscular disease who 
are totally dependent on a ventilator.77 Other clinicians 
consider that the child should be able to breathe 
spontaneously without non-invasive ventilation for a 
minimum time per day so they can be discharged home 
safely. However, this practice is also dependent on local 
experience and patient’s preference. A tracheostomy 
represents a possible option for children with a 
progressive neuromuscular disease, which has to be 
prepared and discussed thoroughly with the child and 
their parents. However, this invasive procedure is not 
always associated with a decrease in quality of life.78
The decision to transition to tracheostomy is complex 
for children with severe underlying disease with a fatal 
outcome and rapid decline, developmental delay, or 
severe physical or cognitive disabilities. Determining 
the best interests of the child is important, and the 
Royal College of Paediatrics and Child Health states that 
the decision must balance the “benefi ts and burdens 
of treatment and outcomes, whilst considering 
ascertainable wishes, beliefs and values and preferences 
of the child and their family, the cultural and religious 
views of the matter, the views of those providing care for 
the child and what choice is less restrictive for future 
options”.79 The transition from non-invasive ventilation 
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to tracheostomy can be associated with a great burden 
with respect to the improvement in quality of life of the 
child and their family.80 Non-invasive ventilation might 
then be used as part of a palliative care approach, 
without prolonging excessively a poor or unbearable 
quality of life. The confi dence, transparency, and quality 
of the relationship of the family with the health-care 
team are of crucial importance and determine the 
individual nature of these decisions. However, this area 
of health-related quality of life remains complex and is 
evolving.81–84
Concluding remarks
Long-term non-invasive ventilation is a very eﬀ ective type 
of respiratory support that has transformed the scope of 
chronic respiratory failure and severe sleep-disordered 
breathing in children by avoiding tracheostomies and 
allowing patients to live at home with a good quality of life 
for themselves and their families. The great heterogeneity 
of disorders, patients’ ages, prognosis, and outcomes 
underline the need for management by skilled 
multidisciplinary centres having technical competence in 
paediatric non-invasive ventilation and expertise in sleep 
studies and therapeutic education. The increased use of 
non-invasive ventilation contrasts with the scant proven 
benefi ts. Future studies should aim to defi ne disease and 
age-appropriate initiation and weaning criteria, and 
objective physiological and quality of life benefi ts (panel 2).
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Objectives: Polysomnography (PSG) is the gold standard for the scoring of residual respiratory events
during continuous positive airway pressure (CPAP). Studies comparing PSG scoring with automatic
scoring by the built-in software of CPAP devices have reported acceptable agreements except for the
hypopnea index (HI) in adult patients, but no study has yet been conducted in children. The aim of the
present study was to compare the automatic scoring by CPAP device and manual scoring using the
software tracings of the CPAP device integrating pulse oximetry (SpO2) with in-lab polygraphy (PG).
Methods: Consecutive clinically stable children treated with constant CPAP (ResMed) for at least one
month and scheduled for a nocturnal PG were recruited. A pulse oximeter was connected to the CPAP
device. The PG apnea-hypopnea index (AHIPG), scored according to modiﬁed AASM guidelines, was
compared with the automatic AHI reported by the CPAP device (AHIA CPAP) and the manual scoring of the
AHI on the CPAP software (AHIM CPAP).
Results: Fifteen children (1.5e18.6 years) were included. Mean residual AHIPGwas 0.9 ± 1.2/hour (0.0e4.6/
hour) vs. AHIA CPAP of 3.6 ± 3.6/hour (0.5e14.7/hour) (p < 0.001), and AHIM CPAP of 1.2 ± 1.6/hour (0.0e5.1/
hour) (p ¼ 0.01). Correlation between AHIPG and AHIA CPAPwas good (r ¼ 0.667; p ¼ 0.007), and improved
when considering AHIM CPAP (r¼ 0.933; p < 0.001). Strong correlations were also observed between the PG
apnea index (AI) and HI, and the manually scored AI and HI on CPAP, respectively.
Conclusions: Manual scoring of respiratory events on the built-in software tracings of CPAP devices
integrating SpO2 signal may be helpful. These results have to be conﬁrmed in patients with higher AHI.
© 2017 Elsevier B.V. All rights reserved.
1. Introduction
In-lab overnight polysomnography (PSG) is considered the gold
standard for continuous positive airway pressure (CPAP) titration
and follow-up, both in children and adults [1,2]. However, there is
considerable interest in validating alternative strategies to reduce
the need for in-lab follow-up sleep studies, which are of limited
access, costly and labor intensive [3].
Several studies have assessed the ability of different CPAP de-
vices to identify residual respiratory events in adult patients with
obstructive sleep apnea, and compared the data of the built-in
software of CPAP devices with respiratory events simultaneously
determined by in-lab PSG [4e14] or home type III polygraphy (PG)
[15]. Despite the good correlation between the automatic apnea-
hypopnea index (AHI) given by the built-in software of the CPAP
device and the AHI scored by PSG/PG, the correlation was weaker
for the hypopnea index (HI) alone. However, variable ranges of
limits of agreement have been observed between the AHI scored by
different CPAP devices and PSG/PG, which may lead to a misdiag-
nosis of residual respiratory events and, thus, inappropriate man-
agement. One explanation for the discrepancy between the AHI
scoring by the CPAP device and that performed by PSG/PG is that
the AHI automatically scored by the CPAP device depends entirely
on the CPAP airﬂow signal, whereas the PSG/PG scoring takes in
account the airﬂow signal and changes in arterial oxygen saturation
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(SpO2) [9,15]. No study has yet assessed the residual respiratory
events in pediatric patients by the different CPAP devices.
As one of the limitations of the CPAP built-in software is the
scoring of hypopneas, the present study investigated the value of
the adjunct of a SpO2 oximeter to the CPAP devices to improve
hypopnea scoring in children. Therefore, the AHI scored automat-
ically by the built-in software of the CPAP device (AHIA CPAP) was
compared with the manual analysis of the CPAP built-in software
tracings with the SpO2 signal (AHIM CPAP) and the AHI scored on an
in-lab PG (AHIPG).
2. Materials and methods
2.1. Patients
All consecutive stable patients treated with noninvasive con-
stant CPAP for at least one month at home and with scheduled
overnight PG between October 2015 and June 2016 were included.
A dedicated noninvasive ventilation and sleep unit in a tertiary
pediatric university hospital performed all sleeps studies. The study
was conducted in agreement with the French regulations and
received appropriate legal and ethical approval from the Ethical
Committee CPP Ile de France II, n# 2015-11-3.
2.2. In-lab polygraphy
In-lab overnight PG (Cidelec, Saint Gemme sur Loire, France or
Alice 6, Respironics, Carquefou, France) was performed with CPAP.
Respiratory movements were recorded by respiratory inductance
plethysmography, tracheal sound, body position, movements by
actigraphy, heart rate, and SpO2 (Nonin Medical Inc., USA) [16]. The
SpO2 signal was averaged on a four pulse-window and displayed
with a sampling frequency of 1 Hz. Airﬂow was recorded using a
pneumotachograph (pediatric/adult ﬂow sensor, Hamilton Medical
AG, Switzerland) placed on the single limb circuit next to the nasal/
facial mask of the patient or a tubular ﬂow sensor (Cidelec or Alice
6). The tubular ﬂow sensor consisted of two connectors that were
placed on the single limb circuit, one at the CPAP device exit and
one next to the nasal/facial mask, which estimated airﬂow as the
pressure difference between the two connectors [2]. The sleep
study was recorded on videotape with an infrared video camera.
Respiratory events were scored according to ‘modiﬁed’ AASM
guidelines, as electroencephalographic (EEG) arousals could not be
scored on PG [16]. Obstructive apnea was deﬁned as a drop in
airﬂow amplitude by 90% of baseline for at least two respiratory
cycles, with continued or increased inspiratory efforts. Central ap-
nea was deﬁned as a drop in airﬂow amplitude by 90% of baseline
without inspiratory effort, duration of at least two breaths, and
associated with an awakening, and/or a 3% oxygen desaturation
(OD), or of a duration of at least 20 s. Mixed apnea was deﬁned as a
drop in airﬂow amplitude by 90% of baseline for at least two res-
piratory cycles with the absence of inspiratory effort during one
portion of the event and the presence of inspiratory effort during
another portion, regardless of which portion came ﬁrst. Hypopnea
was deﬁned as a drop in airﬂow amplitude by 30% of baseline of a
duration of at least two breaths, associated with an awakening,
and/or an OD [16]. Recording time (Trec) was deﬁned as the time
between the reported sleep time and wakefulness. Total sleep time
(TST) was deﬁned as the Trec minus the wake periods recorded by
actigraphy.
AHIPG was calculated as the sum of the apnea and hypopnea
events per hour of TST. The apnea index (AIPG) and HIPG were
calculated as the number of apneas and hypopneas per hour of TST,
respectively. Sleep study was considered normal in case of an AIPG
<1 event/hour and an AHIPG <1.5 events/hour [17]. Mild sleep
apnea was deﬁned as an AHIPG between 1.5 and 5 events/hour,
moderate sleep apnea as an AHIPG between 5 and 10 events/hour,
and severe sleep apnea as an AHIPG $10 events/hour.
2.3. CPAP device
Only devices with a ﬁxed CPAP mode from the ResMed brand
(S9 series, Airsense 10, Stellar) were used because of the necessity
to have a cycle-by-cycle airﬂow display together with SpO2 signal
on the software (ResScan 5.6, ResMed Limited, Australia). A SpO2
sensor (Nonin Xpod, Nonin Medical Inc., USA) was connected
directly to the external port of the CPAP device. The SpO2 signal was
displayed on ResScan software with a sampling frequency of 1 Hz.
In patients treated with another CPAP device, a ResMed device with
the same CPAP pressure was used for the night.
According to information provided by the manufacturer,
obstructive apnea was deﬁned as a 75% reduction of baseline
airﬂow, for at least 10 s, with upper airway closure. Central apnea
was deﬁned as a 75% reduction of baseline airﬂow, for at least 10 s,
without upper airway closure. The distinction between obstructive
and central apneas was performed by means of the forced oscilla-
tion technique that enabled detection of upper airway closure/
opening. Unknown apnea was deﬁned as apneas that could not be
characterized precisely because of total air leak over 30 L/minute.
Hypopnea was deﬁned as a partial upper airway closure (ie, a 50%
reduction of baseline airﬂow associated with inspiratory airﬂow
limitation) for at least 10 s. This scoring did not integrate the
changes in SpO2.
2.4. Procedure
Expert staff manually scored PG, and the residual AHIPG, AIPG
and HIPG were reported. Two readers, who were blinded from the
PG results, scored the respiratory events using the built-in CPAP
software. Automatic AHI (AHIA CPAP), AI (AIA CPAP) and HI (HIA CPAP)
assessed by the built-in CPAP software were reported. Automatic
AHI, AI and HI were also calculated as indexes per hour of poly-
graphic Trec (AHIA CPAP Trec, AIA CPAP Trec, HIA CPAP Trec) and per
hour of polygraphic TST (AHIA CPAP TST, AIA CPAP TST, HIA CPAP TST).
All the respiratory events were then manually scored using the
CPAP software as follows: (i) all the respiratory events following the
AASM guidelines [16] were validated, (ii) all the events preceded by a
sigh [18] or a movement (unstable airﬂow tracing), or central apnea
lasting <20 s and hypopnea not associated with an OD, were
removed, (iii) all the respiratory events scored according to the
AASM guidelines but not scored by the CPAP software were added,
(iv) all the respiratory events falsely scored by CPAP were modiﬁed.
The AHI, AI and HI were calculated as the number of events scored
using the CPAP software per hour of polygraphic Trec (AHIM CPAP Trec,
AIM CPAP Trec, HIM CPAP Trec) and as the number of events per hour of
polygraphic TST (AHIM CPAP TST, AIM CPAP TST, HIM CPAP TST). Periods
with air leaks>24 L/minwere discarded. Fig.1 describes the different
time periods to which the indexes of respiratory events refer.
2.5. Statistical analysis
The data were presented as mean and standard deviation (SD),
or median and range. Comparisons between AHIPG, AIPG and HIPG
and automatic andmanually scored events per hour of Trec and per
hour of TST were performed using the Student t-test (parametric
test) or the ManneWhitney Rank Sum Test (nonparametric test).
Pearson product moment correlation (parametric test) or
Spearman rank order correlation (nonparametric test) coefﬁcient
(r) was calculated to assess the correlation between the respiratory
events scored by PG, and CPAP software. Furthermore, agreement
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between the respiratory events scored by PG and by CPAP software
was assessed by the method of differences against the means [19].
The limits of agreement (95% CI) were calculated. A p-value <0.05
was considered for signiﬁcance.
3. Results
Nineteen patients were included in the study. Four patients had
no exploitable data, due to the intermittent airﬂow recorded on the
CPAP software because of a low weight in two patients and a
technical problem in two patients; therefore, the data of 15 patients
were retained for subsequent analysis. Table 1 summarizes the
anthropometric data of the patients. Mean age was 11.4 ± 5.1 years
(range 1.5e18.6). Mean CPAP level was 9 ± 1 cmH2O (range 6e12).
Five patients were overweight and one patient was obese.
Mean residual AHIPG was 0.9 ± 1.2 events/hour (range 0.0e4.6)
with a mean residual AIPG of 0.7 ± 0.9 events/hour and a mean HIPG
of 0.2 ± 0.4 events/hour. Table 2 shows the PG ﬁndings.
Fig. 1. Explanation of the different time periods used to calculate the indexes of the
respiratory events.
Table 1
Anthropometric data of the patients.
Patient Gender Age
(years)
Height
(cm)
Weight
(kg)
BMI
z-score
Underlying diagnosis
(previous surgery)
CPAP device CPAP level (cmH2O)
1 F 13.9 153 43 %0.3 Crouzon syndrome S9 Autoset EPR 8
2 M 8.9 139 74 2.8 Obesity (adenotonsillectomy) S9 Elite 10
3 M 7.8 125 21 %2.0 Di Georges syndrome (22q11)
(velopharyngoplasty)
AirSense 10 10
4 M 17.5 184 58 %2.2 Treacher-Collins syndrome S9 Autoset EPR 10
5 M 14.9 139 38 0.1 Charge syndrome
Tracheomalacia
Glossoptosis
S9 Autoset EPR 9
6 F 10.4 138 36 0.7 Di Georges syndrome (22q11)
Pharyngolaryngeal hypotonia
S9 VPAP ST 8
7 F 16.7 142 59 1.6 Mucopolysaccharidosis type I AirSense 10 12
8 F 8.6 136 27 %0.9 Laryngeal paralysis
History of tracheostomy
ICON (Fisher & Paykel)
changed for S9 VPAP ST
8
9 F 14.7 152 56 1.1 Crouzon syndrome
History of tracheostomy
S9 Autoset EPR 9
10 M 18.6 166 64 0.3 Crouzon syndrome AirSense 10 11
11 M 16.4 167 75 1.5 Obesity with psychomotor delay S9 Autoset EPR 10
12 M 5.1 103 17 0.5 Cardiomyopathy AirSense 10 10
13 M 8.6 136 35 1.2 Crouzon syndrome
History of tracheostomy
(Adenotonsillectomy)
S9 VPAP ST 8
14 M 1.5 78 10 e Chiari type 2
Myelomeningocele, hydrocephaly
Stellar 150 6
15 M 6.9 110 22 1.5 Pycnodysostosis AirSense 10 8
BMI: body mass index; CPAP: continuous positive airway pressure.
Table 2
In-lab polygraphic ﬁndings during CPAP.
Patient Trec (min) TST (min) AHIPG (events/hour) Total AIPG (events/hour) OAIPG (events/hour) CAIPG (events/hour) HIPG (events/hour)
1 402 402 1.3 0.6 0.6 0.0 0.9
2 391 362 0.3 0.3 0.0 0.3 0.0
3 416 390 3.7 0.6 0.3 0.3 3.1
4 408 408 0.0 0.0 0.0 0.0 0.0
5 394 394 0.9 0.8 0.5 0.3 0.2
6 439 420 0.0 0.0 0.0 0.0 0.0
7 490 490 0.5 0.5 0.5 0.0 0.0
8 410 409 0.4 0.3 0.1 0.1 0.1
9 400 400 0.5 0.5 0.3 0.2 0.0
10 526 526 0.5 0.5 0.5 0.0 0.0
11 210 199 0.3 0.3 0.3 0.0 0.0
12 419 413 0.4 0.4 0.1 0.3 0.0
13 512 509 0.2 0.0 0.0 0.0 0.2
14 389 374 2.1 2.1 0.2 1.9 0.0
15 403 446 0.7 0.6 0.6 0.0 0.1
CPAP: continuous positive airway pressure; Trec: recording time; TST: total sleep time; AHIPG: apnea-hypopnea index; AIPG: apnea index; OAIPG: obstructive apnea index;
CAIPG: central apnea index; HIPG: hypopnea index.
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Fig. 2. Agreements between PG and CPAP software for events detection. A: Obstructive apnea without 3% OD. B: Hypopnea with 3% OD. The event was scored as obstructive apnea
on the CPAP because of the end of the event. C: Central apnea of >20 s but no 3% OD, possibly due to an artifact on SpO2 (note the artifacted pulse wave plethysmography), on PG
compared with a central apnea of >20 s with 3% OD on CPAP. On PG: Flow is expressed in L/min; SpO2 in %. On CPAP software: Flow is expressed in L/min; SpO2 in %; events
represent the type of automatic scored event; leaks is expressed in L/min. The continuous line represents the threshold of excessive leaks (24 L/min). (1 min period-window) Act,
actimetry; CPAP, continuous positive airway pressure; OD, oxygen desaturation; PG, polygraphy; PW, pulse wave plethysmography; SpO2, arterial oxygen saturation; RIP, respiratory
inductance plethysmography.
Fig. 3. Discrepancies between PG and CPAP for events detection. A: Central apnea preceded by a sigh, not scored on PG but automatically scored as “Apnea” on CPAP (S9 VPAP ST).
Note the presence of a 3% OD on CPAP but not present on PG. B: Obstructive hypopnea with consecutive 3% OD scored on PG but not scored automatically on CPAP, neither manually
because of the absence of 3% OD. C: Apnea with 3% OD scored as central on PG because of the absence of inspiratory effort, but falsely characterized as obstructive on CPAP (3% OD
also present on CPAP). On PG: Flow is expressed in L/min; SpO2 in %. On CPAP software: Flow is expressed in L/min; SpO2 in %; events represent the type of automatic scored event;
leaks is expressed in L/min. The continuous line represents the threshold of excessive leaks (24 L/min). (1 min period-window) Act, actimetry; CPAP, continuous positive airway
pressure; OD, oxygen desaturation; PG, polygraphy; PW, pulse wave plethysmography; SpO2, arterial oxygen saturation; RIP, respiratory inductance plethysmography.
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Mean AHIA CPAP was 3.6 ± 3.6 events/hour (range 0.5e14.7) and
was signiﬁcantly higher than AHIPG (p < 0.001). Mean AHIA CPAP
Trec and AHIA CPAP TST were 2.9 ± 3.5 events/hour (range 0.1e14.3)
and 2.8 ± 3.6 events/hour (range 0.1e14.6), respectively, and were
signiﬁcantly higher than AHIPG (p < 0.01). Mean AHIM CPAP Trec and
AHIM CPAP TST were 1.2 ± 1.7 events/hour (range 0.0e5.4) and
1.2 ± 1.6 events/hour (range 0.0e5.1), respectively. Mean AHIM CPAP
values were lower than AHIA CPAP, but still signiﬁcantly higher than
AHIPG (p < 0.05).
Fig. 2 and Fig. 3 show some examples of agreements and dis-
crepancies between the scoring of the respiratory events by PG and
CPAP software, for patients #2, #3 and #6. Discrepancies were
mainly due to the inappropriate scoring of a sigh or a movement by
the CPAP software, the absence of concomitant OD on the PG and
Fig. 4. Correlations between apnea-hypopnea indexes obtained by polygraphic scoring and automatic CPAP scoring (A), automatic CPAP scoring for the recording time (B),
automatic CPAP scoring for TST (C), manual CPAP scoring for the recording time (D), and manual CPAP scoring for the TST (E). AHIPG, polygraphic apnea-hypopnea index; AHIA CPAP,
automatic apnea-hypopnea index assessed by CPAP software; AHIM CPAP, manual apnea-hypopnea index calculated using CPAP software; TST, total sleep time.
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CPAP software, or to the inability or failure to distinguish an
obstructive from a central apnea on the CPAP software.
Fig. 4 shows the correlations between the AHI scored by PG and
CPAP and Table 3 presents the correlations between the indexes
obtained with PG and CPAP software. AHI scored by the CPAP
software tended to overestimate the AHIPG. However, strong cor-
relations were observed between AHIPG, AIPG and HIPG and the
indexes obtained by the manual scoring on the CPAP software
(p < 0.001). The greatest differences were observed for the corre-
lations between HIPG and HIA CPAP versus HIPG and HIM CPAP. Fig. 5
displays the BlandeAltman plots of AHIPG versus AHIA CPAP and
AHIM CPAP. The bias between AHIPG and AHIA CPAP was %2.7 events/
hour with wide limits of agreement (%8.6 to 3.1 events/hour). This
bias reduced slightly when analyzing the agreement between
AHIPG and AHIA CPAP Trec (%2.0 events/hour; limits of
agreement, %8.1 to 4.0 events/hour) and AHIA CPAP TST (%2.0
events/hour; limits of agreement,%8.2 to 4.3 events/hour). The bias
and limits of agreement greatly decreased when comparing AHIPG
with AHIM CPAP Trec (%0.3 events/hour; limits of agreement, %1.8 to
1.1 events/hour) and AHIM CPAP TST (%0.3 events/hour; limits of
agreement, %1.7 to 1.0 events/hour).
Discrepancies between PG and CPAP were mainly observed in
three patients. In patient 3, AHIA CPAPwas higher than AHIPG, due to a
great difference between the time spent with CPAP and PG TST. In
patient 5, artifacts on the respiratory inductance plethysmography
impeded the characterization of apneas on PG, and therefore apneas
were not scored on PG, leading to a higher number of automatic but
also manually scored apneas on CPAP. In patient 14, a majority of
central-like events without OD and lasting <20 s were present and
not scored on PG, while on CPAP, as it was not possible to charac-
terize the apneas, they were manually scored as obstructive apneas,
leading to a high AIM CPAP when compared to PG. Of note, apneas
were scored as hypopneas on the automatic CPAP scoring.
4. Discussion
The present study is the ﬁrst to compare the automatic scoring
of residual respiratory events by the built-in software of CPAP
devices with a manual scoring on the CPAP tracings, integrating
SpO2, and with an in-lab PG in children on long-term, constant
CPAP. The main ﬁnding was that manual scoring integrating SpO2
seems very useful, even though the scoring is still not perfect with
CPAP devices, due in part to a default of apnea characterization.
A limited number of studies have compared the scoring of res-
piratory events by the algorithms of current generation CPAP de-
vices with manual scoring on PSG [9e15]. Good agreements have
been reported between AHI scored on PSG and AHIA CPAP during
constant or autotitrating CPAP, with a tendency to a stronger
correlation for apnea than for hypopnea. Contrary to these ﬁndings,
the current study found no correlation between AIPG and AIA CPAP or
between HIPG and HIA CPAP. This may be explained by the very low
AIPG in the patients (<1 event/hour) except in two patients, and by a
high number of falsely scored hypopneas by the CPAP device
(Stellar™) in the youngest patient of the series.
A number of factors may explain the differences between res-
piratory events detected automatically by the CPAP software and
those manually scored on PG. First, the respiratory events scored
automatically by the CPAP device represented the number of
detected events per hour of CPAP therapy time, whereas the res-
piratory events on PG were only scored during sleep (with the
limitation that wakefulness cannot be scored with PG as compared
to PSG). However, when the number of events for the Trec or TST
was corrected, surprisingly, the only difference was that AHIPG did
not correlate anymore with AHIA CPAP TST. Second, the scoring of
respiratory events by CPAP devices did not comply with the AASM
guidelines. Moreover, this scoring has been designed for adult pa-
tients, with the duration of the events set at 10 s instead of two
respiratory cycles for children. Also, a respiratory event was deﬁned
by an arbitrary percentage of ﬂow reduction. This may also explain
why the CPAP software did not score some events. Also, one com-
mon limitation of the CPAP scoring was the false scoring of a sigh as
an apnea. Third, even if it was possible to integrate an optional SpO2
signal in the CPAP software, the CPAP scoring did not integrate the
changes in SpO2, which may have explained the discrepancies in
the scoring of hypopneas. Finally, the software of the different CPAP
devices was still not able to correctly distinguish obstructive from
central apneas, which may have overestimated the number of ap-
neas scored by CPAP. For all of these reasons, it was decided to
manually score all the respiratory events on the CPAP software in
the present study. The results showed that the manual scoring of
respiratory events, taking in account SpO2 changes, markedly
reduced the differences of AHI, AI and HI values between the CPAP
and PG scoring.
The scoring of respiratory events, and in particular hypopneas,
by the CPAP device could be improved by integrating OD in the
scoring of respiratory events. The addition of a thoracic and/or
abdominal movement signal could help to characterize apneas.
Moreover, combining actimetry or even pulse wave plethysmog-
raphy to the CPAP device, in order to detect movements or artifacts
on the SpO2 recording, could be another window for improvement,
even though some movements may be visible on the CPAP soft-
ware. Finally, it could be very interesting to have the possibility of
discarding selected time periods on the CPAP software, in order to
remove artifacts or periods of movements from the scoring.
The present study had several limitations. First, the number of
patients was small and the AHI values were low. Indeed, because
Table 3
Correlations between the indexes of respiratory events obtained with in-lab PG and the built-in software of the CPAP devices.
AHIA CPAP AHIA CPAP Trec AHIA CPAP TST AHIM CPAP Trec AHIM CPAP TST
AHIPG r ¼ 0.667
p ¼ 0.007
r ¼ 0.569
p ¼ 0.027
r ¼ 0.509
p ¼ 0.053
r ¼ 0.915
p < 0.001
r ¼ 0.933
p < 0.001
AIA CPAP AIA CPAP Trec AIA CPAP TST AIM CPAP Trec AIM CPAP TST
AIPG r ¼ 0.502
p ¼ 0.067
r ¼ 0.443
p ¼ 0.098
r ¼ 0.355
p ¼ 0.194
r ¼ 0.928
p < 0.001
r ¼ 0.940
p < 0.001
HIA CPAP HIA CPAP Trec HIA CPAP TST HIM CPAP Trec HIM CPAP TST
HIPG r ¼ %0.109
p ¼ 0.710
r ¼ %0.086
p ¼ 0.761
r ¼ %0.093
p ¼ 0.742
r ¼ 0.983
p < 0.001
r ¼ 0.985
p < 0.001
PG: polygraphy; CPAP: continuous positive airway pressure; AHIPG: polygraphic apnea-hypopnea index; AIPG: polygraphic apnea index; HIPG: polygraphic hypopnea index;
AHIA CPAP: automatic apnea-hypopnea index assessed by CPAP software; AIA CPAP: automatic apnea index assessed by CPAP software; HIA CPAP: automatic hypopnea index
assessed by CPAP software; AHIM CPAP: manual apnea-hypopnea index calculated using CPAP software; AIM CPAP: manual apnea index calculated using CPAP software; HIM CPAP:
manual hypopnea index calculated using CPAP software; Trec: recording time; TST: total sleep time.
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the PGs were performed on stable patients on long-term CPAP
therapy, the residual AHIPG values were low [20]. One possibility to
have higher residual AHI may be to perform the study during a
titration study, which was not feasible at the time of the present
study. A second limitation was that young children could not be
studied, as airﬂow cannot be detected by the CPAP internal
pneumotachograph below a minimal threshold. This minimal
airﬂow threshold, reported as a minimal weight by the manufac-
turer, varies according to the CPAP device. A third limitation was
that PG was performed instead of PSG, as in routine clinical man-
agement. In children, PG has been shown to underestimate the AHI
when compared to PSG [21], mainly because of an incorrect
Fig. 5. BlandeAltman plots of apnea-hypopnea indexes with the differences between polygraphic scoring and automatic CPAP scoring (A), automatic CPAP scoring for the recording
time (B), automatic CPAP scoring for TST (C), manual CPAP scoring for the recording time (D), and manual CPAP scoring for the TST (E). The continuous line represents the bias (mean
of the difference) and the dashed lines represent the limits of agreement. Note that the difference between the two methods tended to greatly reduce with the manual CPAP scoring.
CPAP, continuous positive airway pressure; OD, oxygen desaturation; PG, polygraphy; PW, pulse wave plethysmography; SpO2, arterial oxygen saturation; TST, total sleep time.
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estimation of TST. However, sleep and wakefulness can be quite
accurately determined in children using cardiorespiratory and
videotape recordings [22], reducing the discrepancy between PSG
and PG. In the present study, PG was combined with cardiorespi-
ratory and videotape recordings. This had the ‘advantage’ that with
PG, central apnea or hypopnea associated with micro-arousal was
not scored, as with the CPAP software. A fourth limitation was that
several CPAP deviceswere used, exclusively from the ResMed brand,
having different detection algorithms. Finally, the average window
for the SpO2 signal integrated in the CPAP software was unknown
and may have been different compared to that of in-lab PG. More-
over, it is well known that two pulse oximeters, even though from
the same brand, may give variable inter-subject SpO2 data.
In conclusion, the manual scoring of respiratory events by CPAP
devices with the addition of an integrated SpO2 signal may be
helpful to assess CPAP efﬁcacy. However, there is room for
improvement for this scoring by the CPAP devices. Conﬁrmation of
the present results in children having higher residual AHI and using
other CPAP devices is necessary.
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